cemp-10q_20170930.htm

0001564590-17-021211.txt : 20171102 0001564590-17-021211.hdr.sgml : 20171102 20171102161814 ACCESSION NUMBER: 0001564590-17-021211 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171102 DATE AS OF CHANGE: 20171102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEMPRA, INC. CENTRAL INDEX KEY: 0001461993 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262644445 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35405 FILM NUMBER: 171172561 BUSINESS ADDRESS: STREET 1: 6320 QUADRANGLE DRIVE STREET 2: SUITE 360 CITY: CHAPEL HILL STATE: NC ZIP: 27517-8149 BUSINESS PHONE: 919-576-2306 MAIL ADDRESS: STREET 1: 6320 QUADRANGLE DRIVE STREET 2: SUITE 360 CITY: CHAPEL HILL STATE: NC ZIP: 27517-8149 FORMER COMPANY: FORMER CONFORMED NAME: Cempra Holdings, LLC DATE OF NAME CHANGE: 20090414 10-Q 1 cemp-10q_20170930.htm 10-Q cemp-10q_20170930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from to

Commission File Number: 001-35405

CEMPRA, INC.

(Exact name of registrant specified in its charter)

Delaware		2834		45-4440364
(State or Other Jurisdiction of Incorporation or Organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification No.)

6320 Quadrangle Drive, Suite 360

Chapel Hill, NC 27517

(Address of Principal Executive Offices)

(919) 313-6601

(Telephone Number, Including Area Code)

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

Title of Each Class		Name of Exchange on which Registered
Common Stock, $0.001 Par Value		Nasdaq Global Market

Securities Registered Pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 27, 2017 there were 52,512,385 shares of the registrant’s common stock, $0.001 par value, outstanding.

CEMPRA, INC.

TABLE OF CONTENTS

		Page
PART I—FINANCIAL INFORMATION		1

Item 1.	Financial Statements (Unaudited)	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	16

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	26

Item 4.	Controls and Procedures	27

PART II—OTHER INFORMATION		28

Item 1A.	Risk Factors	28

Item 6.	Exhibits	31

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

CEMPRA, INC.

Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

	September 30,			December 31,
	2017			2016
Assets
Current assets
Cash and equivalents	$	176,134		$	231,553
Receivables		2,803			6,162
Prepaid expenses		833			579
Total current assets		179,770			238,294
Furniture, fixtures and equipment, net		27			48
Deposits		83			173
Total assets	$	179,880		$	238,515
Liabilities
Current liabilities
Accounts payable	$	6,665		$	15,657
Accrued expenses		1,036			2,929
Accrued payroll and benefits		1,286			4,267
Current portion of long-term debt		6,667			6,667
Total current liabilities		15,654			29,520
Deferred revenue		16,987			16,987
Long-term debt		3,682			8,660
Total liabilities		36,323			55,167
Commitments and contingencies (Notes 4 and 8)
Shareholders' Equity
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2017 and December 31, 2016		-			-
Common stock; $.001 par value; 80,000,000 shares authorized; 52,509,281 and 52,392,905 issued and outstanding at September 30, 2017 and December 31, 2016, respectively		53			52
Additional paid-in capital		626,001			620,279
Accumulated deficit		(482,497	)		(436,983	)
Total shareholders’ equity		143,557			183,348
Total liabilities and shareholders’ equity	$	179,880		$	238,515

The accompanying notes are an integral part of these consolidated financial statements

CEMPRA, INC.

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
Revenue
Contract research	$	1,717		$	3,972		$	7,449		$	10,071
Total revenue		1,717			3,972			7,449			10,071
Operating expenses
Research and development		4,383			21,096			28,338			60,643
General and administrative		7,867			15,021			21,291			35,333
Restructuring		-			-			3,553			-
Total operating expenses		12,250			36,117			53,182			95,976
Loss from operations		(10,533	)		(32,145	)		(45,733	)		(85,905	)
Other income (expense)
Interest income		382			128			896			330
Interest expense		(208	)		(295	)		(677	)		(948	)
Other income (expense), net		174			(167	)		219			(618	)
Net loss	$	(10,359	)	$	(32,312	)	$	(45,514	)	$	(86,523	)
Basic and diluted net loss per share	$	(0.20	)	$	(0.62	)	$	(0.87	)	$	(1.74	)
Basic and diluted weighted average shares outstanding		52,508,598			52,072,536			52,470,568			49,616,785

The accompanying notes are an integral part of these consolidated financial statements

CEMPRA, INC.

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2017			2016
Operating activities
Net loss	$	(45,514	)	$	(86,523	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		21			40
Share-based compensation		5,464			7,518
Amortization of debt issuance costs		22			44
Changes in operating assets and liabilities
Receivables		3,359			3,108
Prepaid expenses		(254	)		(219	)
Deposits		90			(73	)
Accounts payable		(8,992	)		2,896
Accrued expenses		(1,893	)		615
Accrued payroll and benefits		(2,981	)		1,342
Net cash used in operating activities		(50,678	)		(71,252	)
Investing activities
Purchases of furniture, fixtures and equipment		-			(9	)
Net cash used in investing activities		-			(9	)
Financing activities
Payment of long-term debt		(5,000	)		(2,779	)
Proceeds from exercise of stock options		259			364
Proceeds from issuance of common stock, net of underwriting discounts		-			169,112
Payment of offering costs		-			(284	)
Net cash (used in) provided by financing activities		(4,741	)		166,413
Net change in cash and equivalents		(55,419	)		95,152
Cash and equivalents at beginning of the period		231,553			153,765
Cash and equivalents at end of the period	$	176,134		$	248,917
Supplemental cash flow information
Cash paid for interest	$	673		$	916

The accompanying notes are an integral part of these consolidated financial statements

CEMPRA, INC.

September 30, 2017

Notes to Consolidated Financial Statements

(Unaudited)

1. Description of Business

Cempra, Inc. (the “Company” or “Cempra”) is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. Cempra is located in Chapel Hill, North Carolina, and is a pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases.

The Company expects to continue to incur losses and require additional financial resources to advance its products to either commercial stage or liquidity events. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition.

In August 2017, the Company entered into an Agreement and Plan of Merger and Reorganization (“Merger Agreement”), with Melinta Therapeutics Inc. (“Melinta”). Under the terms of the Merger Agreement, shares of Melinta stock will be exchanged for Company shares whereby the current shareholders of Melinta will own approximately 52% of the Company’s stock after completion of the merger. The exchange ratio is subject to adjustment based upon the following; (1) the Company’s net cash balance at the closing of the transaction, (2) incremental debt incurred by Melinta before the close of the transaction, and (3) amount of transaction-related expenses incurred by Melinta. Consummation of the transaction is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company of the transactions contemplated by the Merger Agreement and related matters. The Merger Agreement contains certain termination rights for both the Company and Melinta, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Melinta a termination fee of $7.9 million and/or to reimburse certain expenses incurred by Melinta in an amount up to $2.0 million. The Company is expected to change its name to Melinta Therapeutics, Inc. and trade under the ticker symbol MLNT after the merger closes.

2. Basis of Presentation

Principles of Consolidation and Basis of Presentation

The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.

Unaudited Interim Financial Data

The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary for the fair statement of the Company’s financial position as of September 30, 2017 and the results of operations and cash flows for the three and nine-months ended September 30, 2017 and 2016. The December 31, 2016 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP for complete financial statements.

Use of Estimates

The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Receivables

Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible.

Research and Development Expenses

Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, consultants, central laboratories and clinical research organizations, including costs incurred in connection with clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include insurance or other indirect costs related to the Company’s research and development function to specific product candidates. R&D costs are expensed as incurred. Expenses paid but not yet incurred are recorded in prepaid expenses. The Company expenses purchases of pre-approval inventory as R&D until regulatory approval is received.

Clinical Trial Accruals

As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of fee billings and passthrough expenses from contract research organizations and other third-party vendors as well as the timely processing of any change orders from the contract research organizations.

Revenue Recognition

The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.

For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized.

Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies an entity’s identification of its performance obligations in a contract. The update also clarifies the guidance regarding an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends the guidance in the new revenue standard on collectability, non-cash consideration, presentation of sales tax, and transition. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers which increases shareholders’ awareness of the proposals and expedites improvements to Update 2014-09. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which allows certain public business entities to elect to use the non-public business entities effective dates to adopt new standards on revenue (ASC 606) and leases (ASC 842). The amendments are intended to address implementation issues that were raised by stakeholders and provide additional practical expedients to reduce the cost and complexity of applying the new revenue standard. These pronouncements have the same effective date as the new revenue standard.

The Company has evaluated the contract research agreement with BARDA, and does not anticipate a material impact on the financial statements. The Company is currently evaluating the license agreement with Toyama to determine the impact that the implementation of this standard will have on the financial statements, if any. The Company plans to use the full retrospective method of adoption effective January 1, 2018.

In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance as of January 1, 2017. As of December 31, 2016, the Company has accumulated excess tax benefits from temporary differences in the amount and timing of stock compensation expense and the Company’s deductions on its income tax return from the award compensation that reduces the net operating loss deferred tax asset. The Company provided a full valuation allowance against its net deferred tax assets since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Upon implementation of this standard, the stock compensation excess tax benefit will be eliminated, resulting in an increase to the net operating loss deferred tax asset, with an increase in the valuation allowance of the same. The implementation of this standard has no impact on the Company’s consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business which revises the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

3. Fair Value of Financial Instruments

The carrying values of cash and equivalents, receivables, prepaid expenses, and accounts payable at September 30, 2017 approximated their fair values due to the short-term nature of these items.

The Company’s valuation of financial instruments is based on a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.

At September 30, 2017 and December 31, 2016, the Company held money market funds classified as Level 1 financial instruments of $173.0 million and $228.5 million, respectively. The carrying value of the Term Loan (defined and discussed in Note 7), which is classified as a Level 2 liability, approximates its fair value. At September 30, 2017, the carrying value was $10.3 million. There were no transfers between levels of the fair value hierarchy for any assets or liabilities measured at fair value in the nine months ended September 30, 2017.

4. Significant Agreements and Contracts

License Agreements

Optimer Pharmaceuticals, Inc.

In March 2006, the Company, through its wholly owned subsidiary, Cempra Pharmaceuticals, Inc., entered into a Collaborative Research and Development and License Agreement (“Optimer Agreement”) with Optimer Pharmaceuticals, Inc. (“Optimer”) which was acquired by Cubist Pharmaceuticals, Inc. in October 2013, which was in turn acquired by Merck in January 2015. Under the terms of the Optimer Agreement, the Company acquired exclusive rights to further develop and commercialize certain Optimer technology worldwide, excluding member nations of the Association of Southeast Asian Nations (“ASEAN”).

In exchange for this license, during 2006 and 2007, the Company issued an aggregate of 125,646 common shares with a total fair value of $0.2 million to Optimer. These issuances to Optimer were expensed as incurred in research and development expense.

In July 2010, the Company paid a $0.5 million milestone payment to Optimer after the successful completion of its first solithromycin Phase 1 program. In July 2012, the Company paid a $1.0 million milestone after the successful completion of its first solithromycin Phase 2 program. Both milestones were expensed as incurred in research and development expense. Under the terms of the Optimer Agreement, the Company will owe Optimer additional payments, contingent upon the achievement of various development, regulatory and commercialization milestone events. One such milestone event would be owed upon FDA approval of solithromycin which would result in a payment to Optimer of $9.5 million. The aggregate amount of such milestone payments the Company may need to pay is based in part on the number of products developed under the agreement and would total $27.5 million (including the two milestone payments made to date and the milestone payment for FDA approval) if four products are developed and gain FDA approval. The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products.

The Scripps Research Institute

In June 2012, the Company entered into a license agreement with The Scripps Research Institute (“TSRI”), whereby TSRI licensed to the Company rights, with rights of sublicense, to make, use, sell, and import products for human or animal therapeutic use that use or incorporate one or more macrolides as an active pharmaceutical ingredient (“API”) and is covered by certain patent rights owned by TSRI claiming technology related to copper-catalysed ligation of azides and acetylenes. The rights licensed to the Company are exclusive as to the People’s Republic of China (excluding Hong Kong), South Korea and Australia, and are non-exclusive in all other countries worldwide, except ASEAN member-nations, which are not included in the territory of the license. Under the terms of the agreement with TSRI, the Company paid a one-time only, non-refundable license issue fee in the amount of $0.4 million which was charged to research and development expense in the second quarter of 2012.

The Company is also obligated to pay annual maintenance fees to TSRI in the amount of (i) $50,000 each year for the first three years (beginning on the first anniversary of the agreement), and (ii) $85,000 each year thereafter (beginning on the fourth anniversary of the agreement). Each calendar year’s annual maintenance fees will be credited against sales royalties due under the agreement for

such calendar year. Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. TSRI is eligible to receive milestone payments of up to $1.1 million with respect to regulatory approval in the exclusive territory and first commercial sale, in each of the exclusive territory and nonexclusive territory, of the first licensed product to achieve those milestones that is based upon each macrolide covered by the licensed patents. Each milestone is payable once per each macrolide. Each milestone payment made to TSRI with respect to a particular milestone will be creditable against any payment due to TSRI with respect to any sublicense revenues received in connection with the achievement of such milestone. Pursuant to the terms of the Optimer Agreement, any payments made to TSRI under this license for territories subject to the Optimer Agreement can be deducted from any sales-based royalty payments due under the Optimer Agreement up to a certain percentage reduction of the royalties due to Optimer.

Under the terms of the agreement, the Company is also required to pay additional fees on royalties, sublicensing and milestone payments if the Company, an affiliate with the Company, or a sub licensee challenges the validity or enforceability of any of the patents licensed under the agreement. Such increased payments would be required until all patent claims subject to challenge are invalidated in the particular country where such challenge was mounted. In December 2014, the Company paid a $0.2 million milestone payment to TSRI in relation to license and milestone payments received under the license agreement with Toyama (discussed below).

The term of the license agreement (and the period during which the Company must pay royalties to TSRI in a particular country for a particular product) will end, on a country-by-country and product-by-product basis, at such time as no patent rights licensed from TSRI cover a particular product in the particular country.

TSRI may terminate the agreement in the event (i) the Company fails to cure any non-payment or default on its indemnity or insurance obligations, (ii) the Company declares insolvency or bankruptcy, (iii) the Company is convicted of a felony relating to the development, manufacture, use, marketing, distribution or sale of any products licensed under the agreement, (iv) the Company fails to cure any underreporting or underpayment by a certain amount in any 12-month period, or (v) the Company fails to cure any default on any other obligation under the agreement. The Company may terminate the agreement with or without cause upon written notice. In the event of such termination, (i) all licenses granted to the Company will terminate except in the case of any sublicensee that was not the cause of the termination, is not in default on its obligations under its sublicense, and that pays any unpaid amounts owed by the Company under the agreement with respect to the sublicense, and (ii) the Company may complete any work in progress and sell any completed inventory on hand for a period of time after termination.

Biomedical Advanced Research and Development Authority

In May 2013, the Company entered into an agreement with BARDA, for the evaluation and development of the Company’s lead product candidate solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens.

The agreement is a cost plus fixed fee development contract, with a base performance segment valued at approximately $18.7 million with contract modifications, and four option work segments that BARDA may request at its sole discretion pursuant to the agreement. If all four option segments are requested, the cumulative value of the agreement, as amended to date, would be approximately $68.2 million and the estimated period of performance would be until approximately May 2018. Three of the options are cost plus fixed fee arrangements and one option is a cost sharing arrangement without fixed fee, for which the Company is responsible for a designated portion of the costs associated with that work segment. The period of performance for the base performance segment was May 2013 through February 2016.

BARDA exercised the second option in November 2014. The value of the second option work segment is approximately $16.0 million and the estimated period of performance is November 2014 through September 2018, which was extended in October 2017 at the Company’s request to allow more time to deliver the completed work product. This extension will not increase the cost of the work to be performed under the option nor does it change any other terms or provisions of the BARDA contract, including timeframes for other work options.

In February 2016, BARDA exercised the third option work segment of the agreement which is intended to fund a Phase 2/3 study of intravenous, oral capsule and oral suspension formulations of solithromycin in pediatric patients from newborn to 17 years with community acquired bacterial pneumonia. This option work segment is a cost-sharing arrangement under which BARDA will contribute $25.5 million and the Company will be responsible for an additional designated portion of the costs associated with the work segment. In September 2016, the contract was modified to increase the third option work segment by $8.0 million for increased

manufacturing work related to the development of a second supply source for solithromycin. The amendment raises the value of the third option work segment to approximately $33.5 million. The estimated period of performance of this option work segment runs through May 2018.

Under the agreement, the Company is reimbursed and recognizes revenue as allowable costs are incurred plus a portion of the fixed-fee earned. The Company considers fixed-fees under cost reimbursable agreements to be earned in proportion to the allowable costs incurred in performance of the work as compared to total estimated agreement costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Since inception of the agreement through September 30, 2017, the Company has recognized $46.7 million in revenue under this agreement.

The agreement provides the U.S. government the ability to terminate the agreement for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement of work. The Company believes that if the government were to terminate the agreement for convenience, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs.

Any of the funding sources may request reimbursement for expenses or return of funds, or both, as a result of noncompliance by the Company with the terms of the grant. No reimbursement of expenses or return of funds for noncompliance has been requested or made since inception of the contract.

Toyama Chemical Co., Ltd.

In May 2013, Cempra Pharmaceuticals, Inc., the Company’s wholly owned subsidiary, entered into a license agreement with Toyama Chemical Co., Ltd. (“Toyama”), whereby the Company licensed to Toyama the exclusive right, with the right to sublicense, to make, use and sell any product in Japan that incorporates solithromycin, the Company’s lead compound, as its sole API for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues. Toyama also has a nonexclusive license in Japan and certain other countries, with the right to sublicense, to manufacture or have manufactured API for solithromycin for use in manufacturing such products, subject to limitations and obligations of the concurrently executed supply agreement discussed below. Toyama granted the Company certain rights to intellectual property generated by Toyama under the license agreement with respect to solithromycin or licensed products for use with such products outside Japan or with other solithromycin-based products inside or outside Japan.

Following execution of the agreement, the Company received a $10.0 million upfront payment from Toyama. Toyama is also obligated to pay the Company up to an aggregate of $60.0 million in milestone payments, depending on the achievement of various regulatory, patent, development and commercial milestones. Under the terms of the license agreement, Toyama must also pay the Company a royalty equal to a low-to-high first double decimal digit percentage of net sales, subject to downward adjustment in certain circumstances. In August 2014, the Company received a $10.0 million milestone payment from Toyama (“August 2014 Milestone”), which was triggered by Toyama’s progress of its solithromycin clinical development program in Japan. The payment was made following Toyama’s receipt of regulatory acceptance to begin a Phase 2 trial of solithromycin in Japan following successful completion of a Phase 1 trial. In March 2015, the Company recognized a $10.0 million milestone from Toyama (“March 2015 Milestone”) based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan, which payment was received in April 2015. In October 2016, the Company received the third $10.0 million milestone from Toyama (“October 2016 Milestone”), which was triggered by Toyama’s progress of the solithromycin clinical development program in Japan.

As part of the license agreement, Toyama and the Company also entered into a supply agreement, whereby the Company will be the exclusive supplier (with certain limitations) to Toyama and its sublicensees of API for solithromycin for use in licensed products in Japan, as well as the exclusive supplier to Toyama and its sublicensees of finished forms of solithromycin to be used in Phase 1 and Phase 2 clinical trials in Japan. Pursuant to the supply agreement, which is an exhibit to the license agreement, Toyama will pay the Company for such clinical supply of finished product and all supplies of API for solithromycin for any purpose, other than the manufacture of products for commercial sale in Japan, at prices equal to the Company’s cost. All API for solithromycin supplied by the Company to Toyama for use in the manufacture of finished product for commercial sale in Japan will be ordered from the Company at prices determined by the Company’s manufacturing costs, and which may, depending on such costs, equal, exceed, or be less than such costs. Either party may terminate the supply agreement for uncured material breach or insolvency of the other party, with Toyama’s right to terminate for the Company’s breach subject to certain further conditions in the case of the Company’s failure to supply API for solithromycin or clinical supply, but otherwise the supply agreement will continue until the expiration or termination of the license agreement. Since inception of the agreement through September 30, 2017, the Company has recognized $6.1 million in revenue under this supply agreement.

The Company has determined that there are six deliverables under this agreement including (1) the license to develop and commercialize solithromycin in Japan, (2) the obligation of the Company to conduct Phase 3 studies and obtain regulatory approval in the United States and one other territory, (3) participation in a Joint Development Committee (“JDC”), (4) participation in a Joint Commercialization Committee (“JCC”), (5) the right to use the Company’s trademark, and (6) a supply agreement. The amounts received under the license agreement have been allocated to the deliverables based on their relative fair values and will be recognized into income when the revenue recognition criteria have been achieved.

Royalties are recorded as earned in accordance with the contract terms when third party sales can be reliably measured and collectability is reasonably assured.

The Company recognized $4.3 million in revenue associated with the delivery of the license in May 2013. Additionally, because the milestone event triggering the August 2014 Milestone and October 2016 Milestone payments were considered non-substantive for accounting purposes, these milestone payments are being recognized into revenue proportionately to the six deliverables in the agreement using the same allocation as the upfront payment. Therefore, $4.3 million of the August 2014 Milestone payment was recognized into revenue in August 2014 and $4.3 million of the October 2016 Milestone payment was recognized into revenue in October 2016. The remainder of the upfront and milestone payments which aggregate to $17.0 million are recorded as deferred revenue at September 2017 and will be recognized as revenue when the revenue recognition criteria of each deliverable has been met. The Company also recognized in March 2015 a $10.0 million milestone based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan. The March 2015 Milestone payment is considered substantive for accounting purposes, and therefore the $10.0 million milestone was recognized in its entirety as revenue in March 2015.

FUJIFILM Finechemicals Co., Ltd.

In January 2016, Cempra Pharmaceuticals, Inc. entered into an API manufacturing and supply agreement with FUJIFILM Finechemicals Co., Ltd. (“FFFC”), which will provide the Company with solithromycin in sufficient quantities and at reasonable prices to help ensure it meets its obligation under the May 2013 supply agreement with Toyama. The Company will use reasonable efforts to ensure that the solithromycin supplied by FFFC is for use as the active pharmaceutical ingredient in a human drug product to be used or sold in Japan.

The Company is subject to a minimum purchase obligation for a designated number of years after the successful completion of the manufacturing facility and validation studies by FFFC. Each calendar month, the Company will submit to FFFC a projection of the anticipated volume of solithromycin that it will order for the next designated period (as set forth in the agreement) (or, if earlier, the final calendar month of the current term). Several months of each forecast are binding and the remaining months are non-binding, provided that the quantity of solithromycin ordered for any month is between designated percentages of the quantity specified in the initial forecast and between designated percentages of the most recent previous forecast.

The price of each shipment of solithromycin will be equal to the total number of kilograms in such shipment multiplied by the per-kilogram transfer price as set forth in the agreement.

For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin.

The agreement’s initial term runs until December 2025. After the end of the initial term, and at the end of each year thereafter, the term will automatically extend for an additional year unless either party gives written notice to the other of its intent to terminate within a designated period of time prior to the expiration of the term, in which case the agreement will terminate at the end of such term. The parties may at any time terminate the agreement by mutual written consent. Each party has the right to terminate the agreement immediately if there is a product failure in Japan, the other party becomes involved in bankruptcy, insolvency or similar proceedings or materially breaches the agreement and such breach remains uncured for a period of time following notice of the breach. A violation by the Company of the minimum purchase obligation is considered a material breach. A product failure is not

considered a material breach by the Company. The Company has the right to terminate the agreement upon written notice if there is a supply failure. The Company also may terminate in the event that FFFC cannot provide the Company with solithromycin for more than a designated period of time. Upon termination, any unfulfilled binding portion of the forecast must be delivered by FFFC and paid for by the Company. The Company also may elect to purchase the remaining inventory of FFFC’s solithromycin and any remaining raw materials. If FFFC terminates the agreement for a material breach by the Company and, prior to such termination, (i) FFFC has constructed a facility in Japan for the primary purpose of manufacturing API for the Company under the agreement and (ii) such facility is completed and fully operational and qualified for the manufacture of API for delivery thereunder, then, except to the extent otherwise agreed to by the parties, the Company will pay FFFC an amount equal to (a) the remaining book value of the facility less (b) the product of the number of kilograms of API ordered by the Company under the agreement prior to such termination times a designated dollar amount, provided that if the total direct costs incurred by FFFC in the construction of the facility, net of any tax credits, tax refunds, government subsidies, or similar financial, monetary, or in-kind benefits provided by any governmental agency or authority, do not equal or exceed a designated dollar amount, then the remaining book value will be reduced by a pro rata amount, based on ratios set forth in the agreement, and (z) no amount will be payable if the agreement terminates after December 31, 2025; provided, however, that if FFFC manufactures any product or performs any activities (other than the manufacture of API for the Company under the agreement) in, by, or using the facility prior to such termination and makes any profit thereby, the total amount of such profits will be subtracted from the total payment amount due from the Company to FFFC.

Macrolide Pharmaceuticals, Inc.

On January 29, 2016, Cempra Pharmaceuticals, Inc. entered into an Option and License Agreement with Macrolide Pharmaceuticals, Inc. (“MP”), pursuant to which MP granted the Company an exclusive option to license certain of MP’s patents and know-how involving macrolides, including specifically novel methods of synthesizing solithromycin (the “Compound”). Under the agreement, the Company will support research at MP focused on developing a novel, cost-competitive manufacturing approach to solithromycin. The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program. Under the evaluation program called for in the agreement, MP will conduct research activities for the manufacture of the Compound, which activities the Company will evaluate to determine whether to exercise the option to license.

Upon execution of the agreement, the Company paid MP a non-refundable, non-creditable initial license fee of $0.4 million. For conducting the evaluation program, the Company paid MP a non-refundable, non-creditable fee in the amount of $0.4 million.

In June 2017, the Company entered into a Settlement Agreement with Macrolide Pharmaceuticals, Inc. to terminate the Option and License Agreement and paid the settlement payment of $0.2 million.

5. Receivables

Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with BARDA. At September 30, 2017, the Company’s receivables consisted primarily of earned but unbilled receivables under the BARDA agreement.

6. Accrued Expenses

Accrued expenses are comprised of the following as of (in thousands):

	September 30,		December 31,
	2017		2016
Accrued severance	$	731	$	1,999
Franchise tax		98		570
Deferred rent		81		85
Accrued interest		61		80
Lease liability		41		-
Other accrued expenses		24		50
Accrued professional fees		-		145
Total accrued expenses	$	1,036	$	2,929

7. Long-term Debt

In July 2015, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Comerica Bank (“Comerica”). The Loan and Security Agreement provides that the Company may borrow up to $20.0 million in a term loan (the “Term Loan”) and, upon FDA approval of its New Drug Application for solithromycin, the Company may also borrow an

aggregate amount equal to the lesser of (i) up to 75% of its eligible inventory and 80% of eligible accounts receivable or (ii) $10.0 million (the “Revolver”). After FDA approval of the Company’s New Drug Application for solithromycin, the Company may convert the Term Loan to the Revolver, in which event the Revolver would have a maximum amount available to the Company of $25.0 million. The Loan and Security Agreement specifies the criteria for determining eligible inventory and eligible accounts receivable and sets forth ongoing limitations and conditions precedent to the Company’s ability to borrow under the Revolver. The Company granted Comerica a security interest in substantially all of its personal property assets, excluding its intellectual property and its stock in its subsidiaries, to secure its outstanding obligations under the Loan and Security Agreement. The Company is also obligated to comply with various other customary covenants, including, among other things, restrictions on its ability to: dispose of assets, make acquisitions, be acquired, incur indebtedness, grant liens, make distributions to its stockholders, make investments, enter into certain transactions with affiliates, or pay down subordinated debt, subject to specified exceptions.

Amounts borrowed under the Term Loan may be repaid and reborrowed at any time without penalty or premium. The Term Loan was interest-only through April 30, 2016, followed by an amortization period of 36 months of equal monthly payments of principal plus interest, beginning on May 1, 2016 and continuing on the same day of each month thereafter until paid in full. Any amounts borrowed under the Term Loan will bear interest at a floating interest rate equal to the 30 Day LIBOR rate plus 5.2%. Amounts available to be borrowed under the Revolver may also be repaid and reborrowed at any time without penalty or premium prior to December 31, 2017, at which time all advances under the Revolver shall be immediately due and payable in full. Any amounts borrowed under the Revolver will bear interest at the 30 Day LIBOR rate plus 4.2%. Once available, the Revolver is subject to an annual unused facility fee equal to 0.25%. Under the Loan and Security Agreement, the Company is subject to certain covenants including maintaining a minimum unrestricted cash balance of $15.0 million and continuing the development or commercially launching solithromycin. The Company was in compliance with all covenants at September 30, 2017.

8. Commitments and Contingencies

Legal Proceedings

On November 4, 2016, a securities class action lawsuit was commenced in the United States District Court for the Middle District of North Carolina, Durham Division, naming the Company and certain of the Company’s officers as defendants, and alleging violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between May 1, 2016 and November 1, 2016 (the “Class Period”). The plaintiff seeks to represent a class comprised of purchasers of the Company’s common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court. Two substantially similar lawsuits were filed in the United States District Court, Middle District of North Carolina on November 22, 2016 and December 30, 2016, respectively, seeking to assert claims on behalf of all purchasers of the Company's common stock from July 7, 2015 through December 29, 2016, inclusive. Pursuant to the Private Securities Litigation Reform Act, on July 6, 2017, the court consolidated the three lawsuits into a single action and appointed a lead plaintiff and co-lead counsel in the consolidated case. On August 16, 2017, the plaintiffs in the case filed a consolidated amended complaint. On September 29, 2017, the defendants in the case filed a motion to dismiss the consolidated amended complaint. The Company believes it has meritorious defenses and intends to defend the lawsuits vigorously. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants.

On December 21, 2016, a shareholder derivative lawsuit was commenced in the North Carolina Durham County Superior Court, naming certain of the Company’s former and current officers and directors as defendants and the Company as a nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and corporate waste. A substantially similar lawsuit was filed in the North Carolina Durham County Superior Court on February 16, 2017. The complaints are based on similar allegations as asserted in the putative securities class action described above, and seek unspecified damages and attorneys' fees. Both cases were served and transferred to the North Carolina Business Court as mandatory complex business cases. The Business Court has consolidated the two derivative cases into a single action and appointed lead counsel in the consolidated case. On July 6, 2017, the court entered an order staying the consolidated action pending resolution of the putative securities class action.

On August 3, 2017, a shareholder derivative lawsuit was commenced in the Court of Chancery of the State of Delaware, naming certain of the Company's former and current officers and directors as defendants and the Company as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, and corporate waste. The complaint is based on similar allegations as asserted in the putative securities class action described above, and seeks unspecified damages and attorneys' fees. On October 23, 2017, the defendants in the case filed a motion to dismiss the complaint. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants.

On September 15, 2017, a shareholder derivative lawsuit was commenced in the United State District Court for the Middle District of North Carolina, Durham Division, naming certain of the Company’s former and current officers and directors as defendants and the Company as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and alleged violation of Section 14(a) of the Exchange Act. The complaint is based on similar

allegations as asserted in the putative securities class action described above, and seeks unspecified damages and attorneys’ fees. The complaint has not yet been served. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants.

On September 27, 2017, a putative class action complaint was filed against Cempra and the members of its board of directors on behalf of the public stockholders of Cempra in the United States District Court for the Middle District of North Carolina. The complaint alleges that the preliminary proxy statement issued in connection with the proposed merger between Cempra and Melinta Therapeutics, Inc. omitted material information in violation of Sections 14(a) and 20(a) of the Exchange Act, rendering the preliminary proxy statement false and misleading. Among other remedies, the action seeks to enjoin the merger unless and until additional disclosures are provided, damage, and attorneys’ fees. Cempra believes that the action is without merit and that no further disclosure is required to supplement the preliminary proxy statement under applicable laws.

On October 6, 2017, a putative class action complaint was filed against Cempra and the members of its board of directors on behalf of the public stockholders of Cempra in the United States District Court for the Middle District of North Carolina. The complaint, filed after a definitive proxy statement was issued on October 5, 2017 in connected with the proposed merger between Cempra and Melinta Therapeutics, Inc, alleges that the preliminary proxy statement omitted material information in violation of Sections 14(a) and 20(a) of the Exchange Act, rendering the preliminary proxy statement false and misleading. Among other remedies, the action seeks to enjoin the merger unless and until additional disclosures are provided, damage and attorneys’ fees. Cempra believes that the action is without merit and that no further disclosure is required to supplement the preliminary proxy statement under applicable laws.

Other than as described above, the Company is not a party to any legal proceedings and is not aware of any claims or actions pending or threatened against the Company. In the future, the Company might from time to time become involved in litigation relating to claims arising from its ordinary course of business.

9. Shareholders’ Equity

Common Stock

During January 2016, the Company completed a public offering of 4,166,667 shares of common stock, at a price of $24.00 per share, resulting in net proceeds to the Company of approximately $93.8 million after deducting underwriting discounts and expenses of approximately $6.2 million.

In May 2016, the Company entered into an at-the-market (“ATM”) sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company may, at its discretion, from time to time sell shares of its common stock, with a sales value of up to $150.0 million. The Company has provided Cowen with customary indemnification rights, and Cowen is entitled to a commission at a fixed commission rate of 3.0% of the gross proceeds per share sold. Sales of the shares under the Sales Agreement are to be made in transactions deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended.

The Company began the sale of ATM shares in May 2016 and through July 2016 the Company sold 4,140,307 shares of common stock under the Sales Agreement resulting in net proceeds of $75.1 million after deducting commissions and expenses of $2.3 million. The Company has not sold any shares under the ATM since July 2016.

During the first nine months of 2017, the Company issued 116,376 shares of common stock at a weighted average exercise price of $2.23 per share upon the exercise of option grants.

The following table presents common stock reserved for future issuance for the following equity instruments as of September 30, 2017:

Warrants to purchase common stock			94,912
Outstanding stock options			4,120,220
Outstanding restricted stock units			1,015,000
Available for future grants under the 2011 Equity Incentive Plan			3,578,696
Total common stock reserved for future issuance			8,808,828

10. Stock Option Plans

The Company adopted the 2006 Stock Plan (the “2006 Plan”) in January 2006. The 2006 Plan provided for the granting of incentive share options, nonqualified share options and restricted shares to Company employees, representatives and consultants. As of September 30, 2017, there were options for an aggregate of 341,854 shares issued and outstanding under the 2006 Plan.

The Company’s board of directors and stockholders adopted the 2011 Equity Incentive Plan (the “2011 Plan”) in October 2011, which, as amended, authorizes the issuance of up to 8,697,451 shares under the 2011 Plan, and provides for an automatic annual increase in the number of shares of common stock reserved for issuance thereunder in the amount of 4% of the shares of common stock outstanding on December 31 of the preceding year. As of September 30, 2017, there were 3,578,696 options available under the 2011 Plan for future grant.

Upon adoption of the 2011 Plan, the Company eliminated the authorization for any unissued shares previously reserved under the Company’s 2006 Plan. The stock awards previously issued under the 2006 Plan remain in effect in accordance with the terms of the 2006 Plan.

The following table summarizes the Company’s 2006 and 2011 Plan stock option activity:

				Weighted		Weighted
				Average		Average		Aggregate
	Number of			Exercise		Contractual		Intrinsic
	Options			Price		Term (in years)		Value ⁽¹⁾
Outstanding - December 31, 2016		3,784,346		$	16.26
Granted		1,921,750			3.08
Exercised		(116,376	)		2.23
Forfeited		(1,074,516	)		13.11
Expired		(394,984	)		16.64
Outstanding - September 30, 2017		4,120,220			11.30		6.90	$	607,444
Exercisable - September 30, 2017		2,634,222			12.30		5.77	$	434,044
Vested and expected to vest at September 30, 2017 ⁽²⁾		4,011,877		$	11.44		6.84	$	591,929

(1)	Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2017 over the weighted-average exercise price.

(2)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

The following table summarizes certain information about all stock options outstanding as of September 30, 2017:

	Options Outstanding				Options Exercisable
Exercise Price	Number of Options		Weighted Average Remaining Contractual Term (in years)		Number of Options		Weighted Average Remaining Contractual Term (in years)
$2.09 - $3.15		1,682,841		7.75		661,739		5.31
$3.95 - $6.63		261,598		5.56		239,202		5.18
$6.64 - $12.38		659,093		5.62		630,839		5.47
$12.79 - $19.25		500,797		5.46		412,062		5.11
$22.77 - $34.49		996,141		7.37		676,629		7.06
$35.29 - $43.43		19,750		7.82		13,751		7.82
		4,120,220				2,634,222

During the three-month periods ended September 30, 2017 and 2016, the Company recorded $1.5 million and $2.5 million in share-based compensation expense, respectively. During the nine-month periods ended September 30, 2017 and 2016, the Company recorded $5.5 million and $7.5 million in share-based compensation expense, respectively. As of September 30, 2017, approximately $5.6 million of total unrecognized compensation cost related to unvested share options is expected to be recognized over a weighted-average period of 2.43 years.

In 2016, the Company began issuing time-vested Restricted Stock Units (RSUs) from the 2011 Plan to certain employees, subject to continuous service with the Company at the vesting time. When vested, the RSU represents the right to be issued the number of shares of the Company’s common stock that is equal to the number of RSUs granted.

A summary of the activity related to the Company’s RSUs is as follows:

	Number of			Weighted
	Restricted			Average
	Stock Units			Grant-Date
	Outstanding			Fair Value
Balance - December 31, 2016		50,000		$	7.70
Granted		1,283,000			3.12
Vested		-			-
Forfeited		(318,000	)		3.09
Expired		-			-
Balance - September 30, 2017		1,015,000			3.35

11. Income Taxes

The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2017 as the Company incurred losses for the nine-month period ended September 30, 2017 and is forecasting additional losses through the fourth quarter, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2017. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740.

Due to the Company’s history of losses since inception, there is not enough evidence at this time and it is not more likely than not that the Company will generate sufficient future income of a nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized.

12. Net Loss Per Share

Basic and diluted net loss per common share was determined by dividing net loss attributable to common shareholders by the weighted average common shares outstanding during the period. The Company’s potentially dilutive shares, which include warrants, common share options and restricted stock units, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Warrants outstanding		94,912		94,912		94,912		94,912
Stock options outstanding		4,199,997		3,605,373		4,576,930		3,517,324
Restricted stock units outstanding		1,082,184		-		1,019,013		-
		5,377,093		3,700,285		5,690,855		3,612,236

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

The unaudited interim financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2016, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2016. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to risks and uncertainties, including those set forth under “Part I. Item 1. Business - Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, and elsewhere in this report, that could cause actual results to differ materially from historical results or anticipated results.

Overview

We are a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases. Our lead product, solithromycin, has completed two Phase 3 clinical trials, for which we submitted new drug applications, or NDAs, for both oral and IV formulations for the treatment of community acquired bacterial pneumonia, or CABP, in April 2016. In December 2016, we received a complete response letter, or CRL, from the U.S. Food and Drug Administration, or FDA, on our NDAs. The CRL stated that the FDA could not approve the NDAs in their present form and noted that additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies were required before the NDAs may be approved. We met with the FDA in February 2017 to discuss the CRL and the FDA reiterated their request for additional clinical safety data prior to approval. Importantly, the FDA has agreed that the efficacy of solithromycin has been established. Based on input from the FDA at the meeting, we have developed and provided to the FDA a protocol that includes safety data from 6,000 CABP patients treated with solithromycin at the time we respond to the CRL. Data from an additional 3,000 CABP patients treated with solithromycin would be provided subsequently including in the post approval period. The study will evaluate oral solithromycin with a 5-day treatment regimen, with the goal of enhancing enrollment efficiency and solithromycin safety. The 5-day course of treatment with oral solithromycin excludes selected concomitant medications. Additional safety data for intravenous solithromycin would need to be provided under a separate study to be discussed with the FDA.

We are seeking non-dilutive funding to support the execution of the study and as noted, would plan to seek an initial approval with our oral formulation of solithromycin. To achieve potential approval, our response to the CRL would also need to address the manufacturing items noted in our CRL. We are working with our manufacturing partners to address these items and believe that the time required to accumulate clinical safety data in an additional 6,000 oral solithromycin patients will be the rate-limiting step in our timeline to respond to the CRL. In March 2017, we announced the withdrawal of our previously filed marketing authorization application seeking European Medicines Agency, or EMA, approval of oral capsule and intravenous formulations of solithromycin for the treatment of CABP in adults.

Enrollment in the Phase 2/3 study of solithromycin in pediatric patients with CABP began in late 2016 and is ongoing. We anticipate submitting a request for a pre-IND meeting with the FDA for ophthalmic solithromycin in 2018.

Our second product, fusidic acid, is an antibiotic that has been used for decades outside the U.S., including in Western Europe, but has never been approved in the U.S. In the first quarter of 2017, we completed a successful Phase 3 study evaluating fusidic acid as an oral treatment of acute bacterial skin and skin structure infections, or ABSSSI, which are frequently caused by methicillin-resistant Staphylococcus aureus, or MRSA. Based on the results of this study, we discussed with the FDA in the second quarter of 2017 the next steps required to bring fusidic acid to patients in the United States. The FDA has agreed that a second Phase 3 study with similar design to the first successfully completed Phase 3 study could support potential approval of fusidic acid in patients with ABSSSI. We are also exploring the potential use of fusidic acid for the long-term oral treatment of refractory bone and joint infections, or BJI, including prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and MRSA. Currently, there is no optimal oral, chronic antibiotic for treating these infections.

Following our engagement of Morgan Stanley to assist us in a process to evaluate and assess external late-stage assets and other potential strategic business opportunities to determine the best use of our cash resources and late stage clinical programs, we announced on August 8, 2017 that we had entered into a definitive agreement under which Melinta Therapeutics will merge with a subsidiary of Cempra. The merger is expected to create a NASDAQ-listed company committed to discovering, developing and commercializing important anti-infective therapies for patients and physicians in areas of significant need. Further details regarding the proposed transaction can be found in our definitive proxy statement on Schedule 14A, which is available at www.cempra.com and is filed with the SEC. Assuming stockholder approval and the satisfaction of all conditions to closing, the merger is anticipated to close in November 2017.

Financial Overview

Revenue

To date, we have not generated revenue from the sale of any products. All of our revenue to date has been derived from (1) a government contract and (2) the receipt of proceeds under our license and supply agreements with Toyama Chemical Co., Ltd., or Toyama, a portion of which has been recognized as revenue in accordance with generally accepted accounting principles in the U.S., or U.S. GAAP.

In May 2013, we entered into an agreement with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, or BARDA, for the evaluation and development of solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens, specifically anthrax and tularemia.

The agreement is a cost plus fixed fee development contract, with a base performance segment valued at approximately $18.7 million with contract modifications, and four option work segments that BARDA may request at its sole discretion pursuant to the agreement. If all four option segments are requested, the cumulative value of the agreement, as amended to date, would be approximately $68.2 million and the estimated period of performance would be until approximately May 2018. Three of the options are cost plus fixed fee arrangements and one option is a cost sharing arrangement without fixed fee, for which we are responsible for a designated portion of the costs associated with that work segment. The period of performance for the base performance segment was May 2013 through February 2016.

BARDA exercised the second option in November 2014. The value of the second option work segment is approximately $16.0 million and the estimated period of performance is November 2014 through September 2018, which was extended in October 2017 at our request to allow more time to deliver the completed work product. This extension will not increase the cost of the work to be performed under the option nor does it change any other terms or provisions of the BARDA contract, including timeframes for other work options.

In February 2016, BARDA exercised the third option work segment of the agreement, which is intended to fund a Phase 2/3 study of intravenous, oral capsule and oral suspension formulations of solithromycin in pediatric patients from two months old to 17 years with community acquired bacterial pneumonia. This option work segment is a cost-sharing arrangement under which BARDA will contribute $25.5 million and we will be responsible for an additional designated portion of the costs associated with the work segment. In September 2016, the contract was modified to increase the third option work segment by $8.0 million for increased manufacturing work related to the development of a second supply source for solithromycin. The amendment raises the value of the third option work segment to approximately $33.5 million. The estimated period of performance of this option work segment runs through May 2018.

Under the agreement, we are reimbursed and recognize revenue as allowable costs are incurred plus a portion of the fixed-fee earned. We consider fixed-fees under cost reimbursable contracts to be earned in proportion to the allowable costs incurred in performance of the work as compared to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Since inception of the agreement through September 30, 2017, we recognized $46.7 million in revenue under this agreement.

In October 2017 we submitted an application to BARDA requesting $50 million of support for the solithromycin safety study requested by the FDA. We anticipate a response from BARDA to our application in the first half of 2018.

In May 2013, Cempra Pharmaceuticals, Inc., our wholly owned subsidiary, entered into a license agreement with Toyama, whereby we licensed to Toyama the exclusive right, with the right to sublicense, to make, use and sell any product in Japan that incorporates solithromycin as its sole active pharmaceutical ingredient, or API, for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues. Toyama also has a nonexclusive license in Japan and certain other countries, with the right to sublicense, to manufacture or have manufactured API for solithromycin for use in manufacturing such products, subject to limitations and obligations of the concurrently executed supply agreement discussed below. Toyama has granted us certain rights to intellectual property generated by Toyama under the license agreement with respect to solithromycin or licensed products for use with such products outside Japan or with other solithromycin-based products inside or outside Japan.

Following execution of the agreement, we received a $10.0 million upfront payment from Toyama. Toyama is also obligated to pay us up to an aggregate of $60.0 million in milestone payments, depending on the achievement of various regulatory, patent, development and commercial milestones. The first of these milestones was achieved in the third quarter of 2014 for which we received a payment of $10.0 million from Toyama. The second $10.0 million milestone was recognized in the first quarter of 2015 based on the Japan Patent Office issuing a Decision of Allowance for our patent covering certain crystal forms of solithromycin in

Japan. We received payment for the second milestone in April 2015. In October 2016, we received the third $10.0 million milestone which was triggered by Toyama’s decision to progress to a Phase 3 trial of solithromycin in Japan following successful completion of a Phase 2 trial. Toyama must also pay us a royalty equal to a low-to-high first double decimal digit percentage of net sales, subject to downward adjustment in certain circumstances. Cumulatively, through September 30, 2017, we have recognized $23.0 million in revenue under this agreement with the remaining $17.0 million received being recorded as deferred revenue. Substantially all of this deferred revenue would be recognized upon FDA approval of solithromycin in the United States and subsequent commercial launch in the United States and one additional country. As part of the license agreement, we also entered into a supply agreement with Toyama, whereby we will be the exclusive supplier (with certain limitations) to Toyama and its sublicensees of API for solithromycin for use in licensed products in Japan, as well as the exclusive supplier to Toyama and its sublicensees of finished forms of solithromycin to be used in its clinical trials in Japan. Pursuant to the supply agreement, Toyama will pay us for such clinical supply of finished product and all supplies of API for solithromycin for any purpose, other than the manufacture of products for commercial sale in Japan, at prices equal to our costs. All API for solithromycin supplied by us to Toyama for use in the manufacture of finished product for commercial sale in Japan will be ordered from us at prices determined by our manufacturing costs, and which may, depending on such costs, equal, exceed, or be less than such costs. Either party may terminate the supply agreement for uncured material breach or insolvency of the other party, with Toyama’s right to terminate for our breach subject to certain further conditions in the case of our failure to supply API for solithromycin or clinical supply, but otherwise the supply agreement will continue until the expiration or termination of the license agreement.

In the future, we anticipate generating revenue from a combination of sales of our products, if approved, through our own sales force in the U.S. for solithromycin, and third parties elsewhere, and license fees, milestone payments and royalties in connection with strategic collaborations regarding any of our product candidates. We expect that any revenue we generate will fluctuate from quarter to quarter. If we or our strategic partners fail to complete the development of solithromycin or fusidic acid in a timely manner or obtain regulatory approval for them, or if we fail to develop our own sales force or find one or more strategic partners for the commercialization of approved products, our ability to generate future revenue, and our financial condition and results of operations would be materially adversely affected.

Research and Development Expenses

Since our inception, we have focused our resources on our research and development activities, including conducting pre-clinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our product candidates. We recognize our research and development expenses as they are incurred. Our research and development expenses consist primarily of:

•

employee-related expenses, which include salaries, benefits and share-based compensation expense;

•

fees paid to consultants and clinical research organizations, or CROs, in connection with our clinical trials, and other related clinical trial costs, such as for investigator grants, patient screening, laboratory work and statistical compilation and analysis;

•

costs related to acquiring and manufacturing clinical trial materials and costs for developing additional manufacturing sources for and the manufacture of pre-approval inventory of solithromycin;

•

costs related to compliance with regulatory requirements;

•

consulting fees paid to third parties related to non-clinical research and development;

•

research supplies; and

•

license, research and milestone payments related to in-licensed technologies.

Our direct research and development expenses consist principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, and related clinical trial fees. Our internal resources, employees and infrastructure are not directly tied to any individual research project and are typically deployed across multiple projects. Through our clinical development programs, we are advancing solithromycin and fusidic acid in parallel primarily for the treatment of CABP (for solithromycin) and ABSSSI and refractory bone and joint infections (for fusidic acid) as well as for other indications. Through our pre-clinical development programs, we are seeking to develop macrolide product candidates for non-antibacterial indications. The following table sets forth costs incurred on a program-specific basis for solithromycin and fusidic acid, excluding personnel-related costs. Macrolide research includes costs for discovery programs. All employee-related expenses for those employees working in research and development functions are included in “Research and development personnel cost” in the table, including salary, bonus, employee benefits and share-based compensation. We do not allocate insurance or other indirect costs related to our research and development function to specific product candidates. Those expenses are included in “Indirect research and development expense” in the table.

	Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017		2016
	(In thousands)					(In thousands)
Direct research and development expense by program:
Solithromycin	$	2,466		$	13,036	$	18,512	$	36,943
Fusidic acid		79			3,829		2,253		9,122
Macrolide research		(55	)		425		56		1,886
Research and development personnel cost		1,857			3,599		7,316		11,885
Total direct research and development expense		4,347			20,889		28,137		59,836
Indirect research and development expense		36			207		201		807
Total research and development expense	$	4,383		$	21,096	$	28,338	$	60,643

The successful development of our clinical and pre-clinical product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or pre-clinical product candidates or the period, if any, in which material net cash inflows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

•

the scope, rate of progress, expense and results of our ongoing, as well as any additional, clinical trials required and other research and development activities;

•

future clinical trial costs and results;

•

the costs and the timing of our regulatory submissions and any regulatory approvals; and

•

changes in regulations governing drug approval, manufacturing, marketing and reimbursement.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

We have completed two pivotal trials for solithromycin in CABP, including one with oral solithromycin and one with IV solithromycin progressing to oral solithromycin. We also are conducting a Phase 2/3 trial for solithromycin in pediatric patients with CABP which is funded by BARDA.

While we are conducting an exploratory study of fusidic acid for long-term suppressive therapy of refractory bone and joint infections, including PJI, we concluded a Phase 3 trial for fusidic acid in ABSSSI in the first quarter of 2017 and we expect our research and development expenses to temporarily trend lower. Following the completion of the proposed merger with Melinta Therapeutics, we expect the combined company will conduct a portfolio review to prioritize our future development efforts and determine related research and development expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs, including share-based compensation, for employees in executive, operational, commercial, finance and human resources functions. Other significant general and administrative expenses include professional fees for accounting, legal, and information technology services, facilities costs, expenses associated with obtaining and maintaining patents, and costs of commercial preparation activities.

Our general and administrative expenses have trended downward during 2017, driven primarily by reductions in personnel and expenses related to commercial preparations. If the proposed transaction with Melinta is approved, we expect general and administrative expenses to increase significantly in the fourth quarter primarily driven by costs related to the transaction.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of

contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments, including those related to accrued expenses and share-based compensation, on an ongoing basis. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Our significant accounting policies are described in more detail in the notes to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 that we filed with the U.S. Securities and Exchange Commission, or SEC, on February 28, 2017. We believe the following accounting policies to be most critical to the judgments and estimates used in preparation of our financial statements and such policies have been reviewed and discussed with our audit committee.

Research and Development Prepaids and Accruals

As part of the process of preparing our financial statements, we are required to estimate our expenses resulting from our obligations under contracts with vendors, consultants and clinical site agreements in connection with our research and development efforts. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts.

Our objective is to reflect the appropriate research and development expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of our research and development efforts. We determine prepaid and accrual estimates through reviewing open contracts and purchase orders, communicating with applicable vendor personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our prepaid and accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. We do not currently anticipate the future settlement of existing accruals to differ materially from our estimates.

Revenue Recognition

Our revenue generally consists of research related revenue under federal contracts, supply revenue and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.

For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the fair value of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, we determine the period over which the performance obligations will be performed and revenue recognized. Management exercises significant judgment in the determination of whether a deliverable has stand-alone value, is considered to be a separate unit of accounting, and in estimating the relative fair value of each deliverable in the arrangement.

Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments we may receive under a license agreement will be recognized when received.

Valuation of Financial Instruments

Share-Based Compensation

In accordance with Accounting Standards Codification, or ASC, Topic 718, Stock Compensation, as modified or supplemented, issued by the Financial Accounting Standard Board, or FASB, we measure compensation cost for share-based payment awards granted to employees and non-employee directors at fair value using the Black-Scholes option-pricing model. We recognize compensation expense on a straight-line basis over the service period for awards expected to vest. Share-based compensation cost related to share-based payment awards granted to non-employees is adjusted each reporting period for changes in the fair value of our shares until the measurement date. The measurement date is generally considered to be the date when all services have been rendered or the date that options are fully vested.

We calculate the fair value of share-based compensation awards using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of subjective assumptions, including share price volatility, the expected life of options, risk-free interest rate and the fair value of the underlying common shares on the date of grant. In developing our assumptions, we take into account the following:

•

we do not have sufficient history to estimate the volatility of our common share price. We calculate expected volatility based on reported data for selected reasonably similar publicly traded companies for which the historical information is available. For the purpose of identifying peer companies, we consider characteristics such as industry, market capitalization, length of trading history, similar vesting terms and in-the-money option status. We plan to continue to use the guideline peer group volatility information until the historical volatility of our common shares is relevant to measure expected volatility for future option grants;

•

we determine the risk-free interest rate by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant;

•

the assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future;

•

we determine the average expected life of options based on the mid-point between the vesting date and the contractual term; and

•

we estimate forfeitures based on our historical analysis of actual option forfeitures.

Results of Operations

The following table summarizes the results of our operations for the three and nine-month periods ended September 30, 2017 and 2016, together with the changes in those items in dollars:

	Three Months Ended September 30,					Dollar			Nine Months Ended September 30,					Dollar
	2017		2016			Change			2017		2016			Change
	(In thousands)								(In thousands)
Revenue
Contract research	$	1,717	$	3,972		$	(2,255	)	$	7,449	$	10,071		$	(2,622	)
Total revenue		1,717		3,972			(2,255	)		7,449		10,071			(2,622	)

Research and development expense (1)		4,383		21,096			(16,713	)		28,338		60,643			(32,305	)
General and administrative expense (1)		7,867		15,021			(7,154	)		21,291		35,333			(14,042	)
Restructuring		-		-			-			3,553		-			3,553
Other income (expense), net		174		(167	)		341			219		(618	)		837

(1) Includes the following share-based compensation expenses:
Research and development expense	$	645	$	627		$	18		$	2,244	$	2,348		$	(104	)
General and administrative expense		860		1,851			(991	)		3,220		5,169			(1,949	)

Comparison of the Three Months Ended September 30, 2017 and September 30, 2016

Contract revenue

For the three months ended September 30, 2017, contract research revenue decreased $2.3 million compared to the three months ended September 30, 2016 due to the completion of the first option period of the BARDA contract in the first quarter of 2017 and

decreased activity in the second option period. We expect contract research revenue to decrease somewhat as activity in the second option period of the BARDA contract continues to wind down.

Research and Development Expense

For the three months ended September 30, 2017, our research and development expense decreased $16.7 million compared to the three months ended September 30, 2016. The decrease is primarily related to the following:

•

a decrease of $4.4 million in purchases of commercial API as we purchased significant amounts of API in the third quarter of 2016 in preparation for the then anticipated commercial launch of solithromycin;

•

a decrease in clinical expenses of $3.7 million due to the wrap-up of the phase 3 fusidic acid study for ABSSSI in the first quarter of 2017;

•

a decrease of $2.6 million in clinical and drug product costs due to significantly fewer ongoing studies for solithromycin as a result of the completion of the phase 3 IV trial and cancellation of COPD and NASH studies;

•

a decrease of employee costs of $1.9 million related to the reduction in headcount effected in the first quarter of 2017 as a result of the delay of our planned commercial launch of solithromycin;

•

a decrease in BARDA related expenses of $1.9 million due to decreased activity in the second option period;

•

a decrease in regulatory expenses of $1.7 million related to NDA expenses incurred during 2016; and

•

a decrease of $0.5 million in expenses related to research for other potential indications of solithromycin.

General and Administrative Expense

General and administrative expense decreased $7.2 million for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. The decrease is primarily related to the following:

•

a decrease in employee costs of $5.7 million due to the reduction in workforce;

•

a decrease in professional services of $5.2 million related to pre-commercialization activities during the third quarter of 2016 that did not continue in the third quarter of 2017; and

•

an increase in professional services of $3.7 million related to the strategic review process and potential transaction with Melinta.

Other Income (Expense), Net

Other income increased by $0.3 million for the three months ended September 30, 2017 compared to the three months ended September 30, 2016 due to a higher rate of return on cash equivalents, as well as a lower interest rate and lower balance on the July 2015 Note.

Comparison of the Nine Months Ended September 30, 2017 and September 30, 2016

Contract revenue

For the nine months ended September 30, 2017, contract research revenue decreased $2.6 million compared to the nine months ended September 30, 2016 due to decreased activity in the second option period of the BARDA contract. We expect contract research revenue for the balance of 2017 to decrease somewhat as activity in the second option period of the BARDA contract winds down and then increase as the 2017-2018 northern hemisphere CABP season begins to drive enrollment in the Phase 2/3 pediatric program.

Research and Development Expense

For the nine months ended September 30, 2017, our research and development expense decreased $32.3 million compared to the nine months ended September 30, 2016. The decrease is primarily related to the following:

•

a decrease in regulatory expenses of $11.7 million primarily related to the NDA expenses incurred during 2016;

•

a decrease of $6.9 million in expenses related to fusidic acid due primarily to the wrap-up of the phase 3 study for ABSSSI in the first quarter of 2017;

•

a decrease of $5.2 million in purchases of commercial API as we purchased significant amounts of API in the third quarter of 2016 in preparation for the then anticipated commercial launch of solithromycin;

•

a decrease of employee costs of $5.0 million related to the reduction in headcount effected in the first quarter of 2017 as a result of the delay of our planned commercial launch of solithromycin;

•

a decrease of $1.8 million in expenses related to research for other potential indications of solithromycin;

•

a decrease of $0.9 million in clinical and drug product costs due to significantly fewer ongoing studies for solithromycin as a result of the completion of the phase 3 IV trial and cancellation of COPD and NASH studies;

•

a decrease in BARDA related expenses of $0.6 million due to decreased activity in the second option period during the second and third quarters of 2017; and

•

a decrease in professional services related expenses of $0.2 million due to the delay of our planned commercial launch of solithromycin.

General and Administrative Expense

General and administrative expense decreased $14.0 million for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The decrease is primarily related to the following:

•

a decrease in professional services of $11.1 million related to pre-commercialization activities during 2016 that did not continue in 2017;

•

a decrease in employee costs of $8.2 million due to the reduction in workforce; and

•

an increase in professional services of $5.3 million related to the strategic review process and potential transaction with Melinta.

Restructuring

In February 2017, as a consequence of the solithromycin complete response letter we received from the FDA, and subsequent discussions with the FDA, resulting in the delay of the potential approval of solithromycin, we initiated companywide cost and personnel reductions. These actions resulted in an approximately 67% reduction in our workforce from 136 to 45 employees, and significant reductions in external spending related to commercial preparedness and non-essential activities. We also vacated two of the leased office suites that were no longer necessary for our operations. As a result of these decisions, we recorded a one-time charge of $3.6 million.

Other Income (Expense), Net

Other income increased by $0.8 million for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 due to a higher rate of return on cash equivalents, as well as a lower interest rate and lower outstanding loan balance on the July 2015 Note.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception through September 30, 2017, we have funded our operations principally with $618.6 million from the sale of debt and equity instruments (common and preferred), $46.7 million of research funding from our BARDA contract, and $40.0 million of licensing and milestone payments. As of September 30, 2017, we had cash and equivalents to fund operations of approximately $176.1 million.

Cash Flows

The following table sets forth the major sources and uses of cash for the periods set forth below:

	Nine Months Ended September 30,
	2017			2016
	(In thousands)
Net cash provided by (used in):
Operating activities	$	(50,678	)	$	(71,252	)
Investing activities		-			(9	)
Financing activities		(4,741	)		166,413
Net increase in cash and equivalents	$	(55,419	)	$	95,152

Operating Activities. Cash used in operating activities of $50.7 million for the nine months ended September 30, 2017 was primarily a result of our $45.5 million net loss and cash used in changes in operating assets and liabilities of $10.7 million, primarily a reduction in accounts payable and accrued expenses, partially offset by non-cash items of $5.5 million. Cash used in operating activities of $71.3 million for the nine months ended September 30, 2016 was primarily a result of our $86.5 million net loss offset by changes in operating assets and liabilities of $7.6 million and non-cash items of $7.6 million.

Investing Activities. Net cash used in investing activities of $0 and $9,000 for the nine months ended September 30, 2017 and 2016, respectively related to the purchases of equipment.

Financing Activities. Net cash used in financing activities of $4.7 million for the nine months ended September 30, 2017 was the result of $5.0 million in payment of long-term debt reduced by $0.3 million in proceeds from the exercise of stock options. Net cash provided by financing activities of $166.4 million for the nine months ended September 30, 2016 consisted of net proceeds of $169.1 million from the issuance of common stock, $0.4 million of proceeds from the exercise of stock options, offset by $2.8 million in payment of long-term debt and $0.3 million of offering costs.

Funding Requirements

To date, we have not generated any product revenue from our clinical stage product candidates or from any other source. We do not know when, or if, we will generate any product revenue. We do not expect to generate product revenue unless and until we obtain marketing approval of and commercialize solithromycin and/or fusidic acid or any of our other product candidates. At the same time, we expect our expenses to increase if we continue the research, development and clinical trials of, and seek regulatory approval and engage in commercial readiness activities for, solithromycin and fusidic acid and our other product candidates. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We will need substantial additional funding in connection with our continuing operations.

Based on current assumptions, we believe that our existing cash and equivalents will enable us to fund our current operating expenses and capital requirements for at least the next 12 months from the filing date of this report. Such operating and capital requirements do not contemplate incremental expenses associated with a full scale commercial launch of solithromycin or any additional clinical trials with any of our product candidates or any funds from future financings or partnerships beyond the Toyama relationship and the BARDA contract. We will need to obtain additional financing for the continued development of solithromycin and fusidic acid and our other product candidates and to support the commercialization of solithromycin and/or any of our other product candidates should any receive regulatory approval. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Due to the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our product candidates.

Our future capital requirements will depend on many factors, including:

•

the scope, progress costs, and results of pre-clinical development, laboratory testing and clinical trials for any of our product candidates including any pre- or post-approval safety studies for solithromycin and any additional clinical trials for fusidic acid;

•

the costs, timing and outcome of regulatory review of our product candidates;

•

the costs and timing of commercialization readiness activities for any of our product candidates, including developing manufacturing sources and building our inventory of commercial product, in anticipation of regulatory approval;

•

the costs and timing of commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive regulatory approval;

•

the costs of commercial and clinical supplies of any of our drug candidates;

•

obtaining milestone payments from Toyama;

•

receipt of payments under the BARDA contract;

•

our ability to establish collaborations on favorable terms;

•

the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;

•

the acceptance in the medical community of any of our product candidates for which we receive approval;

•

revenue, if any, and the timing of the related payment, from the sale of our product candidates, should any receive regulatory approval;

•

obtaining a commercially viable price for any of our product candidates, should any receive regulatory approval;

•

the availability of adequate coverage and reimbursement from federal, state and private healthcare payors for any of our product candidates, should any receive regulatory approval;

•

reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of any of our product candidates, should any receive regulatory approval;

•

our ability to enter into any license agreements for the distribution of our product candidates outside the U.S.;

•

the extent to which we acquire or invest in businesses, products and technologies; and

•

our ability to obtain government or other third-party funding.

Until we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. We do not anticipate any substantial product revenue for the foreseeable future. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interests will be diluted, and the terms of any securities may include liquidation or other preferences that adversely affect our stockholders’ rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or declaring dividends, such as those imposed under the Comerica loan. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.

We will need additional financing to continue development activities to obtain regulatory approval of and to commercialize solithromycin, fusidic acid and our other product candidates. We plan, as noted, to seek partners as well as equity or debt financings or other sources of third-party funding, including government grants to support the continued development and commercialization of solithromycin, fusidic acid and our other product candidates. If we are unable to raise additional funds when needed, whether on favorable terms or not, we may be required to delay, limit, reduce or terminate our development of our product candidates, or our commercialization efforts, or to grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Contractual Obligations and Commitments

We enter into contracts in the normal course of business with clinical research organizations for clinical trials and clinical supply manufacturing and with vendors for pre-clinical research studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and therefore we believe that our non-cancelable obligations under these agreements are not material.

During the nine months ended September 30, 2017, there have been no material changes to our contractual obligations and commitments outside the ordinary course of business from those specified in our 2016 Annual Report on Form 10-K.

Off-Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC rules.

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for us for the year ending December 31, 2018. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies an entity’s identification of its performance obligations in a contract. The update also clarifies the guidance regarding an entity’s

evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends the guidance in the new revenue standard on collectability, non-cash consideration, presentation of sales tax, and transition. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers which increases shareholders’ awareness of the proposals and expedites improvements to Update 2014-09. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which allows certain public business entities to elect to use the non-public business entities effective dates to adopt new standards on revenue (ASC 606) and leases (ASC 842). The amendments are intended to address implementation issues that were raised by stakeholders and provide additional practical expedients to reduce the cost and complexity of applying the new revenue standard. These pronouncements have the same effective date as the new revenue standard.

We have evaluated the contract research agreement with BARDA, and do not anticipate a material impact on our consolidated financial statements. We are currently evaluating the license agreement with Toyama to determine the impact that the implementation of this standard will have on our consolidated financial statements, if any. We plan to use the full retrospective method of adoption effective January 1, 2018.

In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. We are currently evaluating the impact that the implementation of this standard will have on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We adopted this guidance as of January 1, 2017. As of December 31, 2016, we had accumulated excess tax benefits from temporary differences in the amount and timing of stock compensation expense and deductions on our income tax return from the award compensation that reduces the net operating loss deferred tax asset. We provided a full valuation allowance against our net deferred tax assets since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Upon implementation of this standard, the stock compensation excess tax benefit will be eliminated, resulting in an increase to the net operating loss deferred tax asset, with an increase in the valuation allowance of the same. The implementation of this standard has no impact on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. This new guidance is effective for fiscal years beginning after December 15, 2017. We are currently evaluating the impact that the implementation of this standard will have on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business which revises the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This new guidance is effective for fiscal years beginning after December 15, 2017. We are currently evaluating the impact that the implementation of this standard will have on our consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation. This new guidance provides clarity and reduces both diversity and complexity to the terms or conditions of a share-based payment award. This new guidance is effective for fiscal years beginning after December 15, 2017. We are currently evaluating the impact that the implementation of this standard will have on our consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have not been any material changes to our exposure to market risk during the quarter ended September 30, 2017. For additional information regarding market risk, refer to “Item 7A. Quantitative and Qualitative Disclosure About Market Risk” of our 2016 Annual Report on Form 10-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act), are designed only to provide reasonable assurance that information to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Acting Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), of the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, our Acting Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report to provide the reasonable assurance discussed above.

Changes in Internal Control over Financial Reporting

No change to our internal control over financial reporting occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, as amended by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, except the additional risks as set forth below.

Risks Related to the Proposed Merger with Melinta Therapeutics, Inc.

We might not be able to successfully integrate our operations with those of Melinta Therapeutics, Inc. and might not realize some or all of the anticipated benefits from the proposed merger with Melinta Therapeutics, Inc.

We expect to complete the proposed merger with Melinta Therapeutics, Inc., or Melinta, in November 2017, whereby Melinta will become our wholly owned subsidiary. Our integration of the operations and personnel of Melinta may require significant efforts, including significant amounts of management’s time, and result in additional expenses. Factors that will affect the success of the merger include the strength of our combined product pipelines, our ability to execute our business strategy, our ability to adequately fund research and development and retain key employees, and results of clinical trials, regulatory approvals and reimbursement levels of any approved product, including Melinta’s FDA-approved product, Baxdela. Our failure to successfully manage the Melinta merger could have a material adverse impact on our business. In addition, we cannot be certain that Melinta’s technology will be successfully developed or, if approved as is the case with Baxdela, become profitable or remain so.

The success of the merger with Melinita also will be dependent on our new management team, including the planned hiring of a new Chief Executive Officer, which will be determined after the merger. Consequently, the new management team will not have worked together before. In addition, we may continue to expand our management team in the future. Our future performance will depend, in part, on our ability to successfully assemble and integrate our management team and their ability to develop and maintain an effective working relationship. Our failure to integrate the management team could result in inefficiencies in the development and commercialization of Baxdela as well as our product candidates, thereby harming sales of Baxdela and our other product candidates, future regulatory approvals, and our results of operations.

Moreover, we have not determined where our company will have its headquarters and the relocation of any member of our management team to our headquarters location, or working outside of our headquarters location, if allowed, may make the integration of our management team and our other employees more challenging. In addition, we could have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.

If the proposed merger with Melinta is not consummated, our business could suffer materially and our stock price could decline.

The consummation of the proposed merger with Melinta is subject to a number of closing conditions, including the approval of the stock issuance pursuant to the merger agreement by our stockholders and other customary closing conditions. We anticipate that the merger will close in November 2017.

If the proposed merger is not consummated, we may be subject to a number of material risks, and our business and stock price could be adversely affected, as follows:

•

We have incurred and expect to continue to incur significant expenses related to the proposed merger with Melinta even if the merger is not consummated.

•

The merger agreement contains covenants relating to our solicitation of competing acquisition proposals and the conduct of our business between the date of signing the merger agreement and the closing of the merger. As a result, significant business decisions and transactions before the closing of the merger require the consent of Melinta. Accordingly, we may be unable to pursue business opportunities that would otherwise be in our best interest as a standalone company. If the merger agreement is terminated after we have invested significant time and resources in the transaction process, we will have a limited ability to launch any approved product candidates without obtaining additional financing to fund our operations.

•

We could be obligated to pay Melinta a $7.9 million termination fee in connection with the termination of the merger agreement, depending on the reason for the termination. Additionally, if our stockholders do not approve the issuance of shares in the merger or the amendments to our certificate of incorporation required under the merger agreement, and either party thereafter terminates the merger agreement, we will be obligated to pay up to $2.0 million of out-of-pocket costs incurred by Melinta in connection with the transactions (and any termination fee subsequently payable by us would be reduced by the amount of any such expense reimbursement).

•

Our prospective customers, collaborators and other business partners and investors in general may view the failure to consummate the merger as a poor reflection on our business or prospects.

•

The market price of our common stock may decline to the extent that the current market price reflects a market assumption that the proposed merger will be completed.

In addition, if the merger agreement is terminated and our board of directors determines to seek another business combination, it may not be able to find a third party willing to provide equivalent or more attractive consideration than the consideration to be provided by each party in the merger. In such circumstances, our board of directors may elect to, among other things, divest all or a portion of our business, or take the steps necessary to liquidate all of our business and assets, and in either such case, the consideration that we receive may be less attractive than the consideration to be received by us pursuant to the merger agreement.

The announcement and pendency of the proposed merger with Melinta could adversely affect our business.

The announcement and pendency of the proposed merger could adversely affect our business for a number of different reasons, many of which are not within our control, including as follows:

•

Some of our suppliers, distributors, collaborators and other business partners may seek to change or terminate their relationships with us as a result of the proposed merger;

•

As a result of the proposed merger, current and prospective employees could experience uncertainty about their future roles within the combined company. This uncertainty may adversely affect our ability to retain our key employees, who may seek other employment opportunities; and

•

Our management team may be distracted from day-to-day operations as a result of the proposed merger.

The merger may be completed even though material adverse changes may result from the announcement of the merger, industry-wide changes and other causes.

In general, either party can refuse to complete the merger if there is a material adverse change affecting the other party between August 8, 2017, the date of the merger agreement, and the closing. However, some types of changes do not permit either party to refuse to complete the merger, even if such changes would have a material adverse effect on us or Melinta, to the extent they resulted from the following (unless, in some cases, they have a materially disproportionate effect on us or Melinta, as the case may be):

•

changes in general economic, business, financial or market conditions;

•

changes or events affecting the industries or industry sectors in which the parties operate generally;

•

changes in generally accepted accounting principles;

•

changes in laws, rules, regulations, decrees, rulings, ordinances, codes or requirements issued, enacted, adopted or otherwise put into effect by or under the authority of any governmental body;

•

changes caused by any action taken with the other party’s prior written consent or any action expressly required by the merger agreement;

•

changes caused by any act of war, terrorism, national or international calamity or any other similar event;

•

changes caused by the announcement or pendency of the merger;

•

with respect to us, changes caused by any decision or action, or inaction, by the FDA or other comparable foreign governmental body, with respect to solithromycin, fusidic acid or any product of any competitor of ours or of any third-party company developing anti-infective products;

•

with respect to us, changes caused by any scientific, treatment or clinical trial results relating to solithromycin, fusidic acid or any product of any competitor of ours or of any third-party company developing anti-infective products; or

•

with respect to us, a decline in our stock price.

If adverse changes occur but we and Melinta must still complete the merger, the combined company’s stock price may suffer.

During the pendency of the merger, we may not be able to enter into a business combination with another party because of restrictions in the merger agreement.

Covenants in the merger agreement impede the ability of us or Melinta to make acquisitions or complete other transactions that are not in the ordinary course of business pending completion of the merger. As a result, if the merger is not completed, the parties may be at a disadvantage to their competitors. In addition, while the merger agreement is in effect and subject to limited exceptions, each party is prohibited from soliciting, initiating, encouraging or taking actions designed to facilitate any inquiries or the making of any proposal or offer that could lead to the entering into certain extraordinary transactions with any third party, such as a sale of assets, an acquisition of our common stock, a tender offer for our common stock or a merger or other business combination outside the ordinary course of business, which transactions could be favorable to such party’s stockholders.

The market price of the combined company’s common stock may decline as a result of the merger.

The market price of the combined company’s common stock may decline as a result of the merger for a number of reasons including if:

•

the combined company does not achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry analysts;

•

the effect of the merger on the combined company’s business and prospects is not consistent with the expectations of financial or industry analysts; or

•

investors react negatively to the effect on the combined company’s business and prospects from the merger.

Our common stock could be delisted from the NASDAQ Global Market if we do not comply with its initial listing standards at the time of the merger.

Pursuant to the NASDAQ Listing Rules, consummation of the merger requires the combined company to submit an initial listing application and, at the time of the merger, meet all of the criteria applicable to a company initially requesting listing (including a $4.00 per share minimum bid price for our common stock). We intend to apply for listing on the NASDAQ Global Market and are seeking stockholder approval of a reverse stock split in order to satisfy the initial listing criteria. While we intend to obtain listing status for the combined company and maintain the same, no guarantees can be made about our ability to do so. In the event the merger is approved by our stockholders but the reverse stock split is not, the merger could still be consummated and shares of our common stock would not be listed on a national securities exchange.

If our common stock is unable to be listed on NASDAQ or another national securities exchange, the common stock may be eligible to trade on the OTC Bulletin Board or another over-the-counter market. Any such alternative would likely result in it being more difficult for the combined company to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, the common stock. In addition, there can be no assurance that the common stock would be eligible for trading on any such alternative exchange or markets.

Item 6. Exhibits

Exhibit

Number

Description of Document

Registrant’s

Form

Filed

Exhibit

Number

Filed

Herewith

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

Financials in XBRL format.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CEMPRA, INC.

Dated: November 2, 2017	By:	/s/ David S. Zaccardelli, Pharm.D.
	David S. Zaccardelli, Pharm.D.
	Acting Chief Executive Officer

Dated: November 2, 2017	By:	/s/ Mark W. Hahn
	Mark W. Hahn
	Chief Financial Officer

EX-31.1 2 cemp-ex311_6.htm EX-31.1 cemp-ex311_6.htm

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David S. Zaccardelli, Pharm.D., certify that:

(1)

I have reviewed this quarterly report on Form 10-Q of Cempra, Inc.;

(2)

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in the report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 2, 2017

/s/ David S. Zaccardelli

David S. Zaccardelli, Pharm.D.

Acting Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 cemp-ex312_7.htm EX-31.2 cemp-ex312_7.htm

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark W. Hahn, certify that:

(1)

I have reviewed this quarterly report on Form 10-Q of Cempra, Inc.;

(2)

(3)

(4)

(a)

(b)

(c)

(d)

(5)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 2, 2017

/s/ Mark W. Hahn

Mark W. Hahn

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 cemp-ex321_8.htm EX-32.1 cemp-ex321_8.htm

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Cempra, Inc. (the “Company”) for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David S. Zaccardelli, Pharm.D., Acting Chief Executive Officer (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 2, 2017

/s/ David S. Zaccardelli

David S. Zaccardelli, Pharm.D.

Acting Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 cemp-ex322_9.htm EX-32.2 cemp-ex322_9.htm

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Cempra, Inc. (the “Company”) for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark W. Hahn, Chief Financial Officer (Principal Financial Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 2, 2017

/s/ Mark W. Hahn

Mark W. Hahn

Chief Financial Officer (Principal Financial Officer)

EX-101.INS 6 cemp-20170930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure cemp:Product cemp:Segment cemp:Deliverables cemp:Lawsuit 0001461993 2017-01-01 2017-09-30 0001461993 2017-10-27 0001461993 2017-09-30 0001461993 2016-12-31 0001461993 2017-07-01 2017-09-30 0001461993 2016-07-01 2016-09-30 0001461993 2016-01-01 2016-09-30 0001461993 2015-12-31 0001461993 2016-09-30 0001461993 cemp:MelintaTherapeuticsMember 2017-08-31 0001461993 cemp:MelintaTherapeuticsMember 2017-08-01 2017-08-31 0001461993 us-gaap:MaximumMember 2017-08-01 2017-08-31 0001461993 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001461993 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-09-30 0001461993 cemp:TermLoanFacilityMember 2017-09-30 0001461993 cemp:OptimerPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2017-01-01 2017-09-30 0001461993 cemp:OptimerPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2010-07-01 2010-07-31 0001461993 cemp:OptimerPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2012-07-01 2012-07-31 0001461993 cemp:OptimerPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2017-09-30 0001461993 cemp:ScrippsResearchInstituteMember 2012-04-01 2012-06-30 0001461993 cemp:ScrippsResearchInstituteMember 2017-01-01 2017-09-30 0001461993 cemp:ScrippsResearchInstituteMember cemp:FirstThreeYearsMember 2017-01-01 2017-09-30 0001461993 cemp:ScrippsResearchInstituteMember cemp:FourthThroughSixYearsMember 2017-01-01 2017-09-30 0001461993 cemp:ScrippsResearchInstituteMember 2014-12-01 2014-12-31 0001461993 cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2017-09-30 0001461993 cemp:SecondOptionWorkMember cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2017-09-30 0001461993 cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2017-01-01 2017-09-30 0001461993 cemp:SecondOptionWorkMember cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2017-01-01 2017-09-30 0001461993 cemp:SecondOptionWorkMember cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember us-gaap:SubsequentEventMember 2017-10-01 2017-10-31 0001461993 cemp:ThirdOptionWorkMember cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2016-02-29 0001461993 cemp:ThirdOptionWorkMember cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2017-09-30 0001461993 cemp:ThirdOptionWorkMember cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2016-09-01 2016-09-30 0001461993 cemp:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2013-05-01 2017-09-30 0001461993 cemp:ToyamaChemicalMember 2013-05-31 0001461993 cemp:ToyamaChemicalMember 2014-08-30 2014-08-31 0001461993 cemp:ToyamaChemicalMember 2016-10-01 2016-10-31 0001461993 cemp:ToyamaChemicalMember 2015-03-01 2015-03-31 0001461993 cemp:ToyamaChemicalMember 2013-05-01 2017-09-30 0001461993 cemp:ToyamaChemicalMember 2017-01-01 2017-09-30 0001461993 cemp:ToyamaChemicalMember 2013-05-30 2013-05-31 0001461993 cemp:ToyamaChemicalMember 2016-10-31 2016-10-31 0001461993 cemp:ToyamaChemicalMember 2017-09-30 0001461993 cemp:FUJIFILMFinechemicalsCompanyLimitedMember 2017-01-01 2017-09-30 0001461993 cemp:MacrolidePharmaceuticalsIncMember cemp:OptionAndLicenseAgreementMember 2017-01-01 2017-09-30 0001461993 cemp:MacrolidePharmaceuticalsIncMember cemp:OptionAndLicenseAgreementMember 2016-01-28 2016-01-29 0001461993 cemp:MacrolidePharmaceuticalsIncMember cemp:SettlementAgreementMember 2017-06-01 2017-06-30 0001461993 cemp:LoanAndSecurityAgreementMember cemp:TermLoanFacilityMember 2015-07-31 0001461993 cemp:LoanAndSecurityAgreementMember us-gaap:RevolvingCreditFacilityMember 2015-07-31 0001461993 cemp:TermLoanFacilityMember cemp:LoanAndSecurityAgreementMember 2015-07-01 2015-07-31 0001461993 cemp:TermLoanFacilityMember cemp:LoanAndSecurityAgreementMember 2017-01-01 2017-09-30 0001461993 us-gaap:LondonInterbankOfferedRateLIBORMember cemp:TermLoanFacilityMember cemp:LoanAndSecurityAgreementMember 2015-07-01 2015-07-31 0001461993 us-gaap:RevolvingCreditFacilityMember cemp:LoanAndSecurityAgreementMember 2015-07-01 2015-07-31 0001461993 us-gaap:RevolvingCreditFacilityMember cemp:LoanAndSecurityAgreementMember 2017-01-01 2017-09-30 0001461993 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember cemp:LoanAndSecurityAgreementMember 2015-07-01 2015-07-31 0001461993 cemp:LoanAndSecurityAgreementMember 2015-07-31 0001461993 cemp:SecuritiesClassActionMember 2017-01-01 2017-09-30 0001461993 cemp:SecuritiesClassActionMember 2017-07-06 2017-07-06 0001461993 cemp:ShareholderDerivativeActionMember 2017-01-01 2017-09-30 0001461993 cemp:ShareholderDerivativeActionMember us-gaap:PendingLitigationMember 2017-01-01 2017-09-30 0001461993 cemp:LegalProceedingsCaseFourMember 2017-01-01 2017-09-30 0001461993 cemp:LegalProceedingsCaseFiveMember 2017-01-01 2017-09-30 0001461993 cemp:LegalProceedingsCaseSixMember 2017-01-01 2017-09-30 0001461993 us-gaap:CommonStockMember 2016-01-01 2016-01-31 0001461993 us-gaap:CommonStockMember 2016-01-31 0001461993 cemp:AtTheMarketSalesAgreementMember cemp:CowenAndCompanyLimitedLiabilityCompanyMember 2016-05-31 0001461993 us-gaap:CommonStockMember 2016-05-01 2016-07-31 0001461993 us-gaap:CommonStockMember 2016-07-01 2017-06-30 0001461993 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001461993 us-gaap:WarrantMember 2017-09-30 0001461993 us-gaap:EmployeeStockOptionMember 2017-09-30 0001461993 us-gaap:RestrictedStockUnitsRSUMember 2017-09-30 0001461993 cemp:TwoThousandElevenPlanMember cemp:OptionsAvailableForFutureGrantsMember 2017-09-30 0001461993 cemp:TwoThousandSixPlanMember 2017-09-30 0001461993 cemp:TwoThousandElevenPlanMember 2011-10-31 0001461993 cemp:TwoThousandElevenPlanMember 2017-09-30 0001461993 cemp:TwoThousandElevenPlanMember 2017-01-01 2017-09-30 0001461993 cemp:ExercisePriceOneMember 2017-01-01 2017-09-30 0001461993 cemp:ExercisePriceTwoMember 2017-01-01 2017-09-30 0001461993 cemp:ExercisePriceThreeMember 2017-01-01 2017-09-30 0001461993 cemp:ExercisePriceFourMember 2017-01-01 2017-09-30 0001461993 cemp:ExercisePriceFiveMember 2017-01-01 2017-09-30 0001461993 cemp:ExercisePriceSixMember 2017-01-01 2017-09-30 0001461993 cemp:ExercisePriceOneMember 2017-09-30 0001461993 cemp:ExercisePriceTwoMember 2017-09-30 0001461993 cemp:ExercisePriceThreeMember 2017-09-30 0001461993 cemp:ExercisePriceFourMember 2017-09-30 0001461993 cemp:ExercisePriceFiveMember 2017-09-30 0001461993 cemp:ExercisePriceSixMember 2017-09-30 0001461993 us-gaap:RestrictedStockUnitsRSUMember cemp:TwoThousandElevenPlanMember 2016-12-31 0001461993 us-gaap:RestrictedStockUnitsRSUMember cemp:TwoThousandElevenPlanMember 2017-01-01 2017-09-30 0001461993 us-gaap:RestrictedStockUnitsRSUMember cemp:TwoThousandElevenPlanMember 2017-09-30 0001461993 us-gaap:ScenarioForecastMember 2017-01-01 2017-12-31 0001461993 cemp:USFederalStateIncomeTaxMember 2017-01-01 2017-09-30 0001461993 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001461993 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001461993 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001461993 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001461993 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001461993 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001461993 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001461993 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001461993 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-09-30 0001461993 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 10-Q false 2017-09-30 2017 Q3 CEMP CEMPRA, INC. 0001461993 --12-31 Large Accelerated Filer 52512385

176134000

231553000

2803000

6162000

833000

579000

179770000

238294000

27000

48000

83000

173000

179880000

238515000

6665000

15657000

1036000

2929000

1286000

4267000

6667000

15654000

29520000

16987000

3682000

8660000

36323000

55167000

53000

52000

626001000

620279000

-482497000

-436983000

143557000

183348000

179880000

238515000

0.001

5000000

0.001

80000000

52509281

52392905

52509281

52392905

1717000

3972000

7449000

10071000

1717000

3972000

7449000

10071000

4383000

21096000

28338000

60643000

7867000

15021000

21291000

35333000

3553000

12250000

36117000

53182000

95976000

-10533000

-32145000

-45733000

-85905000

382000

128000

896000

330000

208000

295000

677000

948000

174000

-167000

219000

-618000

-10359000

-32312000

-45514000

-86523000

-0.20

-0.62

-0.87

-1.74

52508598

52072536

52470568

49616785

21000

40000

5464000

7518000

22000

44000

-3359000

-3108000

254000

219000

-90000

73000

-8992000

2896000

-1893000

615000

-2981000

1342000

-50678000

-71252000

9000

-9000

5000000

2779000

259000

364000

169112000

284000

-4741000

166413000

-55419000

95152000

153765000

248917000

673000

916000

<div> 1. Description of Business Cempra, Inc. (the “Company” or “Cempra”) is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. Cempra is located in Chapel Hill, North Carolina, and is a pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases. The Company expects to continue to incur losses and require additional financial resources to advance its products to either commercial stage or liquidity events.  There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. In August 2017, the Company entered into an Agreement and Plan of Merger and Reorganization (“Merger Agreement”), with Melinta Therapeutics Inc. (“Melinta”). Under the terms of the Merger Agreement, shares of Melinta stock will be exchanged for Company shares whereby the current shareholders of Melinta will own approximately 52% of the Company’s stock after completion of the merger.  The exchange ratio is subject to adjustment based upon the following; (1) the Company’s net cash balance at the closing of the transaction, (2) incremental debt incurred by Melinta before the close of the transaction, and (3) amount of transaction-related expenses incurred by Melinta. Consummation of the transaction is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company of the transactions contemplated by the Merger Agreement and related matters. The Merger Agreement contains certain termination rights for both the Company and Melinta, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Melinta a termination fee of $7.9 million and/or to reimburse certain expenses incurred by Melinta in an amount up to $2.0 million. The Company is expected to change its name to Melinta Therapeutics, Inc. and trade under the ticker symbol MLNT after the merger closes.  </div>

<div> 5. Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with BARDA. At September 30, 2017, the Company’s receivables consisted primarily of earned but unbilled receivables under the BARDA agreement.</div>

<div> 9. Shareholders’ Equity Common Stock During January 2016, the Company completed a public offering of 4,166,667 shares of common stock, at a price of $24.00 per share, resulting in net proceeds to the Company of approximately $93.8 million after deducting underwriting discounts and expenses of approximately $6.2 million. In May 2016, the Company entered into an at-the-market (“ATM”) sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company may, at its discretion, from time to time sell shares of its common stock, with a sales value of up to $150.0 million. The Company has provided Cowen with customary indemnification rights, and Cowen is entitled to a commission at a fixed commission rate of 3.0% of the gross proceeds per share sold.  Sales of the shares under the Sales Agreement are to be made in transactions deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended. The Company began the sale of ATM shares in May 2016 and through July 2016 the Company sold 4,140,307 shares of common stock under the Sales Agreement resulting in net proceeds of $75.1 million after deducting commissions and expenses of $2.3 million. The Company has not sold any shares under the ATM since July 2016. During the first nine months of 2017, the Company issued 116,376 shares of common stock at a weighted average exercise price of $2.23 per share upon the exercise of option grants. The following table presents common stock reserved for future issuance for the following equity instruments as of September 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,912</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120,220</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015,000</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available for future grants under the 2011 Equity Incentive Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,578,696</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock reserved for future issuance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,808,828</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> 10. Stock Option Plans The Company adopted the 2006 Stock Plan (the “2006 Plan”) in January 2006. The 2006 Plan provided for the granting of incentive share options, nonqualified share options and restricted shares to Company employees, representatives and consultants. As of September 30, 2017, there were options for an aggregate of 341,854 shares issued and outstanding under the 2006 Plan. The Company’s board of directors and stockholders adopted the 2011 Equity Incentive Plan (the “2011 Plan”) in October 2011, which, as amended, authorizes the issuance of up to 8,697,451 shares under the 2011 Plan, and provides for an automatic annual increase in the number of shares of common stock reserved for issuance thereunder in the amount of 4% of the shares of common stock outstanding on December 31 of the preceding year. As of September 30, 2017, there were 3,578,696 options available under the 2011 Plan for future grant. Upon adoption of the 2011 Plan, the Company eliminated the authorization for any unissued shares previously reserved under the Company’s 2006 Plan. The stock awards previously issued under the 2006 Plan remain in effect in accordance with the terms of the 2006 Plan. The following table summarizes the Company’s 2006 and 2011 Plan stock option activity:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding - December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,784,346</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.26</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,921,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.08</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116,376</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,074,516</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(394,984</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.64</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding - September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120,220</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.30</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607,444</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable - September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,634,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434,044</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at September 30, 2017 (2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,011,877</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.44</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591,929</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (1)</td> <td valign="top"> Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2017 over the weighted-average exercise price. </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (2)</td> <td valign="top"> The number of stock options expected to vest takes into account an estimate of expected forfeitures. </td></tr></table></div> The following table summarizes certain information about all stock options outstanding as of September 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.09 - $3.15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,682,841</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661,739</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.31</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.95 - $6.63</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,598</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239,202</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.18</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.64 - $12.38</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630,839</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12.79 - $19.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500,797</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412,062</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.77 - $34.49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996,141</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676,629</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.06</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$35.29 - $43.43</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,751</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120,220</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,634,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   During the three-month periods ended September 30, 2017 and 2016, the Company recorded $1.5 million and $2.5 million in share-based compensation expense, respectively.  During the nine-month periods ended September 30, 2017 and 2016, the Company recorded $5.5 million and $7.5 million in share-based compensation expense, respectively.  As of September 30, 2017, approximately $5.6 million of total unrecognized compensation cost related to unvested share options is expected to be recognized over a weighted-average period of 2.43 years. In 2016, the Company began issuing time-vested Restricted Stock Units (RSUs) from the 2011 Plan to certain employees, subject to continuous service with the Company at the vesting time. When vested, the RSU represents the right to be issued the number of shares of the Company’s common stock that is equal to the number of RSUs granted. A summary of the activity related to the Company’s RSUs is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant-Date</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance - December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.70</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,283,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(318,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance - September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.35</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   </div>

<div> Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. </div>

<div> Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers.  This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP.  The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance.  This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018.  In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations.  In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies an entity’s identification of its performance obligations in a contract.  The update also clarifies the guidance regarding an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time.  In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends the guidance in the new revenue standard on collectability, non-cash consideration, presentation of sales tax, and transition. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers which increases shareholders’ awareness of the proposals and expedites improvements to Update 2014-09. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which allows certain public business entities to elect to use the non-public business entities effective dates to adopt new standards on revenue (ASC 606) and leases (ASC 842). The amendments are intended to address implementation issues that were raised by stakeholders and provide additional practical expedients to reduce the cost and complexity of applying the new revenue standard.  These pronouncements have the same effective date as the new revenue standard.   The Company has evaluated the contract research agreement with BARDA, and does not anticipate a material impact on the financial statements. The Company is currently evaluating the license agreement with Toyama to determine the impact that the implementation of this standard will have on the financial statements, if any. The Company plans to use the full retrospective method of adoption effective January 1, 2018. In February 2016, the FASB issued ASU 2016-02, Leases.  The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.  This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.  The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation.  The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance as of January 1, 2017.  As of December 31, 2016, the Company has accumulated excess tax benefits from temporary differences in the amount and timing of stock compensation expense and the Company’s deductions on its income tax return from the award compensation that reduces the net operating loss deferred tax asset.  The Company provided a full valuation allowance against its net deferred tax assets since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Upon implementation of this standard, the stock compensation excess tax benefit will be eliminated, resulting in an increase to the net operating loss deferred tax asset, with an increase in the valuation allowance of the same.  The implementation of this standard has no impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.  ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows.  This new guidance is effective for fiscal years beginning after December 15, 2017.  The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business which revises the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses.  This new guidance is effective for fiscal years beginning after December 15, 2017.  The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.   In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation.  This new guidance provides clarity and reduces both diversity and complexity to the terms or conditions of a share-based payment award. This new guidance is effective for fiscal years beginning after December 15, 2017.  The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.  </div>

<div> Accrued expenses are comprised of the following as of (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued severance</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">731</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,999</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Franchise tax</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,929</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table presents common stock reserved for future issuance for the following equity instruments as of September 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,912</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120,220</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015,000</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available for future grants under the 2011 Equity Incentive Plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,578,696</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock reserved for future issuance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,808,828</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table summarizes the Company’s 2006 and 2011 Plan stock option activity:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding - December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,784,346</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.26</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,921,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.08</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116,376</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,074,516</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(394,984</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.64</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding - September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120,220</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.30</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607,444</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable - September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,634,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434,044</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at September 30, 2017 (2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,011,877</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.44</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591,929</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (1)</td> <td valign="top"> Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2017 over the weighted-average exercise price. </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (2)</td> <td valign="top"> The number of stock options expected to vest takes into account an estimate of expected forfeitures. </td></tr></table></div></div>

<div> The following table summarizes certain information about all stock options outstanding as of September 30, 2017:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.09 - $3.15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,682,841</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661,739</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.31</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.95 - $6.63</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,598</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239,202</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.18</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.64 - $12.38</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659,093</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">630,839</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12.79 - $19.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500,797</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412,062</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.77 - $34.49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996,141</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676,629</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.06</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$35.29 - $43.43</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,750</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,751</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120,220</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,634,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,912</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,912</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,912</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,912</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,199,997</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,605,373</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,576,930</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,517,324</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,082,184</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,019,013</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,377,093</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,700,285</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,690,855</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612,236</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

0.52

7900000

2000000

228500000

173000000

10300000

125646 200000 500000 1000000 9500000 27500000 4 The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products.

400000

Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances.

50000

85000

1100000 200000 18700000 16000000 4 68200000 3 1 2018-05 2013-05 2014-11 2016-02 2018-09 2017-10 25500000 33500000 8000000

46700000

10000000

60000000 10000000 10000000

10000000

6100000

4300000

17000000

2016-01-31 2013-05-31 For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin.

2025-12-31

The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program. 400000 400000 200000 731000 1999000

98000

570000

81000

85000

61000

80000

41000

24000

50000

145000

20000000

10000000

0.75 0.80 25000000 2016-04-30 P36M

30 Day LIBOR

2016-05-01

0.052

2017-12-31

30 Day LIBOR

0.042

0.0025

15000000 2016-11-04

United States District Court for the Middle District of North Carolina, Durham Division

officers

between May 1, 2016 and November 1, 2016

The plaintiff seeks to represent a class comprised of purchasers of the Company’s common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court

November 22, 2016 and December 30, 2016

Two substantially similar lawsuits were filed in the United States District Court, Middle District of North Carolina on November 22, 2016 and December 30, 2016, respectively, seeking to assert claims on behalf of all purchasers of the Company's common stock from July 7, 2015 through December 29, 2016, inclusive. 3 2016-12-21

North Carolina Durham County Superior Court

officers and directors

February 16, 2017

2 2017-08-03

Court of Chancery of the State of Delaware

officers and directors

October 23, 2017

2017-09-15

United State District Court for the Middle District of North Carolina, Durham Division

officers and directors

September 27, 2017

United States District Court for the Middle District of North Carolina

October 6, 2017

United States District Court for the Middle District of North Carolina

4166667

24.00

93800000 6200000

150000000

0.030

4140307

75100000

2300000

116376

2.23

94912

4120220

1015000

3578696

8808828

341854

8697451

3578696

0.04

3784346

1921750

116376

1074516

394984

4120220

2634222

4011877

16.26

3.08

2.23

13.11

16.64

11.30

12.30

11.44

P6Y10M24D

P5Y9M7D

P6Y10M2D

607444

434044

591929

2.09

3.95

6.64

12.79

22.77

35.29

3.15

6.63

12.38

19.25

34.49

43.43

1682841

261598

659093

500797

996141

19750

P7Y9M

P5Y6M22D

P5Y7M14D

P5Y5M16D

P7Y4M14D

P7Y9M25D

661739

239202

630839

412062

676629

13751

P5Y3M21D

P5Y2M5D

P5Y5M20D

P5Y1M9D

P7Y22D

P7Y9M25D

1500000

2500000

5500000

7500000

5600000

P2Y5M5D

50000

1283000

318000

1015000

7.70

3.12

3.09

3.35

0.00

94912

4199997

3605373

4576930

3517324

1082184

1019013

5377093

3700285

5690855

3612236

EX-101.SCH 7 cemp-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100050 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Significant Agreements and Contracts link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Receivables link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Stock Option Plans link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Shareholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Stock Option Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Description of Business - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Basis of Presentation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Significant Agreements and Contracts - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Accrued Expenses - Accrued Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Long-Term Debt - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Shareholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Shareholders' Equity - Common Stock Reserved for Future Issuance (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Stock Option Plans - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Stock Option Plans - Stock Option Plans (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Stock Option Plans - Stock Options Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Stock Option Plans - Summary of RSUs Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 cemp-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cemp-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cemp-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and equivalents Cash And Cash Equivalents At Carrying Value Receivables Receivables Net Current Prepaid expenses Prepaid Expense Current Total current assets Assets Current Furniture, fixtures and equipment, net Property Plant And Equipment Net Deposits Deposits Assets Noncurrent Total assets Assets Liabilities Liabilities [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Accrued payroll and benefits Employee Related Liabilities Current Current portion of long-term debt Long Term Debt Current Total current liabilities Liabilities Current Deferred revenue Deferred Revenue Noncurrent Long-term debt Long Term Debt Noncurrent Total liabilities Liabilities Commitments and contingencies (Notes 4 and 8) Commitments And Contingencies Shareholders' Equity Stockholders Equity [Abstract] Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2017 and December 31, 2016 Preferred Stock Value Common stock; $.001 par value; 80,000,000 shares authorized; 52,509,281 and 52,392,905 issued and outstanding at September 30, 2017 and December 31, 2016, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders’ equity Stockholders Equity Total liabilities and shareholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenue Revenues [Abstract] Contract research Contracts Revenue Total revenue Revenues Operating expenses Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Restructuring Restructuring Charges Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense) Nonoperating Income Expense [Abstract] Interest income Investment Income Interest Interest expense Interest Expense Other income (expense), net Other Nonoperating Income Expense Net loss Net Income Loss Basic and diluted net loss per share Earnings Per Share Basic And Diluted Basic and diluted weighted average shares outstanding Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Cash Flows [Abstract] Operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Share-based compensation Allocated Share Based Compensation Expense Amortization of debt issuance costs Amortization Of Financing Costs Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Receivables Increase Decrease In Receivables Prepaid expenses Increase Decrease In Prepaid Expense Deposits Increase Decrease In Deposit Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Accrued payroll and benefits Increase Decrease In Employee Related Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of furniture, fixtures and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Financing activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Payment of long-term debt Repayments Of Long Term Debt Proceeds from exercise of stock options Proceeds From Stock Options Exercised Proceeds from issuance of common stock, net of underwriting discounts Proceeds From Issuance Initial Public Offering Payment of offering costs Payments Of Stock Issuance Costs Net cash (used in) provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net change in cash and equivalents Cash And Cash Equivalents Period Increase Decrease Cash and equivalents at beginning of the period Cash and equivalents at end of the period Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business Nature Of Operations Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] The entire disclosure for significant agreements and contracts. Significant agreements and contracts. Significant Agreements And Contracts [Abstract] Significant Agreements and Contracts Significant Agreements And Contracts [Text Block] Receivables [Abstract] Receivables Loans Notes Trade And Other Receivables Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Long-Term Debt Long Term Debt [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Equity [Abstract] Shareholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock Option Plans Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Principles of Consolidation and Basis of Presentation Consolidation Policy [Text Block] Unaudited Interim Financial Data Comparability Of Prior Year Financial Data Use of Estimates Use Of Estimates Receivables Receivables Policy [Text Block] Research and Development Expenses Research And Development Expense Policy Clinical trial accrual policy. Clinical Trial Accruals Clinical Trial Accrual Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Common Stock Reserved for Future Issuance Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Stock Option Plans Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Stock Options Outstanding Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block] Summary of RSUs Activity Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block] Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Reimbursement of merger related expenses upon agreement termination. Accounting Changes And Error Corrections [Abstract] Basis of presentation. Basis of presentation. Basis Of Presentation [Table] Basis Of Presentation [Table] Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Minimum [Member] Minimum [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Melinta therapeutics. Melinta Melinta Therapeutics [Member] Basis Of Presentation [Line Items] Basis Of Presentation [Line Items] Percentage of outstanding common stock Equity Method Investment Ownership Percentage Termination fee Business Exit Costs1 Reimbursement of merger agreement expenses upon agreement termination Reimbursement Of Merger Related Expenses Upon Agreement Termination Organization Consolidation And Presentation Of Financial Statements [Abstract] Allowance for doubtful accounts receivable recorded Allowance For Doubtful Accounts Receivable Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value Measurement Frequency [Domain] Recurring Basis Fair Value Measurements Recurring [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Money Market Funds Money Market Funds [Member] Fair Value, Hierarchy Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value Inputs Level1 [Member] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Term loan facility. Term Loan Term Loan Facility [Member] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Assets classified as fair value of financial instruments Assets Fair Value Disclosure Carrying value of notes Debt Instrument Face Amount Transfers between levels of the fair value hierarchy Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net Issuance of common shares in exchange for license. Issuance of common shares in exchange for license fair value. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Optimer Pharmaceuticals, Inc. Optimer Pharmaceuticals Inc Optimer Pharmaceuticals Inc [Member] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] Collaborative Arrangement Collaborative Arrangement [Member] Scripps research institute. The Scripps Research Institute Scripps Research Institute [Member] Scenario Statement Scenario [Axis] Scenario, Unspecified Scenario Unspecified [Domain] First three years. First Three Years First Three Years [Member] Fourth through six years. Fourth Through Six Years Fourth Through Six Years [Member] Biomedical advanced research and development authority. Biomedical Advanced Research and Development Authority Biomedical Advanced Research And Development Authority [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Second option work. Second Option Work Second Option Work [Member] Third option work. Third Option Work Third Option Work [Member] Toyama chemical. Toyama Chemical Toyama Chemical [Member] FUJIFILM Finechemicals Co., Ltd. ("FFFC"). FUJIFILM Finechemicals Co., Ltd. F U J I F I L M Finechemicals Company Limited [Member] Option and license agreement. Option and License Agreement Option And License Agreement [Member] Macrolide Pharmaceuticals, Inc. ("MP"). Macrolide Pharmaceuticals, Inc. Macrolide Pharmaceuticals Inc [Member] Settlement agreement. Settlement Agreement Settlement Agreement [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Common shares issued to Optimer in exchange for license Issuance Of Common Shares In Exchange For License Fair value of common shares issued to Optimer Issuance Of Common Shares In Exchange For License Fair Value Milestone payment amount paid. Number of products required to be developed through approval of authority. Description of royalty payment. Milestone payment amount due. Aggregate amount of milestone payment. Milestone payment paid Milestone Payment Amount Paid Milestone payment owed upon FDA approval Milestone Payment Amount Due Aggregate amount of milestone payment Aggregate Amount Of Milestone Payment Number of products required to be developed through FDA approval Number Of Products Required To Be Developed Through Approval Of Authority Royalty payment based on annual net sales description Description Of Royalty Payment Non refundable license issue fee License Costs EX-101.PRE 11 cemp-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Oct. 27, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Trading Symbol	CEMP
Entity Registrant Name	CEMPRA, INC.
Entity Central Index Key	0001461993
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		52,512,385

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and equivalents	$ 176,134	$ 231,553
Receivables	2,803	6,162
Prepaid expenses	833	579
Total current assets	179,770	238,294
Furniture, fixtures and equipment, net	27	48
Deposits	83	173
Total assets	179,880	238,515
Current liabilities
Accounts payable	6,665	15,657
Accrued expenses	1,036	2,929
Accrued payroll and benefits	1,286	4,267
Current portion of long-term debt	6,667	6,667
Total current liabilities	15,654	29,520
Deferred revenue	16,987	16,987
Long-term debt	3,682	8,660
Total liabilities	36,323	55,167
Commitments and contingencies (Notes 4 and 8)
Shareholders' Equity
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2017 and December 31, 2016
Common stock; $.001 par value; 80,000,000 shares authorized; 52,509,281 and 52,392,905 issued and outstanding at September 30, 2017 and December 31, 2016, respectively	53	52
Additional paid-in capital	626,001	620,279
Accumulated deficit	(482,497)	(436,983)
Total shareholders’ equity	143,557	183,348
Total liabilities and shareholders’ equity	$ 179,880	$ 238,515

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	52,509,281	52,392,905
Common stock, shares outstanding	52,509,281	52,392,905

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue
Contract research	$ 1,717	$ 3,972	$ 7,449	$ 10,071
Total revenue	1,717	3,972	7,449	10,071
Operating expenses
Research and development	4,383	21,096	28,338	60,643
General and administrative	7,867	15,021	21,291	35,333
Restructuring			3,553
Total operating expenses	12,250	36,117	53,182	95,976
Loss from operations	(10,533)	(32,145)	(45,733)	(85,905)
Other income (expense)
Interest income	382	128	896	330
Interest expense	(208)	(295)	(677)	(948)
Other income (expense), net	174	(167)	219	(618)
Net loss	$ (10,359)	$ (32,312)	$ (45,514)	$ (86,523)
Basic and diluted net loss per share	$ (0.20)	$ (0.62)	$ (0.87)	$ (1.74)
Basic and diluted weighted average shares outstanding	52,508,598	52,072,536	52,470,568	49,616,785

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities
Net loss	$ (45,514)	$ (86,523)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	21	40
Share-based compensation	5,464	7,518
Amortization of debt issuance costs	22	44
Changes in operating assets and liabilities
Receivables	3,359	3,108
Prepaid expenses	(254)	(219)
Deposits	90	(73)
Accounts payable	(8,992)	2,896
Accrued expenses	(1,893)	615
Accrued payroll and benefits	(2,981)	1,342
Net cash used in operating activities	(50,678)	(71,252)
Investing activities
Purchases of furniture, fixtures and equipment		(9)
Net cash used in investing activities		(9)
Financing activities
Payment of long-term debt	(5,000)	(2,779)
Proceeds from exercise of stock options	259	364
Proceeds from issuance of common stock, net of underwriting discounts		169,112
Payment of offering costs		(284)
Net cash (used in) provided by financing activities	(4,741)	166,413
Net change in cash and equivalents	(55,419)	95,152
Cash and equivalents at beginning of the period	231,553	153,765
Cash and equivalents at end of the period	176,134	248,917
Supplemental cash flow information
Cash paid for interest	$ 673	$ 916

XML 17 R6.htm IDEA: XBRL DOCUMENT

Description of Business	9 Months Ended
Description of Business	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Cempra, Inc. (the “Company” or “Cempra”) is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. Cempra is located in Chapel Hill, North Carolina, and is a pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases. The Company expects to continue to incur losses and require additional financial resources to advance its products to either commercial stage or liquidity events. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. In August 2017, the Company entered into an Agreement and Plan of Merger and Reorganization (“Merger Agreement”), with Melinta Therapeutics Inc. (“Melinta”). Under the terms of the Merger Agreement, shares of Melinta stock will be exchanged for Company shares whereby the current shareholders of Melinta will own approximately 52% of the Company’s stock after completion of the merger. The exchange ratio is subject to adjustment based upon the following; (1) the Company’s net cash balance at the closing of the transaction, (2) incremental debt incurred by Melinta before the close of the transaction, and (3) amount of transaction-related expenses incurred by Melinta. Consummation of the transaction is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company of the transactions contemplated by the Merger Agreement and related matters. The Merger Agreement contains certain termination rights for both the Company and Melinta, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Melinta a termination fee of $7.9 million and/or to reimburse certain expenses incurred by Melinta in an amount up to $2.0 million. The Company is expected to change its name to Melinta Therapeutics, Inc. and trade under the ticker symbol MLNT after the merger closes.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Unaudited Interim Financial Data The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary for the fair statement of the Company’s financial position as of September 30, 2017 and the results of operations and cash flows for the three and nine-months ended September 30, 2017 and 2016. The December 31, 2016 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible. Research and Development Expenses Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, consultants, central laboratories and clinical research organizations, including costs incurred in connection with clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include insurance or other indirect costs related to the Company’s research and development function to specific product candidates. R&D costs are expensed as incurred. Expenses paid but not yet incurred are recorded in prepaid expenses. The Company expenses purchases of pre-approval inventory as R&D until regulatory approval is received. Clinical Trial Accruals As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of fee billings and passthrough expenses from contract research organizations and other third-party vendors as well as the timely processing of any change orders from the contract research organizations. Revenue Recognition The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies an entity’s identification of its performance obligations in a contract. The update also clarifies the guidance regarding an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends the guidance in the new revenue standard on collectability, non-cash consideration, presentation of sales tax, and transition. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers which increases shareholders’ awareness of the proposals and expedites improvements to Update 2014-09. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which allows certain public business entities to elect to use the non-public business entities effective dates to adopt new standards on revenue (ASC 606) and leases (ASC 842). The amendments are intended to address implementation issues that were raised by stakeholders and provide additional practical expedients to reduce the cost and complexity of applying the new revenue standard. These pronouncements have the same effective date as the new revenue standard. The Company has evaluated the contract research agreement with BARDA, and does not anticipate a material impact on the financial statements. The Company is currently evaluating the license agreement with Toyama to determine the impact that the implementation of this standard will have on the financial statements, if any. The Company plans to use the full retrospective method of adoption effective January 1, 2018. In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance as of January 1, 2017. As of December 31, 2016, the Company has accumulated excess tax benefits from temporary differences in the amount and timing of stock compensation expense and the Company’s deductions on its income tax return from the award compensation that reduces the net operating loss deferred tax asset. The Company provided a full valuation allowance against its net deferred tax assets since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Upon implementation of this standard, the stock compensation excess tax benefit will be eliminated, resulting in an increase to the net operating loss deferred tax asset, with an increase in the valuation allowance of the same. The implementation of this standard has no impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business which revises the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation. This new guidance provides clarity and reduces both diversity and complexity to the terms or conditions of a share-based payment award. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments The carrying values of cash and equivalents, receivables, prepaid expenses, and accounts payable at September 30, 2017 approximated their fair values due to the short-term nature of these items. The Company’s valuation of financial instruments is based on a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. At September 30, 2017 and December 31, 2016, the Company held money market funds classified as Level 1 financial instruments of $173.0 million and $228.5 million, respectively. The carrying value of the Term Loan (defined and discussed in Note 7), which is classified as a Level 2 liability, approximates its fair value. At September 30, 2017, the carrying value was $10.3 million. There were no transfers between levels of the fair value hierarchy for any assets or liabilities measured at fair value in the nine months ended September 30, 2017.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Significant Agreements and Contracts	9 Months Ended
Significant Agreements and Contracts	Sep. 30, 2017
Significant Agreements And Contracts [Abstract]
Significant Agreements and Contracts	4. Significant Agreements and Contracts License Agreements Optimer Pharmaceuticals, Inc. In March 2006, the Company, through its wholly owned subsidiary, Cempra Pharmaceuticals, Inc., entered into a Collaborative Research and Development and License Agreement (“Optimer Agreement”) with Optimer Pharmaceuticals, Inc. (“Optimer”) which was acquired by Cubist Pharmaceuticals, Inc. in October 2013, which was in turn acquired by Merck in January 2015. Under the terms of the Optimer Agreement, the Company acquired exclusive rights to further develop and commercialize certain Optimer technology worldwide, excluding member nations of the Association of Southeast Asian Nations (“ASEAN”). In exchange for this license, during 2006 and 2007, the Company issued an aggregate of 125,646 common shares with a total fair value of $0.2 million to Optimer. These issuances to Optimer were expensed as incurred in research and development expense. In July 2010, the Company paid a $0.5 million milestone payment to Optimer after the successful completion of its first solithromycin Phase 1 program. In July 2012, the Company paid a $1.0 million milestone after the successful completion of its first solithromycin Phase 2 program. Both milestones were expensed as incurred in research and development expense. Under the terms of the Optimer Agreement, the Company will owe Optimer additional payments, contingent upon the achievement of various development, regulatory and commercialization milestone events. One such milestone event would be owed upon FDA approval of solithromycin which would result in a payment to Optimer of $9.5 million. The aggregate amount of such milestone payments the Company may need to pay is based in part on the number of products developed under the agreement and would total $27.5 million (including the two milestone payments made to date and the milestone payment for FDA approval) if four products are developed and gain FDA approval. The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products. The Scripps Research Institute In June 2012, the Company entered into a license agreement with The Scripps Research Institute (“TSRI”), whereby TSRI licensed to the Company rights, with rights of sublicense, to make, use, sell, and import products for human or animal therapeutic use that use or incorporate one or more macrolides as an active pharmaceutical ingredient (“API”) and is covered by certain patent rights owned by TSRI claiming technology related to copper-catalysed ligation of azides and acetylenes. The rights licensed to the Company are exclusive as to the People’s Republic of China (excluding Hong Kong), South Korea and Australia, and are non-exclusive in all other countries worldwide, except ASEAN member-nations, which are not included in the territory of the license. Under the terms of the agreement with TSRI, the Company paid a one-time only, non-refundable license issue fee in the amount of $0.4 million which was charged to research and development expense in the second quarter of 2012. The Company is also obligated to pay annual maintenance fees to TSRI in the amount of (i) $50,000 each year for the first three years (beginning on the first anniversary of the agreement), and (ii) $85,000 each year thereafter (beginning on the fourth anniversary of the agreement). Each calendar year’s annual maintenance fees will be credited against sales royalties due under the agreement for such calendar year. Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. TSRI is eligible to receive milestone payments of up to $1.1 million with respect to regulatory approval in the exclusive territory and first commercial sale, in each of the exclusive territory and nonexclusive territory, of the first licensed product to achieve those milestones that is based upon each macrolide covered by the licensed patents. Each milestone is payable once per each macrolide. Each milestone payment made to TSRI with respect to a particular milestone will be creditable against any payment due to TSRI with respect to any sublicense revenues received in connection with the achievement of such milestone. Pursuant to the terms of the Optimer Agreement, any payments made to TSRI under this license for territories subject to the Optimer Agreement can be deducted from any sales-based royalty payments due under the Optimer Agreement up to a certain percentage reduction of the royalties due to Optimer. Under the terms of the agreement, the Company is also required to pay additional fees on royalties, sublicensing and milestone payments if the Company, an affiliate with the Company, or a sub licensee challenges the validity or enforceability of any of the patents licensed under the agreement. Such increased payments would be required until all patent claims subject to challenge are invalidated in the particular country where such challenge was mounted. In December 2014, the Company paid a $0.2 million milestone payment to TSRI in relation to license and milestone payments received under the license agreement with Toyama (discussed below). The term of the license agreement (and the period during which the Company must pay royalties to TSRI in a particular country for a particular product) will end, on a country-by-country and product-by-product basis, at such time as no patent rights licensed from TSRI cover a particular product in the particular country. TSRI may terminate the agreement in the event (i) the Company fails to cure any non-payment or default on its indemnity or insurance obligations, (ii) the Company declares insolvency or bankruptcy, (iii) the Company is convicted of a felony relating to the development, manufacture, use, marketing, distribution or sale of any products licensed under the agreement, (iv) the Company fails to cure any underreporting or underpayment by a certain amount in any 12-month period, or (v) the Company fails to cure any default on any other obligation under the agreement. The Company may terminate the agreement with or without cause upon written notice. In the event of such termination, (i) all licenses granted to the Company will terminate except in the case of any sublicensee that was not the cause of the termination, is not in default on its obligations under its sublicense, and that pays any unpaid amounts owed by the Company under the agreement with respect to the sublicense, and (ii) the Company may complete any work in progress and sell any completed inventory on hand for a period of time after termination. Biomedical Advanced Research and Development Authority In May 2013, the Company entered into an agreement with BARDA, for the evaluation and development of the Company’s lead product candidate solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens. The agreement is a cost plus fixed fee development contract, with a base performance segment valued at approximately $18.7 million with contract modifications, and four option work segments that BARDA may request at its sole discretion pursuant to the agreement. If all four option segments are requested, the cumulative value of the agreement, as amended to date, would be approximately $68.2 million and the estimated period of performance would be until approximately May 2018. Three of the options are cost plus fixed fee arrangements and one option is a cost sharing arrangement without fixed fee, for which the Company is responsible for a designated portion of the costs associated with that work segment. The period of performance for the base performance segment was May 2013 through February 2016. BARDA exercised the second option in November 2014. The value of the second option work segment is approximately $16.0 million and the estimated period of performance is November 2014 through September 2018, which was extended in October 2017 at the Company’s request to allow more time to deliver the completed work product. This extension will not increase the cost of the work to be performed under the option nor does it change any other terms or provisions of the BARDA contract, including timeframes for other work options. In February 2016, BARDA exercised the third option work segment of the agreement which is intended to fund a Phase 2/3 study of intravenous, oral capsule and oral suspension formulations of solithromycin in pediatric patients from newborn to 17 years with community acquired bacterial pneumonia. This option work segment is a cost-sharing arrangement under which BARDA will contribute $25.5 million and the Company will be responsible for an additional designated portion of the costs associated with the work segment. In September 2016, the contract was modified to increase the third option work segment by $8.0 million for increased manufacturing work related to the development of a second supply source for solithromycin. The amendment raises the value of the third option work segment to approximately $33.5 million. The estimated period of performance of this option work segment runs through May 2018. Under the agreement, the Company is reimbursed and recognizes revenue as allowable costs are incurred plus a portion of the fixed-fee earned. The Company considers fixed-fees under cost reimbursable agreements to be earned in proportion to the allowable costs incurred in performance of the work as compared to total estimated agreement costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Since inception of the agreement through September 30, 2017, the Company has recognized $46.7 million in revenue under this agreement. The agreement provides the U.S. government the ability to terminate the agreement for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement of work. The Company believes that if the government were to terminate the agreement for convenience, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs. Any of the funding sources may request reimbursement for expenses or return of funds, or both, as a result of noncompliance by the Company with the terms of the grant. No reimbursement of expenses or return of funds for noncompliance has been requested or made since inception of the contract. Toyama Chemical Co., Ltd. In May 2013, Cempra Pharmaceuticals, Inc., the Company’s wholly owned subsidiary, entered into a license agreement with Toyama Chemical Co., Ltd. (“Toyama”), whereby the Company licensed to Toyama the exclusive right, with the right to sublicense, to make, use and sell any product in Japan that incorporates solithromycin, the Company’s lead compound, as its sole API for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues. Toyama also has a nonexclusive license in Japan and certain other countries, with the right to sublicense, to manufacture or have manufactured API for solithromycin for use in manufacturing such products, subject to limitations and obligations of the concurrently executed supply agreement discussed below. Toyama granted the Company certain rights to intellectual property generated by Toyama under the license agreement with respect to solithromycin or licensed products for use with such products outside Japan or with other solithromycin-based products inside or outside Japan. Following execution of the agreement, the Company received a $10.0 million upfront payment from Toyama. Toyama is also obligated to pay the Company up to an aggregate of $60.0 million in milestone payments, depending on the achievement of various regulatory, patent, development and commercial milestones. Under the terms of the license agreement, Toyama must also pay the Company a royalty equal to a low-to-high first double decimal digit percentage of net sales, subject to downward adjustment in certain circumstances. In August 2014, the Company received a $10.0 million milestone payment from Toyama (“August 2014 Milestone”), which was triggered by Toyama’s progress of its solithromycin clinical development program in Japan. The payment was made following Toyama’s receipt of regulatory acceptance to begin a Phase 2 trial of solithromycin in Japan following successful completion of a Phase 1 trial. In March 2015, the Company recognized a $10.0 million milestone from Toyama (“March 2015 Milestone”) based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan, which payment was received in April 2015. In October 2016, the Company received the third $10.0 million milestone from Toyama (“October 2016 Milestone”), which was triggered by Toyama’s progress of the solithromycin clinical development program in Japan. As part of the license agreement, Toyama and the Company also entered into a supply agreement, whereby the Company will be the exclusive supplier (with certain limitations) to Toyama and its sublicensees of API for solithromycin for use in licensed products in Japan, as well as the exclusive supplier to Toyama and its sublicensees of finished forms of solithromycin to be used in Phase 1 and Phase 2 clinical trials in Japan. Pursuant to the supply agreement, which is an exhibit to the license agreement, Toyama will pay the Company for such clinical supply of finished product and all supplies of API for solithromycin for any purpose, other than the manufacture of products for commercial sale in Japan, at prices equal to the Company’s cost. All API for solithromycin supplied by the Company to Toyama for use in the manufacture of finished product for commercial sale in Japan will be ordered from the Company at prices determined by the Company’s manufacturing costs, and which may, depending on such costs, equal, exceed, or be less than such costs. Either party may terminate the supply agreement for uncured material breach or insolvency of the other party, with Toyama’s right to terminate for the Company’s breach subject to certain further conditions in the case of the Company’s failure to supply API for solithromycin or clinical supply, but otherwise the supply agreement will continue until the expiration or termination of the license agreement. Since inception of the agreement through September 30, 2017, the Company has recognized $6.1 million in revenue under this supply agreement. The Company has determined that there are six deliverables under this agreement including (1) the license to develop and commercialize solithromycin in Japan, (2) the obligation of the Company to conduct Phase 3 studies and obtain regulatory approval in the United States and one other territory, (3) participation in a Joint Development Committee (“JDC”), (4) participation in a Joint Commercialization Committee (“JCC”), (5) the right to use the Company’s trademark, and (6) a supply agreement. The amounts received under the license agreement have been allocated to the deliverables based on their relative fair values and will be recognized into income when the revenue recognition criteria have been achieved. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. Royalties are recorded as earned in accordance with the contract terms when third party sales can be reliably measured and collectability is reasonably assured. The Company recognized $4.3 million in revenue associated with the delivery of the license in May 2013. Additionally, because the milestone event triggering the August 2014 Milestone and October 2016 Milestone payments were considered non-substantive for accounting purposes, these milestone payments are being recognized into revenue proportionately to the six deliverables in the agreement using the same allocation as the upfront payment. Therefore, $4.3 million of the August 2014 Milestone payment was recognized into revenue in August 2014 and $4.3 million of the October 2016 Milestone payment was recognized into revenue in October 2016. The remainder of the upfront and milestone payments which aggregate to $17.0 million are recorded as deferred revenue at September 2017 and will be recognized as revenue when the revenue recognition criteria of each deliverable has been met. The Company also recognized in March 2015 a $10.0 million milestone based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan. The March 2015 Milestone payment is considered substantive for accounting purposes, and therefore the $10.0 million milestone was recognized in its entirety as revenue in March 2015. FUJIFILM Finechemicals Co., Ltd. In January 2016, Cempra Pharmaceuticals, Inc. entered into an API manufacturing and supply agreement with FUJIFILM Finechemicals Co., Ltd. (“FFFC”), which will provide the Company with solithromycin in sufficient quantities and at reasonable prices to help ensure it meets its obligation under the May 2013 supply agreement with Toyama. The Company will use reasonable efforts to ensure that the solithromycin supplied by FFFC is for use as the active pharmaceutical ingredient in a human drug product to be used or sold in Japan. The Company is subject to a minimum purchase obligation for a designated number of years after the successful completion of the manufacturing facility and validation studies by FFFC. Each calendar month, the Company will submit to FFFC a projection of the anticipated volume of solithromycin that it will order for the next designated period (as set forth in the agreement) (or, if earlier, the final calendar month of the current term). Several months of each forecast are binding and the remaining months are non-binding, provided that the quantity of solithromycin ordered for any month is between designated percentages of the quantity specified in the initial forecast and between designated percentages of the most recent previous forecast. The price of each shipment of solithromycin will be equal to the total number of kilograms in such shipment multiplied by the per-kilogram transfer price as set forth in the agreement. For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin. The agreement’s initial term runs until December 2025. After the end of the initial term, and at the end of each year thereafter, the term will automatically extend for an additional year unless either party gives written notice to the other of its intent to terminate within a designated period of time prior to the expiration of the term, in which case the agreement will terminate at the end of such term. The parties may at any time terminate the agreement by mutual written consent. Each party has the right to terminate the agreement immediately if there is a product failure in Japan, the other party becomes involved in bankruptcy, insolvency or similar proceedings or materially breaches the agreement and such breach remains uncured for a period of time following notice of the breach. A violation by the Company of the minimum purchase obligation is considered a material breach. A product failure is not considered a material breach by the Company. The Company has the right to terminate the agreement upon written notice if there is a supply failure. The Company also may terminate in the event that FFFC cannot provide the Company with solithromycin for more than a designated period of time. Upon termination, any unfulfilled binding portion of the forecast must be delivered by FFFC and paid for by the Company. The Company also may elect to purchase the remaining inventory of FFFC’s solithromycin and any remaining raw materials. If FFFC terminates the agreement for a material breach by the Company and, prior to such termination, (i) FFFC has constructed a facility in Japan for the primary purpose of manufacturing API for the Company under the agreement and (ii) such facility is completed and fully operational and qualified for the manufacture of API for delivery thereunder, then, except to the extent otherwise agreed to by the parties, the Company will pay FFFC an amount equal to (a) the remaining book value of the facility less (b) the product of the number of kilograms of API ordered by the Company under the agreement prior to such termination times a designated dollar amount, provided that if the total direct costs incurred by FFFC in the construction of the facility, net of any tax credits, tax refunds, government subsidies, or similar financial, monetary, or in-kind benefits provided by any governmental agency or authority, do not equal or exceed a designated dollar amount, then the remaining book value will be reduced by a pro rata amount, based on ratios set forth in the agreement, and (z) no amount will be payable if the agreement terminates after December 31, 2025; provided, however, that if FFFC manufactures any product or performs any activities (other than the manufacture of API for the Company under the agreement) in, by, or using the facility prior to such termination and makes any profit thereby, the total amount of such profits will be subtracted from the total payment amount due from the Company to FFFC. Macrolide Pharmaceuticals, Inc. On January 29, 2016, Cempra Pharmaceuticals, Inc. entered into an Option and License Agreement with Macrolide Pharmaceuticals, Inc. (“MP”), pursuant to which MP granted the Company an exclusive option to license certain of MP’s patents and know-how involving macrolides, including specifically novel methods of synthesizing solithromycin (the “Compound”). Under the agreement, the Company will support research at MP focused on developing a novel, cost-competitive manufacturing approach to solithromycin. The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program. Under the evaluation program called for in the agreement, MP will conduct research activities for the manufacture of the Compound, which activities the Company will evaluate to determine whether to exercise the option to license. Upon execution of the agreement, the Company paid MP a non-refundable, non-creditable initial license fee of $0.4 million. For conducting the evaluation program, the Company paid MP a non-refundable, non-creditable fee in the amount of $0.4 million. In June 2017, the Company entered into a Settlement Agreement with Macrolide Pharmaceuticals, Inc. to terminate the Option and License Agreement and paid the settlement payment of $0.2 million.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Receivables	9 Months Ended
Receivables	Sep. 30, 2017
Receivables [Abstract]
Receivables	5. Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with BARDA. At September 30, 2017, the Company’s receivables consisted primarily of earned but unbilled receivables under the BARDA agreement.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Accrued Expenses

9 Months Ended

Sep. 30, 2017

Payables And Accruals [Abstract]

Accrued Expenses

6. Accrued Expenses

Accrued expenses are comprised of the following as of (in thousands):

	September 30,		December 31,
	2017		2016
Accrued severance	$	731	$	1,999
Franchise tax		98		570
Deferred rent		81		85
Accrued interest		61		80
Lease liability		41		-
Other accrued expenses		24		50
Accrued professional fees		-		145
Total accrued expenses	$	1,036	$	2,929

XML 23 R12.htm IDEA: XBRL DOCUMENT

Long-Term Debt	9 Months Ended
Long-Term Debt	Sep. 30, 2017
Debt Disclosure [Abstract]
Long-Term Debt	7. Long-term Debt In July 2015, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Comerica Bank (“Comerica”). The Loan and Security Agreement provides that the Company may borrow up to $20.0 million in a term loan (the “Term Loan”) and, upon FDA approval of its New Drug Application for solithromycin, the Company may also borrow an aggregate amount equal to the lesser of (i) up to 75% of its eligible inventory and 80% of eligible accounts receivable or (ii) $10.0 million (the “Revolver”). After FDA approval of the Company’s New Drug Application for solithromycin, the Company may convert the Term Loan to the Revolver, in which event the Revolver would have a maximum amount available to the Company of $25.0 million. The Loan and Security Agreement specifies the criteria for determining eligible inventory and eligible accounts receivable and sets forth ongoing limitations and conditions precedent to the Company’s ability to borrow under the Revolver. The Company granted Comerica a security interest in substantially all of its personal property assets, excluding its intellectual property and its stock in its subsidiaries, to secure its outstanding obligations under the Loan and Security Agreement. The Company is also obligated to comply with various other customary covenants, including, among other things, restrictions on its ability to: dispose of assets, make acquisitions, be acquired, incur indebtedness, grant liens, make distributions to its stockholders, make investments, enter into certain transactions with affiliates, or pay down subordinated debt, subject to specified exceptions. Amounts borrowed under the Term Loan may be repaid and reborrowed at any time without penalty or premium. The Term Loan was interest-only through April 30, 2016, followed by an amortization period of 36 months of equal monthly payments of principal plus interest, beginning on May 1, 2016 and continuing on the same day of each month thereafter until paid in full. Any amounts borrowed under the Term Loan will bear interest at a floating interest rate equal to the 30 Day LIBOR rate plus 5.2%. Amounts available to be borrowed under the Revolver may also be repaid and reborrowed at any time without penalty or premium prior to December 31, 2017, at which time all advances under the Revolver shall be immediately due and payable in full. Any amounts borrowed under the Revolver will bear interest at the 30 Day LIBOR rate plus 4.2%. Once available, the Revolver is subject to an annual unused facility fee equal to 0.25%. Under the Loan and Security Agreement, the Company is subject to certain covenants including maintaining a minimum unrestricted cash balance of $15.0 million and continuing the development or commercially launching solithromycin. The Company was in compliance with all covenants at September 30, 2017.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Legal Proceedings On November 4, 2016, a securities class action lawsuit was commenced in the United States District Court for the Middle District of North Carolina, Durham Division, naming the Company and certain of the Company’s officers as defendants, and alleging violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between May 1, 2016 and November 1, 2016 (the “Class Period”). The plaintiff seeks to represent a class comprised of purchasers of the Company’s common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court. Two substantially similar lawsuits were filed in the United States District Court, Middle District of North Carolina on November 22, 2016 and December 30, 2016, respectively, seeking to assert claims on behalf of all purchasers of the Company's common stock from July 7, 2015 through December 29, 2016, inclusive. Pursuant to the Private Securities Litigation Reform Act, on July 6, 2017, the court consolidated the three lawsuits into a single action and appointed a lead plaintiff and co-lead counsel in the consolidated case. On August 16, 2017, the plaintiffs in the case filed a consolidated amended complaint. On September 29, 2017, the defendants in the case filed a motion to dismiss the consolidated amended complaint. The Company believes it has meritorious defenses and intends to defend the lawsuits vigorously. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants. On December 21, 2016, a shareholder derivative lawsuit was commenced in the North Carolina Durham County Superior Court, naming certain of the Company’s former and current officers and directors as defendants and the Company as a nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and corporate waste. A substantially similar lawsuit was filed in the North Carolina Durham County Superior Court on February 16, 2017. The complaints are based on similar allegations as asserted in the putative securities class action described above, and seek unspecified damages and attorneys' fees. Both cases were served and transferred to the North Carolina Business Court as mandatory complex business cases. The Business Court has consolidated the two derivative cases into a single action and appointed lead counsel in the consolidated case. On July 6, 2017, the court entered an order staying the consolidated action pending resolution of the putative securities class action. On August 3, 2017, a shareholder derivative lawsuit was commenced in the Court of Chancery of the State of Delaware, naming certain of the Company's former and current officers and directors as defendants and the Company as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, and corporate waste. The complaint is based on similar allegations as asserted in the putative securities class action described above, and seeks unspecified damages and attorneys' fees. On October 23, 2017, the defendants in the case filed a motion to dismiss the complaint. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants. On September 15, 2017, a shareholder derivative lawsuit was commenced in the United State District Court for the Middle District of North Carolina, Durham Division, naming certain of the Company’s former and current officers and directors as defendants and the Company as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and alleged violation of Section 14(a) of the Exchange Act. The complaint is based on similar allegations as asserted in the putative securities class action described above, and seeks unspecified damages and attorneys’ fees. The complaint has not yet been served. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants. On September 27, 2017, a putative class action complaint was filed against Cempra and the members of its board of directors on behalf of the public stockholders of Cempra in the United States District Court for the Middle District of North Carolina. The complaint alleges that the preliminary proxy statement issued in connection with the proposed merger between Cempra and Melinta Therapeutics, Inc. omitted material information in violation of Sections 14(a) and 20(a) of the Exchange Act, rendering the preliminary proxy statement false and misleading. Among other remedies, the action seeks to enjoin the merger unless and until additional disclosures are provided, damage, and attorneys’ fees. Cempra believes that the action is without merit and that no further disclosure is required to supplement the preliminary proxy statement under applicable laws. On October 6, 2017, a putative class action complaint was filed against Cempra and the members of its board of directors on behalf of the public stockholders of Cempra in the United States District Court for the Middle District of North Carolina. The complaint, filed after a definitive proxy statement was issued on October 5, 2017 in connected with the proposed merger between Cempra and Melinta Therapeutics, Inc, alleges that the preliminary proxy statement omitted material information in violation of Sections 14(a) and 20(a) of the Exchange Act, rendering the preliminary proxy statement false and misleading. Among other remedies, the action seeks to enjoin the merger unless and until additional disclosures are provided, damage and attorneys’ fees. Cempra believes that the action is without merit and that no further disclosure is required to supplement the preliminary proxy statement under applicable laws. Other than as described above, the Company is not a party to any legal proceedings and is not aware of any claims or actions pending or threatened against the Company. In the future, the Company might from time to time become involved in litigation relating to claims arising from its ordinary course of business.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Shareholders' Equity

9. Shareholders’ Equity

Common Stock

During the first nine months of 2017, the Company issued 116,376 shares of common stock at a weighted average exercise price of $2.23 per share upon the exercise of option grants.

The following table presents common stock reserved for future issuance for the following equity instruments as of September 30, 2017:

Warrants to purchase common stock			94,912
Outstanding stock options			4,120,220
Outstanding restricted stock units			1,015,000
Available for future grants under the 2011 Equity Incentive Plan			3,578,696
Total common stock reserved for future issuance			8,808,828

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stock Option Plans

9 Months Ended

Sep. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Plans

10. Stock Option Plans

The following table summarizes the Company’s 2006 and 2011 Plan stock option activity:

				Weighted		Weighted
				Average		Average		Aggregate
	Number of			Exercise		Contractual		Intrinsic
	Options			Price		Term (in years)		Value ⁽¹⁾
Outstanding - December 31, 2016		3,784,346		$	16.26
Granted		1,921,750			3.08
Exercised		(116,376	)		2.23
Forfeited		(1,074,516	)		13.11
Expired		(394,984	)		16.64
Outstanding - September 30, 2017		4,120,220			11.30		6.90	$	607,444
Exercisable - September 30, 2017		2,634,222			12.30		5.77	$	434,044
Vested and expected to vest at September 30, 2017 ⁽²⁾		4,011,877		$	11.44		6.84	$	591,929

(1)	Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2017 over the weighted-average exercise price.

(2)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

The following table summarizes certain information about all stock options outstanding as of September 30, 2017:

	Options Outstanding				Options Exercisable
Exercise Price	Number of Options		Weighted Average Remaining Contractual Term (in years)		Number of Options		Weighted Average Remaining Contractual Term (in years)
$2.09 - $3.15		1,682,841		7.75		661,739		5.31
$3.95 - $6.63		261,598		5.56		239,202		5.18
$6.64 - $12.38		659,093		5.62		630,839		5.47
$12.79 - $19.25		500,797		5.46		412,062		5.11
$22.77 - $34.49		996,141		7.37		676,629		7.06
$35.29 - $43.43		19,750		7.82		13,751		7.82
		4,120,220				2,634,222

A summary of the activity related to the Company’s RSUs is as follows:

	Number of			Weighted
	Restricted			Average
	Stock Units			Grant-Date
	Outstanding			Fair Value
Balance - December 31, 2016		50,000		$	7.70
Granted		1,283,000			3.12
Vested		-			-
Forfeited		(318,000	)		3.09
Expired		-			-
Balance - September 30, 2017		1,015,000			3.35

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2017 as the Company incurred losses for the nine-month period ended September 30, 2017 and is forecasting additional losses through the fourth quarter, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2017. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. Due to the Company’s history of losses since inception, there is not enough evidence at this time and it is not more likely than not that the Company will generate sufficient future income of a nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Net Loss Per Share

12. Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Warrants outstanding		94,912		94,912		94,912		94,912
Stock options outstanding		4,199,997		3,605,373		4,576,930		3,517,324
Restricted stock units outstanding		1,082,184		-		1,019,013		-
		5,377,093		3,700,285		5,690,855		3,612,236

XML 29 R18.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Data	Unaudited Interim Financial Data The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary for the fair statement of the Company’s financial position as of September 30, 2017 and the results of operations and cash flows for the three and nine-months ended September 30, 2017 and 2016. The December 31, 2016 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP for complete financial statements.
Use of Estimates	Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Receivables	Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible.
Research and Development Expenses	Research and Development Expenses Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, consultants, central laboratories and clinical research organizations, including costs incurred in connection with clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include insurance or other indirect costs related to the Company’s research and development function to specific product candidates. R&D costs are expensed as incurred. Expenses paid but not yet incurred are recorded in prepaid expenses. The Company expenses purchases of pre-approval inventory as R&D until regulatory approval is received.
Clinical Trial Accruals	Clinical Trial Accruals As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of fee billings and passthrough expenses from contract research organizations and other third-party vendors as well as the timely processing of any change orders from the contract research organizations.
Revenue Recognition	Revenue Recognition The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies an entity’s identification of its performance obligations in a contract. The update also clarifies the guidance regarding an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends the guidance in the new revenue standard on collectability, non-cash consideration, presentation of sales tax, and transition. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers which increases shareholders’ awareness of the proposals and expedites improvements to Update 2014-09. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which allows certain public business entities to elect to use the non-public business entities effective dates to adopt new standards on revenue (ASC 606) and leases (ASC 842). The amendments are intended to address implementation issues that were raised by stakeholders and provide additional practical expedients to reduce the cost and complexity of applying the new revenue standard. These pronouncements have the same effective date as the new revenue standard. The Company has evaluated the contract research agreement with BARDA, and does not anticipate a material impact on the financial statements. The Company is currently evaluating the license agreement with Toyama to determine the impact that the implementation of this standard will have on the financial statements, if any. The Company plans to use the full retrospective method of adoption effective January 1, 2018. In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance as of January 1, 2017. As of December 31, 2016, the Company has accumulated excess tax benefits from temporary differences in the amount and timing of stock compensation expense and the Company’s deductions on its income tax return from the award compensation that reduces the net operating loss deferred tax asset. The Company provided a full valuation allowance against its net deferred tax assets since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Upon implementation of this standard, the stock compensation excess tax benefit will be eliminated, resulting in an increase to the net operating loss deferred tax asset, with an increase in the valuation allowance of the same. The implementation of this standard has no impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business which revises the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation. This new guidance provides clarity and reduces both diversity and complexity to the terms or conditions of a share-based payment award. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2017

Payables And Accruals [Abstract]

Accrued Expenses

Accrued expenses are comprised of the following as of (in thousands):

	September 30,		December 31,
	2017		2016
Accrued severance	$	731	$	1,999
Franchise tax		98		570
Deferred rent		81		85
Accrued interest		61		80
Lease liability		41		-
Other accrued expenses		24		50
Accrued professional fees		-		145
Total accrued expenses	$	1,036	$	2,929

XML 31 R20.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Common Stock Reserved for Future Issuance

The following table presents common stock reserved for future issuance for the following equity instruments as of September 30, 2017:

Warrants to purchase common stock			94,912
Outstanding stock options			4,120,220
Outstanding restricted stock units			1,015,000
Available for future grants under the 2011 Equity Incentive Plan			3,578,696
Total common stock reserved for future issuance			8,808,828

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stock Option Plans (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Plans

The following table summarizes the Company’s 2006 and 2011 Plan stock option activity:

				Weighted		Weighted
				Average		Average		Aggregate
	Number of			Exercise		Contractual		Intrinsic
	Options			Price		Term (in years)		Value ⁽¹⁾
Outstanding - December 31, 2016		3,784,346		$	16.26
Granted		1,921,750			3.08
Exercised		(116,376	)		2.23
Forfeited		(1,074,516	)		13.11
Expired		(394,984	)		16.64
Outstanding - September 30, 2017		4,120,220			11.30		6.90	$	607,444
Exercisable - September 30, 2017		2,634,222			12.30		5.77	$	434,044
Vested and expected to vest at September 30, 2017 ⁽²⁾		4,011,877		$	11.44		6.84	$	591,929

(1)	Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2017 over the weighted-average exercise price.

(2)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.

Stock Options Outstanding

The following table summarizes certain information about all stock options outstanding as of September 30, 2017:

	Options Outstanding				Options Exercisable
Exercise Price	Number of Options		Weighted Average Remaining Contractual Term (in years)		Number of Options		Weighted Average Remaining Contractual Term (in years)
$2.09 - $3.15		1,682,841		7.75		661,739		5.31
$3.95 - $6.63		261,598		5.56		239,202		5.18
$6.64 - $12.38		659,093		5.62		630,839		5.47
$12.79 - $19.25		500,797		5.46		412,062		5.11
$22.77 - $34.49		996,141		7.37		676,629		7.06
$35.29 - $43.43		19,750		7.82		13,751		7.82
		4,120,220				2,634,222

Summary of RSUs Activity

A summary of the activity related to the Company’s RSUs is as follows:

	Number of			Weighted
	Restricted			Average
	Stock Units			Grant-Date
	Outstanding			Fair Value
Balance - December 31, 2016		50,000		$	7.70
Granted		1,283,000			3.12
Vested		-			-
Forfeited		(318,000	)		3.09
Expired		-			-
Balance - September 30, 2017		1,015,000			3.35

XML 33 R22.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding

The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Warrants outstanding		94,912		94,912		94,912		94,912
Stock options outstanding		4,199,997		3,605,373		4,576,930		3,517,324
Restricted stock units outstanding		1,082,184		-		1,019,013		-
		5,377,093		3,700,285		5,690,855		3,612,236

XML 34 R23.htm IDEA: XBRL DOCUMENT

Description of Business - Additional Information (Details)	1 Months Ended
	Aug. 31, 2017 USD ($)
Melinta
Basis Of Presentation [Line Items]
Percentage of outstanding common stock	52.00%
Termination fee	$ 7,900,000
Maximum
Basis Of Presentation [Line Items]
Reimbursement of merger agreement expenses upon agreement termination	$ 2,000,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Basis of Presentation - Additional Information (Details)	Sep. 30, 2017 USD ($)
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Allowance for doubtful accounts receivable recorded	$ 0

XML 36 R25.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Transfers between levels of the fair value hierarchy	$ 0
Term Loan
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Carrying value of notes	10,300,000
Recurring Basis \| Money Market Funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Assets classified as fair value of financial instruments	$ 173,000,000	$ 228,500,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Significant Agreements and Contracts - Additional Information (Details)					1 Months Ended								3 Months Ended			9 Months Ended		53 Months Ended
	Oct. 31, 2016 USD ($)	Jan. 29, 2016 USD ($)	Aug. 31, 2014 USD ($)	May 31, 2013 USD ($)	Oct. 31, 2017	Jun. 30, 2017 USD ($)	Oct. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jul. 31, 2012 USD ($)	Jul. 31, 2010 USD ($)	Sep. 30, 2017 USD ($) Segment	Sep. 30, 2016 USD ($)	Jun. 30, 2012 USD ($)	Sep. 30, 2017 USD ($) Product Segment Deliverables shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Segment	Dec. 31, 2016 USD ($)	Feb. 29, 2016 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract research													$ 1,717,000	$ 3,972,000		$ 7,449,000	$ 10,071,000
Deferred revenue													16,987,000			$ 16,987,000		$ 16,987,000	$ 16,987,000
Optimer Pharmaceuticals Inc \| Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common shares issued to Optimer in exchange for license \| shares																125,646
Fair value of common shares issued to Optimer																$ 200,000
Milestone payment paid											$ 1,000,000	$ 500,000
Milestone payment owed upon FDA approval													9,500,000			9,500,000		9,500,000
Aggregate amount of milestone payment													27,500,000			$ 27,500,000		27,500,000
Number of products required to be developed through FDA approval \| Product																4
Royalty payment based on annual net sales description																The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products.
The Scripps Research Institute
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment paid										$ 200,000
Royalty payment based on annual net sales description																Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances.
Non refundable license issue fee															$ 400,000
Eligible milestone payment																$ 1,100,000
The Scripps Research Institute \| First Three Years
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Annual maintenance fees																50,000
The Scripps Research Institute \| Fourth Through Six Years
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Annual maintenance fees																85,000
Biomedical Advanced Research and Development Authority
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Value of cost plus fixed fee development contract with base performance segment													$ 18,700,000			$ 18,700,000		$ 18,700,000
Number of option work segments \| Segment													4			4		4
Cumulative value of cost plus fixed fee development contract with base performance segment of four option work segments													$ 68,200,000			$ 68,200,000		$ 68,200,000
Number of options under cost plus fixed fee arrangements \| Segment																3
Number of options under cost sharing arrangement without fixed fee \| Segment																1
Estimated period of performance for the base performance segment																2018-05
Aggregate milestone payments receivable under license agreement																2013-05
Estimated period of performance for the base performance segment ending date																2016-02
Contract research																		46,700,000
Reimbursement of expenses or return of funds for noncompliance																		0
Biomedical Advanced Research and Development Authority \| Second Option Work
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Value of cost plus fixed fee development contract with base performance segment													16,000,000			$ 16,000,000		16,000,000
Aggregate milestone payments receivable under license agreement																2014-11
Estimated period of performance for the base performance segment ending date																2018-09
Biomedical Advanced Research and Development Authority \| Second Option Work \| Subsequent Event
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Estimated period of performance for the base performance segment ending date					2017-10
Biomedical Advanced Research and Development Authority \| Third Option Work
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Value of cost plus fixed fee development contract with base performance segment													33,500,000			$ 33,500,000		33,500,000		$ 25,500,000
Increase in value of cost plus fixed fee development contract with base performance segment								$ 8,000,000
Toyama Chemical
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract research																		6,100,000
Deferred revenue				$ 10,000,000									$ 17,000,000			$ 17,000,000		$ 17,000,000
Aggregate milestone payments				60,000,000
Milestone payment amount received			$ 10,000,000				$ 10,000,000
Milestone payment recognized as revenue	$ 4,300,000		$ 4,300,000	$ 4,300,000					$ 10,000,000
Number of deliverables under license agreement \| Deliverables																6
Supply agreement date																May 31, 2013
FUJIFILM Finechemicals Co., Ltd.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Manufacturing and supply agreement date																Jan. 31, 2016
Prohibition term																For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin.
Aggregate initial term of agreement																Dec. 31, 2025
Macrolide Pharmaceuticals, Inc. \| Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement description																The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program.
Non-refundable non-creditable initial license fee		$ 400,000
Non-refundable non-creditable fee		$ 400,000
Macrolide Pharmaceuticals, Inc. \| Settlement Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Settlement payment for termination of option and license agreement						$ 200,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued expenses
Accrued severance	$ 731	$ 1,999
Franchise tax	98	570
Deferred rent	81	85
Accrued interest	61	80
Lease liability	41
Other accrued expenses	24	50
Accrued professional fees		145
Total accrued expenses	$ 1,036	$ 2,929

XML 39 R28.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Additional Information (Details) - Loan and Security Agreement - USD ($)	1 Months Ended	9 Months Ended
	Jul. 31, 2015	Sep. 30, 2017
Debt Instrument [Line Items]
Minimum unrestricted cash balance requirement	$ 15,000,000
Term Loan
Debt Instrument [Line Items]
Loan and security agreement	$ 20,000,000
Eligible inventory percentage for additional borrowings	75.00%
Eligible accounts receivable for additional borrowings	80.00%
End date of interest-only payment	Apr. 30, 2016
Amortization period of principal and interest payments	36 months
Description of variable rate basis		30 Day LIBOR
Beginning date for principal plus interest payment	May 01, 2016
Term Loan \| LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate	5.20%
Revolver
Debt Instrument [Line Items]
Loan and security agreement	$ 10,000,000
Maximum borrowing capacity if term loans are converted	$ 25,000,000
Description of variable rate basis		30 Day LIBOR
Last date for repayment and reborrowed without penalty or premium	Dec. 31, 2017
Annual unused facility fee percentage	0.25%
Revolver \| LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate	4.20%

XML 40 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details) - Lawsuit		9 Months Ended
	Jul. 06, 2017	Sep. 30, 2017
Securities Class Action
Loss Contingencies [Line Items]
Lawsuit commencement date		Nov. 04, 2016
Lawsuit action domicile		United States District Court for the Middle District of North Carolina, Durham Division
Name of defendant		officers
Allegations in the class period		between May 1, 2016 and November 1, 2016
Loss contingency, actions determined by court		The plaintiff seeks to represent a class comprised of purchasers of the Company’s common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court
Number of lawsuits filed		2
Lawsuit filing date		November 22, 2016 and December 30, 2016
Lawsuit description		Two substantially similar lawsuits were filed in the United States District Court, Middle District of North Carolina on November 22, 2016 and December 30, 2016, respectively, seeking to assert claims on behalf of all purchasers of the Company's common stock from July 7, 2015 through December 29, 2016, inclusive.
Number of lawsuits consolidated	3
Shareholder Derivative
Loss Contingencies [Line Items]
Lawsuit commencement date		Dec. 21, 2016
Lawsuit action domicile		North Carolina Durham County Superior Court
Name of defendant		officers and directors
Lawsuit filing date		February 16, 2017
Number of lawsuits consolidated		2
Shareholder Derivative \| Pending Litigation
Loss Contingencies [Line Items]
Lawsuit commencement date		Aug. 03, 2017
Lawsuit action domicile		Court of Chancery of the State of Delaware
Name of defendant		officers and directors
Lawsuit filing date		October 23, 2017
Legal Proceedings Case Four
Loss Contingencies [Line Items]
Lawsuit commencement date		Sep. 15, 2017
Lawsuit action domicile		United State District Court for the Middle District of North Carolina, Durham Division
Name of defendant		officers and directors
Legal Proceedings Case Five
Loss Contingencies [Line Items]
Lawsuit action domicile		United States District Court for the Middle District of North Carolina
Lawsuit filing date		September 27, 2017
Legal Proceedings Case Six
Loss Contingencies [Line Items]
Lawsuit action domicile		United States District Court for the Middle District of North Carolina
Lawsuit filing date		October 6, 2017

XML 41 R30.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jul. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Dec. 31, 2016	May 31, 2016
Shareholders' Equity (Deficit) (Textual) [Abstract]
Common stock sale value			$ 53			$ 52
Proceeds from issuance of common stock, net of underwriting discounts				$ 169,112
Issuance of common shares upon exercise of options, shares			116,376
Weighted average exercise price of common stock			$ 2.23
Cowen And Company Limited Liability Company \| At The Market Sales Agreement
Shareholders' Equity (Deficit) (Textual) [Abstract]
Common stock sale value							$ 150,000
Commission on sale of common stock under the ATM							3.00%
Common Stock
Shareholders' Equity (Deficit) (Textual) [Abstract]
Number of common stocks issued through public offering	4,166,667	4,140,307			0
Common share price	$ 24.00
Proceeds from issuance of common stock, net of underwriting discounts and offering costs	$ 93,800
Underwriting discounts and commissions, and expenses	$ 6,200
Proceeds from issuance of common stock, net of underwriting discounts		$ 75,100
Commissions and expenses		$ 2,300
Issuance of common shares upon exercise of options, shares			116,376
Weighted average exercise price of common stock			$ 2.23

XML 42 R31.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Common Stock Reserved for Future Issuance (Details)	Sep. 30, 2017 shares
Class Of Stock [Line Items]
Common stock reserved for future issuance	8,808,828
Warrants to Purchase Common Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance	94,912
Outstanding Stock Options
Class Of Stock [Line Items]
Common stock reserved for future issuance	4,120,220
Outstanding Restricted Stock Units
Class Of Stock [Line Items]
Common stock reserved for future issuance	1,015,000
Options Available For Future Grants \| 2011 Equity Incentive Plan
Class Of Stock [Line Items]
Common stock reserved for future issuance	3,578,696

XML 43 R32.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Oct. 31, 2011
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options for shares issued and outstanding	4,120,220		4,120,220		3,784,346
Share-based compensation	$ 1.5	$ 2.5	$ 5.5	$ 7.5
Unrecognized compensation cost	$ 5.6		$ 5.6
Expected weighted average recognition period, Unvested shares			2 years 5 months 5 days
2006 Stock Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options for shares issued and outstanding	341,854		341,854
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares authorized for future issuances						8,697,451
Options shares available under the 2011 Plan	3,578,696		3,578,696
Percent of annual increase in share reserved for future issuance			4.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Stock Option Plans (Details)	9 Months Ended
Stock Option Plans - Stock Option Plans (Details)	Sep. 30, 2017 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding - December 31, 2016 \| shares	3,784,346
Number of Options, Granted \| shares	1,921,750
Number of Options, Exercised \| shares	(116,376)
Number of Options, Forfeited \| shares	(1,074,516)
Number of Options, Expired \| shares	(394,984)
Number of Options, Outstanding - September 30, 2017 \| shares	4,120,220
Number of Options, Exercisable - September, 2017 \| shares	2,634,222
Number of Options, Vested and expected to vest at September 30, 2017 \| shares	4,011,877
Weighted Average Exercise Price, Outstanding - December 31, 2016 \| $ / shares	$ 16.26
Weighted Average Exercise Price, Granted \| $ / shares	3.08
Weighted Average Exercise Price, Exercised \| $ / shares	2.23
Weighted Average Exercise Price, Forfeited \| $ / shares	13.11
Weighted Average Exercise Price, Expired \| $ / shares	16.64
Weighted Average Exercise Price, Outstanding - September, 2017 \| $ / shares	11.30
Weighted Average Exercise Price, Exercisable - September 30, 2017 \| $ / shares	12.30
Weighted Average Exercise Price, Vested and expected to vest at September 30, 2017 \| $ / shares	$ 11.44
Weighted Average Contractual Term (in years), Outstanding - September 30, 2017	6 years 10 months 24 days
Weighted Average Contractual Term (in years), Exercisable - September 30, 2017	5 years 9 months 7 days
Weighted Average Contractual Term (in years), Vested and expected to vest at September 30, 2017	6 years 10 months 2 days
Aggregate Intrinsic Value, Outstanding - September 30, 2017 \| $	$ 607,444
Aggregate Intrinsic Value, Exercisable - September 30, 2017 \| $	434,044
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2017 \| $	$ 591,929

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Stock Options Outstanding (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number of Options Outstanding	4,120,220	3,784,346
Number of Options, Exercisable	2,634,222
Exercise Price $2.09 - $3.15
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 2.09
Exercise price range upper range limit	$ 3.15
Number of Options Outstanding	1,682,841
Weighted Average Remaining Contractual Term (in years), Outstanding	7 years 9 months
Number of Options, Exercisable	661,739
Weighted Average Remaining Contractual Term (in years), Exercisable	5 years 3 months 21 days
Exercise Price $3.95 - $6.63
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 3.95
Exercise price range upper range limit	$ 6.63
Number of Options Outstanding	261,598
Weighted Average Remaining Contractual Term (in years), Outstanding	5 years 6 months 22 days
Number of Options, Exercisable	239,202
Weighted Average Remaining Contractual Term (in years), Exercisable	5 years 2 months 5 days
Exercise Price $6.64 - $12.38
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 6.64
Exercise price range upper range limit	$ 12.38
Number of Options Outstanding	659,093
Weighted Average Remaining Contractual Term (in years), Outstanding	5 years 7 months 14 days
Number of Options, Exercisable	630,839
Weighted Average Remaining Contractual Term (in years), Exercisable	5 years 5 months 20 days
Exercise Price $12.79 - $19.25
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 12.79
Exercise price range upper range limit	$ 19.25
Number of Options Outstanding	500,797
Weighted Average Remaining Contractual Term (in years), Outstanding	5 years 5 months 16 days
Number of Options, Exercisable	412,062
Weighted Average Remaining Contractual Term (in years), Exercisable	5 years 1 month 9 days
Exercise Price $22.77 - $34.49
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 22.77
Exercise price range upper range limit	$ 34.49
Number of Options Outstanding	996,141
Weighted Average Remaining Contractual Term (in years), Outstanding	7 years 4 months 14 days
Number of Options, Exercisable	676,629
Weighted Average Remaining Contractual Term (in years), Exercisable	7 years 22 days
Exercise Price $35.29 - $43.43
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 35.29
Exercise price range upper range limit	$ 43.43
Number of Options Outstanding	19,750
Weighted Average Remaining Contractual Term (in years), Outstanding	7 years 9 months 25 days
Number of Options, Exercisable	13,751
Weighted Average Remaining Contractual Term (in years), Exercisable	7 years 9 months 25 days

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Summary of RSUs Activity (Details) - Restricted Stock Units - 2011 Equity Incentive Plan	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Restricted Stock Units Outstanding, Balance - December 31, 2016 \| shares	50,000
Number of Restricted Stock Units Outstanding, Granted \| shares	1,283,000
Number of Restricted Stock Units Outstanding, Forfeited \| shares	(318,000)
Number of Restricted Stock Units Outstanding, Balance - September 30, 2017 \| shares	1,015,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant-Date Fair Value, Balance - December 31, 2016 \| $ / shares	$ 7.70
Weighted Average Grant-Date Fair Value, Granted \| $ / shares	3.12
Weighted Average Grant-Date Fair Value, Forfeited \| $ / shares	3.09
Weighted Average Grant-Date Fair Value, Balance - September 30, 2017 \| $ / shares	$ 3.35

XML 47 R36.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2017
U.S. Federal or State Income Tax
Income Tax Contingency [Line Items]
Income tax expense	$ 0
Scenario Forecast
Income Tax Contingency [Line Items]
Effective tax rate		0.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	5,377,093	3,700,285	5,690,855	3,612,236
Warrants Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	94,912	94,912	94,912	94,912
Stock Options Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	4,199,997	3,605,373	4,576,930	3,517,324
Outstanding Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	1,082,184		1,019,013

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 103 212 1 false 49 0 false 8 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cempra.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.cempra.com/20170930/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.cempra.com/20170930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.cempra.com/20170930/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Cash Flows Sheet http://www.cempra.com/20170930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 100050 - Disclosure - Description of Business Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 6 false false R7.htm 100060 - Disclosure - Basis of Presentation Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureBasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 100070 - Disclosure - Fair Value of Financial Instruments Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 8 false false R9.htm 100080 - Disclosure - Significant Agreements and Contracts Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureSignificantAgreementsAndContracts Significant Agreements and Contracts Notes 9 false false R10.htm 100090 - Disclosure - Receivables Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureReceivables Receivables Notes 10 false false R11.htm 100100 - Disclosure - Accrued Expenses Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 11 false false R12.htm 100110 - Disclosure - Long-Term Debt Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureLongTermDebt Long-Term Debt Notes 12 false false R13.htm 100120 - Disclosure - Commitments and Contingencies Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 100130 - Disclosure - Shareholders' Equity Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureShareholdersEquity Shareholders' Equity Notes 14 false false R15.htm 100140 - Disclosure - Stock Option Plans Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureStockOptionPlans Stock Option Plans Notes 15 false false R16.htm 100150 - Disclosure - Income Taxes Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 100160 - Disclosure - Net Loss Per Share Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 17 false false R18.htm 100170 - Disclosure - Basis of Presentation (Policies) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureBasisOfPresentationPolicies Basis of Presentation (Policies) Policies 18 false false R19.htm 100180 - Disclosure - Accrued Expenses (Tables) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.cempra.com/20170930/taxonomy/role/DisclosureAccruedExpenses 19 false false R20.htm 100190 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.cempra.com/20170930/taxonomy/role/DisclosureShareholdersEquity 20 false false R21.htm 100200 - Disclosure - Stock Option Plans (Tables) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureStockOptionPlansTables Stock Option Plans (Tables) Tables http://www.cempra.com/20170930/taxonomy/role/DisclosureStockOptionPlans 21 false false R22.htm 100210 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.cempra.com/20170930/taxonomy/role/DisclosureNetLossPerShare 22 false false R23.htm 100220 - Disclosure - Description of Business - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails Description of Business - Additional Information (Details) Details 23 false false R24.htm 100230 - Disclosure - Basis of Presentation - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails Basis of Presentation - Additional Information (Details) Details 24 false false R25.htm 100240 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails Fair Value of Financial Instruments - Additional Information (Details) Details 25 false false R26.htm 100250 - Disclosure - Significant Agreements and Contracts - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureSignificantAgreementsAndContractsAdditionalInformationDetails Significant Agreements and Contracts - Additional Information (Details) Details 26 false false R27.htm 100260 - Disclosure - Accrued Expenses - Accrued Expenses (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureAccruedExpensesAccruedExpensesDetails Accrued Expenses - Accrued Expenses (Details) Details 27 false false R28.htm 100270 - Disclosure - Long-Term Debt - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails Long-Term Debt - Additional Information (Details) Details 28 false false R29.htm 100280 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Shareholders' Equity - Common Stock Reserved for Future Issuance (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureShareholdersEquityCommonStockReservedForFutureIssuanceDetails Shareholders' Equity - Common Stock Reserved for Future Issuance (Details) Details 31 false false R32.htm 100310 - Disclosure - Stock Option Plans - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureStockOptionPlansAdditionalInformationDetails Stock Option Plans - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Stock Option Plans - Stock Option Plans (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureStockOptionPlansStockOptionPlansDetails Stock Option Plans - Stock Option Plans (Details) Details 33 false false R34.htm 100330 - Disclosure - Stock Option Plans - Stock Options Outstanding (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureStockOptionPlansStockOptionsOutstandingDetails Stock Option Plans - Stock Options Outstanding (Details) Details 34 false false R35.htm 100340 - Disclosure - Stock Option Plans - Summary of RSUs Activity (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureStockOptionPlansSummaryOfRsusActivityDetails Stock Option Plans - Summary of RSUs Activity (Details) Details 35 false false R36.htm 100350 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) Sheet http://www.cempra.com/20170930/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetails Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) Details 37 false false All Reports Book All Reports cemp-20170930.xml cemp-20170930.xsd cemp-20170930_cal.xml cemp-20170930_def.xml cemp-20170930_lab.xml cemp-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 55 0001564590-17-021211-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-021211-xbrl.zip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
B,?66KJ77P12,@C M[TQ81/*X @6?C'U=*9GM5=7"-=S(I#SMR$[IXDG?HJ=1\J"!+UX7+7QH<=#I MTP4W9+?_>C.QC_FTV++3REI"(*EB,ZFY15:MUX71BP($#B%U!YS?Z>N+[WV] M:&GDR<_3@4%2#T!(WI2)>KEG9<5DO#Y]95;N$*HK4HO\45&6>4D#;TF-+&FT MY4;?D/3 =OG?BR[-#>Q;"?EE;J?24GV.O&Q71&+(J[QIC&4]C;)R [*L/<7Z M\,:2\);TI)C-@&6XR WA9P@7X:,M'+VX;T-RTZ/D9M%B@FT<"Q=9Y.3))#H? M?.TCB#%@VA6:M^C7EXB_P2#)"B$,>!O ?PISDE<7-V\+DY$N&!\0\I6W?YWQ MTI1\_\7-U\+M.)1S?=3*DQ->%K@L5I OTXALM<7FD:$/C+Q/7-$=;WO #AY7 MB@PC7]R"L42FF7(.)DV!8:1A!],I]T'BUR@EB-^>M_RM&0M;#"-(8D]41K/8 M!0N3(9M@!@A69!I *,0?"C")QIPTB$Z;_5.&BE&G(P6SEU??EPKM6>":AF\) MYFF0A HN3(,HSCM&E@(:;J"S8:_G<79%B\=C4]&Q?#?7 %/$L7>.4H6!/V]H M1 IQY&,WPI+6G#L',44M>M!%9";&S@T^EM#%97<,M,CGI;8Q7)QW/6M&3W1% MM])8[LG;9(N]W&F/S\N?E+9-#U>2R_4$4WMLK$XU!00_%W9!V# M_#47&X^OI[%!82SL$TE ^6WM+HEU-RQ?9,Q>8#:-M\:J+/R^.>N99?B1K.C;X O?B,.!-##S@!K^*M<"Q4&L M_]?R$YP$SN+"$ZKP@9F_8G&Y-\ M51Y6C' 2N#"C?#7%A\!SD8 M?Q:/XJ19D")U4G*S)8'9EID,6]MS'/F!RUPNHX0':]6:)3";U[^U3TH?RJ5W MHQ;G5=:V>WZ#_;R%KS9J283(B,0B8@]\-GBIHVHIR^\.UWW M+:^>7JQK7NI80\/*?9BL4Z)UJ6AA!RL=_ 6_G>-!=8L_+-,F:MWF_ M([+A#N+B,6^$XNTE;#H+0GQGUHED2]5E4 :@_B"!=ZM;-FKZP O4I[',9; M$_G>"Z(12X(&G% 2^HN&%PY%\1UICH=A6181Q=E2K,8B_V"5EG MK[I::C@WM]FY5!@&UW:6N-T((PK>7B[>_ M@*8%']Y G=\E2C*0O+M1ZKJI& ]G;./O&_88@^?I[TC-L0Z43H?_PMV[;B1J)?]*NVP -]G0V6D)^OU9,60 M3TIWTNKX1KTIFQAL%: T0HO$'$0Z 9 %@L G7#R!4SO93U*9+@U0, [CPBOU MG'"]6Y5,\- S;:9[\8*\3]RS<8-4G/+?O&_KDW:/7?LWBMT?-_8$1,5CU^,+ ML5KDST4J=XLM."O[/OK'V]I4M0:(BR>+:L)T5I[7U9_T<8G$]1=1NDDB$,#H MUU?[50:W2LZ1@^55.^O^(&$MMH+F?5QBA^8W9[@_%O,\W(,9F)/_G>[NS/]. M]XW&?AH6YKM$IUL\X^2=-8O8J^S#:RW=!EK7?Y9VUHM1I#U>KB 23, =5 MX/2D3? @X Y J;!3H[(J]//QMLU7!AFR;(W&A>Q:K2C)4R_*Z@^9M>UG@1P[ MB"Y$S$N'NA3.[*GO!"UU@[GCG6^&GN< ="CV5L]';8*SL#O62_)C6+]20^7( M6=6/ 9D],GLOQ>PI<[(?F;W]8G0@7,;E\NI*O[IL:I5;I;,OL]D?T8SIVZR4 MIAP;#B7JWHV3LHB9A5CA0-1.70,''4-9((\83Z@$ M20.,(ODK9:$A?T7^ZH0UT&B-1B-EH22/55T2W.Q6+Y7@N<+,=\+W);&^[Y, MGU9[A$K0*%,U)YO6/&1$X$!Q 5([&BH+$RF0JLB0UU$6&E(:59$AK[. JS?0 ME<6)-(@F9-6#YUVVDP;VW=!DK$K0-**X339-360H*EC -:0I5<40:8 "D==1 M%AI2&E61(:\C>9V>LC"1 M&TJ'KP9+W!?.=>%NV5C5*-6EGO0Q6VEXL,Q04+ MN/K[9J.D0"]7@1UEH2&E4149\CK2 MRE&:'U4,$:7G1QMPU$:=+;RS,!BS*'(#W_*T,=LO5ZT6JT9M0*^JOM5>G2NS MXSQ92S71,TN?&4 AB0I5\E)*)QM-4CP%X"(WUQ"\R,V=)GKDYG:#U.C6O5"6 M'%WCYX@WY>-.D-QY3#/;5>?C_?:PISQLMT$,.;A*<\<; I5=H#IUN]B G*) M7?(W ?RB(YE]SS\XUK3 $9$]=4TV6GI'F2,!RUK<%ZF4RMC<9OG(C6,W9Y?\VV[?&(TZ?YOPNV[HAO@PZNAG?R %*0$__K # M0PTSDYHZM%V&LMON==.VO=L)T\:!YP6/H)0:EQEM%K((+HN *]-IX -QR##\ M,GQ@#EP>:N,D3D*FN5&4X&G"_+NX\"C&,=!5L[M>DJIRP)7)D)12L%@;OS9D.(L@\/&/> M!N;E?Z?&DO^=FF%QY5]>*VE5E77Y0;-U<7!J>LX'CMJ MN7ZHM\WN2UA#DED@+0ZT61+:$]S>0%8L92=4VJ,7 =".N4P-ND*=B,HBTVL/ MJ)4W.WJLVQH9IK)0D1(=,'WX%+!GS_5?3(1PG<11;/G(A334#F:Q&_CE)@MK M6?5#D8$:.D)&35ED*#)8P-5M&:;>,LUR:WU(CY32HWV" RH?/$=P@)OSAZX= M,R>-$Q+?C?>-$JA^H(HOHM3GY2)#44*A7J1D":$0$M"BX'Q1 M\(/E>GR629JQNQ>3$0F,6B(BH65492'MM'J#8:L_*M=H_-Q.D!93-;O@L2F4>;;U5.K#)A93 ME6Y'JKDDLB%R><$8-B ;IY[QDX:W&-I0\_C!F ];0QW^F<.:(:<&\B8UD.=M MN7OWB._8Z[VV97P"TO#6BIAS&4QQ?;:%;1?\X=>B ^/"CMT'>'RQ!5WN'1]2 M[WBA=SQ*IC!L&&/$JTO(6,N?BX[HH6D,7D>:J>M]S?(=47K"2E.A[46S4J93 M-W@]W> U=!3U]';GV28+%^@/U;2Z=7=SF?7OX4S(*#K?1,"L &;4-DK/VA(V MI#0$#/F9;[O0W9OQ6335$*%"M&-AX=LFGJU3L+QVO)0=0"Y_QB^&L)QP8RX(M>LE6=$Z:K_5[I._NO9[ MY)-)2JMJN:W.#ZE"22?LGFOOF,UX3U_':.$&Y>6.=7INR%961G9![)C;T37@ M])'GPVO39!@=+G.Z\(X*P1"=+7,PY)W68-AM=;J*&. FG2WSDA64_&4C\3K0 M=+YX_?M)"1@K<(*[(WGJJFKTVR8YP28@I9I1)2?8++S("9X4GN0-3Q]C1BE3MA-ZSKUEZ21-ZV:[F^T[I/?_Z0 H0E(6&#)NBR%" L$#K%\/H MMSJ#NI>*D!8MX;+O_D?D<5ZN77NINJ(^,N1Q%FB9;;.C*DZD0,H *M"*4.1Z8C*22Z(U*G^], 0F? M^>N,NJW1L*N&]6S02;^7> Y!^)X &C721S%EH^\TLZU&S:+V?2.A5I';VFF;@QJ[C:@@XQ/ MISODH(-P:?94:7@K..J8IE=ER+LMP]1;IEGW@8-TRG&C%)3\92/Q(O5J$EPK M<_D#$3MUC3.,=H=\61.04DS9R)#?]$&KV]VW+99I3F[S@E:^X_)4N>[D7J'GFZ9N%%GNXDT2-/MQNBO?9 MD9H:.;IFJ!XYNF;A1250E69TJ?+9-*2[G6Y+WWO*EYRD:D:7UMDJ-N7[+Q;% MS-$LW]'8]QFS\8\XT![@:\V*5\P!:\B+*,FYL1CKL =L?6!A[-J6EQHE8(G8 ME=,46SW"C;E8U-["05'4";6]411U>O!2.%7YZEW=,%K#O:L.U$/W(A64_&6S M\")_J5+5@=QDTY VC#:UF3<"*65,+KG(9N%%+O)EPDN^LO)%QWN?M4.N\D7J M)KG*9N%%KI*R2?*0!W1YC8S6R!RI876;Y"35M+GR%/9O,:Z5S:]RW(<].%1@ MR,\E9GN+@OP,'/B'T=B@T(8/YW M*I#\[Y0OJ1@"^IXUB]BK[,-K+15579=/IE_=+8#SR]D#Q6W==J^[ZL3G7677 MS/A;7P#@B5<^G6FOY5Q-0\S@XQ6EI_"SZ?]]^%[9\'=0*#[8#WX*L@E3GG%GQCW>.[^$)\ILU"UV9M;26S)6.TQ1:]--W527>+NFL> M1W>K]TF[ZNXM:).?<#4#G8OBP/ZF!;/8#?SH:7]3;'V#![H^_&W9=I 7):O MP2_NU(JY7N>WP##'S(T3T.=#M%'^_/MO271^;UFS5S?VA#F)QZ['-V@QWEH1 M=PN723Q M) B!?;H;"/N,-NB+Y=\OWJ>YSINSJ[\A7C,&([ 2@ 3\ M](6-WYQ=\F^[?6,TZOR-9DXW=$-\&'7TLS]2>X0<^/&''63+J-4ARS&:L%*Y MN(W!]@6/:/:%-8V2*0P;QAB!]0QCR_5!Q/#QG/>:=1>MR2=@73@Q9+' M6,1DF>MX)=/6,^-E0S M'ZN[9DGH;$$'1@PL 7CZ9W76M4RSW=\,7L;4S34J85>J*%+)D&SL B^%[0% MIK&%)AVZI&IUJK46T1'KP M8A4SJU9HO%Q!/K#Y/M"LU0<:^EY'!Y(R(JV?LA+LNC+5:9.?!@EJ&*%5$RKD MX6MT!'N9$O(4Y"E.T53^E4Y]OTQ'<2'F^U\F\5_8U'+]0JWQ)9%_";^$EATG MEOXC(EXC(*IRB<.A4%H\1;I<2[ M;$)'CJ!NK,HEZ.0IR%.Z[IPZUTJCB;Z@1X,4B M0Y& % GH>FLPVC<8("5ZL4I$CD89)$A'%$6&'$TAY:0E:(IAHKX&D9=1!@G2 M$461(2^S0*MKF"U][U8-4J(7JT3D:)1!@G1$463(T126H.V[QR-I4)-FT&@) M6F4S:*;9'@SX>7+==E?=+B>*!%1!@NR8HLA0)+! :S3JMPPZ#$XU6-17(G(T MRB!!.J(H,N1H%F@-VAUJVE0,$_4UB+R,,DB0CBB*#'D9:0W:H-_JF^I69TB) M5$6&'(TJ2)".*(H,.1HYG='W;0@D#6K2#%I5\YV%Z;+L$+N4\X5S[#BY,RL$ M%K\ S'[J]-HF7YC6[;2[=9^-)L<"A%%S>CN,S7#1T9!*HU<\GO5P $\]]C!& MK4%/5\-4EK>3I'P*P$6>36EX2)N:!-=VO[4[8J?NNP;M8=WK&TC7&JAKY+D4 MA8=RLI-$CW*R'7.R#N1D=:^I(,_6*.4CS]8$>$B;F@07Y624D[UH7:MMB>"F M"4XG2.X\IIEMUM0MLB#8(GOKA*9-'(XM7YF";\*1$6VEXBP'+$1 ^]6BF MVS),O66:^TZ05FQORQM;4E %X"+WJ#0\I$U-@FME,DZ(*8P8*5BSX")WI28\ ME,V]3'@IFZL8//VC:[T_?]RGP'U@4,^<+_"_< M!I_X<[_Z;AQ=V+'[X,;S6T0F?Y3F.F_.KOX& 3.&^IEF _WPTQJV>]F&O!=:E$QA MD',M&&OQA&E6RBXM9)X%C-3B@'^/2%K^7(C#T#0&KR/MR\W72',CS8JT<>!Y MP6/T:B$D50E]?Q:OU\4?)#"$Z4244XOVY@R199Z'-@NL7_YW:@WYWZF=M>&] M+,RM:FH2P1)YUBQBK[(/K[74;.JZO!7(ZBZ*&GIR^_WV:/AX8B% M_M$WB!DJ"P2,&/0.D##/:@6ETQZNU@BI+B*TOXK"B,SON\!S#@/N )0^)=,[ M%H)55U9;CK@%B3*HD!$C(T9&K#1*?_$Q,$=992$;MF^+\4D&QTV!YW1=3--@ M( =3*TJ+@I&RRD(N1DE8R(:1#5,#I8L'%EKW3%E-(0-&,7(#X2'_H@H,Y%]J M18E/I6I\+E59;2$?HR0L9,3(B*F!TC_APOC\G153G*P2+*K'R86@N-X-F!J% MV5$WQ^K7OCE6T[!1RQF5V4+PQ3FLZR2.8LM'QJFA9N2>ZL> 3!V9NM,S=5>6 M&VK_LKRD[MB<+%WE@7BUJU56!^)'7JY7&K-R7=('@/;6\BS?9MJY]H[9C/=[ M=HR69NI&W0?/;?!7M+BR_K5?FXH0M/? "<-K%J(0VGS@8,Q[>@L&H8:U;=)2 MSI>LGN0<0F *7Z[-MS=ZD9G?9 >9#XS+7" M_>DUK!=455=J;R"0G1B%'@V"[FD,0O'%6CR-ECGL')!VGU0KCTK -$#1R%NI M@@1YJ\9"1]YJ!SP[;:/NH]/(435LMIL27Z#O7WQ+/V7+AA1)J(($&3%5D1&! M L4!2.VYLBB1_JB*#/D859 @'5$5&?(QY&.4!81F6!N0:%X%X9BY-,=:.Q - M*'V2'5,5&8H#%G#]TC&&-$&J'BZ_*@L(>1A5D'BAJM$ 9,C#R+.:^DA9H$B% ME)S5K&4SG49DH.^_S]RP]KE.=3:94 F;!I1 R^TK03913?3,TCN#4.BA0I&[ ME-+1VB)5%(^\FM+PD%<[3?3(JY%7>YF*I^I^M;1-EG;#9G&Z3Y;.]\D:U%S# MHJU &EH+IJU 3AI>VA.D\C6[NM%38$J:-@9IE(:2?U0:'O*/+Q1>\H^5SZ=W M>FK8VB:Y1C5U4RX _!9;P+S\*L=]V(-#!8;\7")7SJ5X\YC3T?S^6Q*=WUO6 M[-6-/6%.XK'K\:? ?^#K;Q3$#0\N=KKO/F[.IO$ %C:)QI-E */WUAXS=GE_S;;M\8C3I_8UJO M&[HA/HPZ^MD?2&U*[(\_[,!\P\PDK [#(,/>;?>Z:8/>[81IX\#S@D=@DS8+ M8OC=M3QOKF58B_XK@5C<3O\+@B #Y8X M65:+$(=("Q9'DK0T*\)'S+7'(/$<>(%F23"_6@A:!:+.>=^O2=?_8?3UUTOD MR%K,]3NUF&_.=)!+YN&)$S9P*?\[M;;\[]2.BW,<,3S*2IVDDB>=DVTX":94"0"IQ-,H&;E4X H6,Y$D@K5( M2$;RV'7@9U^_F9:&3[_9]B\KQ ,6"]U->^K5$?8#5R#.?_;E>@U8W%S":=7? M'-O$[JCGA\XH%7)04SI2.^JV1GL?7D5[BK]<)2,_I08.Y*<:"QWY*?)3S4:E M 4KVC'Z*D"!/]3*@(T]%GJK9J#1 R2BC4@,'\E.-A8[\%/FI9J.B^JH2FDWD M>V1HP0RW5*AB2O'Y6S H!58%"3)JJB+#(P<*#)#:;LL8C5JC4=T-FJ1&S5,C M&I&K404)TA%5D2%7(V4U/6/0ZIA=9<$B-:ITEL 2I-5KZT&P9 MPWW#$CJ&]D7J'SDWI>$AYW::Z)%SVPE1.EN]"2@IHW?DU)2&AYS:::)'3FW7 MC,T8P;]]VV/(N;U(_2/GIC0\Y-Q.$SUR;I2QO4B]4_64J[6GFA-L1\9G92Q" M\-0/3YE8I.RFW04\*5A1&]YR.R54A_"I1S.XBF70TD=UKV19%]6L-;:DH K M1>Y137C(/;Y0>,D]5MT2/=#UECGLJ6%OR3TV0T')/2H-#[G'%PHON<>JL\?^ M2&\->^0>FX"6,@I*[E%I>,@]OE!XR3U6ODV08;;,CJJG82KL'M743WG&^+?8 M N;E5SGNPQX<*C#D9YD!9DT<^(?1UYO[="'X0S^LS" MFPG(VBT,\*T7V-_^^/$'3?L]>_[[_R1N//_(XDG@?/ ?6!1/@4/7CSX+HXD[ M@[OQV%SKGFFN\^;LZF\0'F-HGFDVT 9/_,+&;\XN^;?=OC$:=?YVF/LGN[>\ M]S#<>'[QW8W^MMET]I%Y+CSG=L) Q!D084O#O[8S#B*KH@]>F8!4WX^E=?F#N]2\*(D7 M'ZWO[C29EJ'WPZ>KM02;>DKPP005L;[PO.#1\FUV%83OP/[&X\2[L.T@\>/H M"[.9^X!F169";P,3.%6CCEZ6*@G <@-9&GP4L3BZLMSP7Y:7L'=N9'M!!(H@ MC[>_';3\"6_G_)&7GA5%!1#!4LT_6N$W%E\EOI-)[]/;\X__XX*LA_9D_B=[ M8)[\K/R2#SX8HHC_;JQ]X$=F(4&(X57(_I,PWYZO?)IT(?(K"4,P; NI \]? M6KE,<]A;4J^UG-X#D $!LDI/-@!B##KZ?H"\8W?Q!S^*PX0/& *HBRFJE(S' M<#L>ER%S7+S=]62[CE;ES\#RLQ_VI$[O+!&W;M1%VE9Q^B\WGGSU@[N(A=Q> M"$B!_8&/0^0&, ?CK16YT9^N=<<'?\OC$O",GUB!/:-M]L[(S/E^AN\9R9!< MX(- 4$T>L#6S[X=E&U;N!YUF0)%@8 MSTG7R()6EOT1IQC$S>SUN_W4D99GRUZ\S+&5F6HTF*F;O(83&;F>%3OS:U/@K@:_ MS(Q?YB[\,O2*&/:NJ*HY*B-6[@A9>W$/V< \IA?@1THREFV1F M;\PM@QF\,N!O)*X_HY% M=NC.1%GG2S"WO'B^0DQ+Y!YJ01AH,?.'??>C;604^^R2+NS(K@@\+48'F*)P#\8:Y;O)Y:G^1#G1A;( M,7Z'.\%9G,-PQRR%HYW"M(&YQ9 \]>F\ ".SO4R*L8[M-_CJ&8A&Q#!_P[S MC9.8R6ZCF[F-?GD5[RXE'?+8=Q>L35G"X10N"\57WV$A1Q4>..4 \*@5Y&6V*%\N1"<5FH*,X!>9: "U#US\[N;\>_[H M&5A(R':U<2 &Y[ECEMTH7]#2K(W#@%O\P#\7HYEK47+G<7#@*]+7$7_KKZX2G1ZY_ 1\[OY\ L,(/G_5\V$A;&%CP"$ *T^!%K"9>9 M[ ?;#>UDBAL_VFQW/4I'>?A.#4.$0 M;X"55N@&^?U7;AC%X#T8^S<\(-K':SV)RQ?V8C,/]N77(I.[V MQOU>"==X*7$WKG%9?.^!.MYY;'W0:>J'9( [&]V2Q2Q#CAO7$;%C[F;JA^1N MVRGM@N0=*Y*<5V5 MFJ7#?9J:/:%(HOHRF28>3V6J8.?U&!W0D_<5W.,A^=N1-+X_+!C&X_!HK2A& M/%58?J>4>1;8>TB>=A![=ZDBY*+:62FJVRDNP2RL5T-4+M^%H 1)G#U09MLA MR=_QV69L8=MVVN4P#8*)*;8=@*RZ@7,]EF3V*@BWNASCD 2A.MY!,&,,S_5> M%K?M0Y7$E5UND[^)@41@_3MXMGQ"QS.=#\I)J);-_KIN'\6M!X7-QJXY\I5JI!!LY4IW+34IBLON2 MNXCW$L7O'[!;;SXK]! N_2PA9.@I0H8.B3LB-#@W]&= J.),TZ@C%]H*TNW$ M#5=J0E\WS5'9/HA>[QD3S:IQJ".AVA^'7?*P3ND1A=4];6T7N[EY6[_:R,N(ZR]>WN M64/X=?B%Q4GH7X]YRRRX@D^!;P?3F>UZ;OX>'@N/*[Q8*HX@7_+7+@ MD!QB'0=Z>D=P #XX.ZR.N8[YH$8A*CU MT593=DCJQ\G"!X*6B[%9BJI3V0T+.379=W]7 =Y=7@APJ[(?QY9 ( ML5*3KQ9?.H>$AQO\0V=G_U Y7\I$@)WGB !W6PZV3P3XT?*3,5C0A$_N^,Y- M,IMY\]R>+%71.H?$>E=?__?#U8<_/UZY/K-34J.T&_%/=^K&S-E6RS7..UGY MN\3 )3*WD/4<4=R:>9(%!9M'_#D,)NX=%U9<4">/]I! [" 0KH)%>^F3[E)M M!LFY9OD:;NV P[8\;8PMBG-L&-/@5AB2ZZ7]BS,W% NILP[2M$G4Q5T&W+&+ MIL5?;E^]NKJZU-P(VTTY;^"B<1A,M8AS$N2@I47,\[!Q$E[GN'BR]5V"LQT: M;A(23^#BN8W/#5IX!?/!D^*O^)YI+E"BQ[-PP]V\I6'3;(P5#XVSE?>SXG>S M))P%$6MK\:ZR?O*)%1?ZO,?8[ZH%=]C@&VE7[R[2CGY4 MSTR"1?LV:)P=@"PC JE2X$. 7XYF<=6^^/R!*\XO=[]J_POZ8H5SS1RT-!./ MTN(_N.[R6$ 3(O<["+H?3^ AXSCM45\BX./G__>/(?BRUW YO#]"54SM0]:= M/,V<=I0/0B(TOSV6MFF NZ4'!Z#M]Y;<^,P' JQ(Q.7 B/O0FF;:M4'HY$PC M\$,VAN=A6(Y.EB^+%@MT03,M+UO36&@/Z1R2:QQ'5/NZ80ZS#V4G.K(%%+NR MIA1#EUAX2(;2?!86F986/\!%2[MZ9&T\*\8H\_&0C*8"/MZP./;$5ZOL93^S ME_W2L7"AUVY7SLCU4=L.$^;<,$RZL1W]2=C?W93UK(S@.^NWK^D84AES]:MW M&]RFG&3E]A_K!P?WC$J.+M^- B^R/&2\]9U%UV!LP]N)Y7_ 4COCWZT8\Z84 M8T>&CH:%?*C\>*J@8U-.L2/O>P.]$D(6":$?B\T[5HQ[4W:Q(_^'QII\=.GU M>XQRRWY#NW!W:2U*R5%^0',(X0A8%S3&*X:X*1;=D9'](B-7OWO7\6T*0'9E MH5YZ?"*PPF _WYQDQ=@V>?8=>=>5C.K*]Q;YQI4I-6_9E>Y*!=^Z!4SY,9K= M O\VCV'/\?:V>*J=#)*^]WC3RR!Q';,HXEDN!#*KQENE\^KVGAK0M8-87KWL M8_=!8:^C=/NVMT$8!H^0*UU:,_A%7J9O]LJ4RG;:0"F]J;@-4GX3WH!E,+&] MX7Q%)-7;9?L,\\D,TRY\J(:#9:IR3SF8_O*%/03> SZY^-X:>/ETMFYW7J8] M,=CH%X3S; 4A1 7>;$HOS-*MW"4>5FF9JB6-&9;5PYZ>4?03M07(^6E'0-W M9V"98IF:#!Q*0?M>;"B4X9X*[H?Q90#0A%CR*Z'594IT3=!JLU?H0MB3,]MX MNXBD<*CO?6=IZJ)7IHQT;+G,&AH&:?=Q_USOGG\ M@SET?=N=61X,:.D!\OJU7N5;&5;-HL^=_L=,1W>D<]/&CH6-&_Z%FRF#JG\! MOO*] 64.E2D '95#RU7RCJZ]L^;:GQ_>7G]9MR/D9G*WAR0H<==COCU$MN-0 MRF5YUJ1?9II; 87KG>O&YH!C [V;I(IS\V86,LNY]F4V%[A49C;\>%Q*;Y9' M*WN5/P/?"7RN6G>6_^UZ/,9-;/ J+G!K65W"^>KRSMME&;F)_9>6YR%R?\*_ M2(Y0^OLE',=RK,LB.EB> -Q$9B56KJ]P/O'<]FX?%=XO97A^=M6HS-V#E7F5 M(?[J)Q%SLH@0MT9U^9;\5XRM.D3 [.^7B]2AZ1)3NZM9"M''9C=5BCN%K=D* M=B1XP)V$XJ\^1DVA:\?XK&CRUO)PWB)U?$L38OT2.K! M+:E0$$78^ LBC-NLOPNF+D@*R,UB4#(U):+_:JCYZO..)+Y<*M+>N0(2[1+W MS\HWO_OH.H['%K\&8^T31/P3[=+":53?:FGODG!B3>&2!Q=+DY)V;"=\(Z=P MWA9[B,?,=ZRBP)=( *IA4C >NS8+H[54+0UR(T$7GL>R?HX%,8,2$7HUQ-RQ M^)$Q7_L(KMK@73!]O@W?)U!,O"?[%+M][=(Q-<_8$WAKF>T@NM_'8?(MP+8H#^YOF\#9/<1U_F,B-.;?%*QUK M"GX@:L%]N'D>_L#2U5[BJL2>: %.5,#0/)>-L:7)8:)9:+%C)>?M>KS*X;!9 M"]DCD.!.HRO074=T]LO E0CC*P%NRT*$U!2#D5ZOJBLHV4AZ^DRX_.D"_4&) MZ+P:@S0LT3HXJT1XB+M3%"E[7:;O)@K>VN"[>'+\4,0Y*Q,OK*,0C(":!Y[#P'9CT![$%=JFXT3PWC>>+&P<'1,'[T+2D M2FD0R-ONYMI-,D-_%VYQ3Q5&A(,#PN9]R,_B0FXN'$A;;/"CU42)&[W. 8'O M/F1>L;N0=TVCO<&O]_(R)0W/\(! > _B=@@HJC4_PP-BW:UT/KD?O6-2.';L M,^-[XRPNV6BY!N?Z\%SO/)_EVGC&I%KL$+DQ^/'+"58L0"]2G\Y#$/SC'8-X M!09U#)NW\1!+M1A7D[DL<]:E(ARZ!H[P\*YS@*$M87OV#^[XF:B?P\!F#(F* M\$?(NP[B-*R MTWTYK6:W+7<++T9=W!\ I2_"T^NS;3F0:<,7@:/S!=CD?8#6*R[$5^7W67R(KZ= M,'&J]PV>;;5RF>T..^7UGK3C+_-!WCC$0JO*?UIT&XCS:P67L<>#;TD)/W-% ME9EXR!KO^IG86=VQD3?R[LZ;0WU2B8#T$*7L94JYI4-CX9.ZP(U#?=+.7"@1 ML1["A<&:]=;KN* ?1G]I0[]@0:?, 7+/(0@;S,J@M[PY76G"Y+-S"M;[J5_J ME#D*[LB4FQW9+ZVF8 >1YS^FIX^\_PYVA;<,2!QXUL!TCY/CC7YGT"^I RN) M6Q&CXB[&W/(#]W@T+Y^[\G:^N";;\_+1RG9BSI\;?4A7$/S%W/L)^(X+7*Q_ MS[+?E^+@3IGCY)Z#L>;6<+AM=I:BX:/Q9VW =&G-W-CR!*RXEW'XP)RK(+Q* M< >I3-]E]E85,TQ6S[TX/UTY@5S MQB1%VH,1>+2A::Z. (_.BA*1]DI6?,F;/OF+L<00?;GYN@<[#-U8/H^S/G:4 MB)F+[%ALQ1-=/%BN9XD%C>(-_T15B8I1\F?/\HM;^#T&MY,@B2QP6!YNEHA7 M[,''3F\P[(_Z:O!QURT4UA$U'.K#H3FLC*BM]GN+^;Y.8NQJPKK;HEH *\_*-)ZPU([/>PC]0MS%S M,;+)F2C3OW6_KYWIU]$55J@@*PBHED.+_7M7VPPJAKQ?B/ M:%BKBMB?9+>*&]947?D&IT^8LNLN:^N88O8[7=,TJY25I5%7RY1_07;/G+2$ MBDG^;8!?;1*@C0=T[21 $+ /!X/J>%66F&=3MI(ET(W'>*V*;;;6+HU^VWR> M$*=\U?+@BFDQ<"C+RZT;N>Y=$.ZT]6&%!>'RY"E2J=]XZMBIU-H/?O>*:*.Y;?;@T[;V*6Z43&1E0OPDWBI+(OWSA;*F-S^+C%AQ436[L-VW7=X.T.- M=N=YHLGC\5&*ULKR<6NVLC,?S4KY6)*D8X>E9=F[:[931DR[%>:"AU&Z@NMW MV\=RM[/*?&%3R_5Q-Y] '(686![NH&;*K-Z:0Q6;E3_W_VWH'\WNNR5F'I> M:CFX7EG6#4#:"ZNS\6R[51SL_7OT<5 A__88?K7\VUD;2K%U2[JU1C KY&MU M9#V;V_\ [W']R+676G0[&P_C6V5!UQ^7W=<'W2IMY]KA/YM2%U]3$+*MR5)I M-G4[7?T)FYYE_,=VVOFAV>NE;==S0=:SL3^4$2O11'86'A,S#8MF-[1 MF_7:V^-)Y2'[.INM@ZS,HI]FA8R=MO%< <@2'^M!K,PBI6:%C!!^;)T9;#)B M958_-2UDQ!F'K3/E30:MS)JJIL6,H[9YTJ91E?I'A3%CI]ON/E< H@1FJE1 MJHL9NYUV5R%_5DT+Z<8S?6L,%,LV//>'YK!;Q>*?XS2N;H1"E7+&4@18NEW6 MZ(UV:;)3& E5BA1/(KN26/1[([CT)+#8> AUG0%;22AZNCX85=@872<4JA05 MEN.PLIL9C/K&B?B*,F>%UQ%>E5ZH5NDRM3) /)ETWS-2D]Z5OGV/_JHR!Y77 M7I[[X_/@WZ./VWH7CLY&Y;%5I<*PJ9"'_6;]C^;VQBB"=QE>58H1FZM^"/#@ MH[&](Y, 7@98E1Z-/^.Z,KRH5C\T;?X/S[9+^[H.O*F64C=M[ M\]C*[#4"WFI6G#S-852ILNQ7>NSWC4&GPI[49UX=O@F)OBHUECTKCYV1J3=G MG?Y&)%0IL>Q=>>SHPU/1"E5J+'M6'G%3C_Z)J(4J]9(]*X_]0;]?Y?J%.J%0 MI;RQ9^6Q,ZADK\ =@*@JII/>M7]TW%>E?+&Y\MC[=^>C:3Q7=+P_)Y6'5Y7B MQ;;BH_GQV7*?$T97E=+%]MIC[Z.I$\ [ ZQ*[6)K[='X.")X=X97E8K'UM+C M\\T,G2ZZ U6J*'46'BN%]PFC9&YOW0EBL*;5<_M)7]OR@UV'NF7;A?P I?X. M0S6?9ZA[[Q.W8:B]YQGJENT%I!/SR@]UL,]0\Q-&6/B ZK?RED^!_R!V'<#T M,;H-8LN3?\?S"#\%\;\9#,L.[OVE+?8'6W<_VP&/_A*1ST; D?@DMEB["L+T M*[Q.WM!CL-M&RW]\-B%^E4WD<4=>43%'G CTP8_B,.&[UEW'$Q;>3BP_M08['ZF2?OEEXPDSZ46[;JA?>G_X7AG=?0;.'0NPXK:C,EXE\H;CX;7' MON7FL',DZ(H\/!9RZ::;S%D%7HFL0&7P.L;P2-@]X6+]EG)8(N@_)GC[GM]U M*^UCO!7V)JN2'P;]]2[=A\5MO8EYC)KM%UEP"\ MLW75?YW&_OUXS.S8?6 ??#N8LEOK.Y[NCF4_UT]X8R)+-TF702DS/[WRS/KL MQ_0[$%-F6U&\2K)Y+U=>;*^; NSW.E/S"PY:\%TYH7T-"D@FRZ(;9"8S19='[[[:7 M.,S!\\Q1*I.8\^AZ_-X*L00<@0OA0GDQ#9+""8C#,@6(P][Y=K[Z 5L.3EY7 M52YY@G(EC'IFWI 8G-%8"]?(6A#TUC MV# T2N2N:J"Q^T'*QD@W&N8OMAX_MJM,@LL<%/:1:@(7MIP2MD?L,-!U<]AK M%A=V.\"KC"ST1_JPUR@N=/4MAW#MX3/[AFEV^M5SX???OM^%WA__/U!+ P04 M " !F@F)+H]4)4:X0 "6J $0 &-E;7 M,C Q-S Y,S N>'-D[5U; M<]LZDG[?JOT/7#]LY=2.+,E.[&-/!%%&\@)26F=YF7F$1WHQM? V@T0.CSWUX=VWBF7##/_7+2/^V=&-0U M/8NYRR\GON@083)V\K??_OW?/O]'IV/\#G],'WXQ?CG MS=/8F)HKZA#CUC-]A[K2Z!@K*=?7W>[+R\NIM1"F=VIZ3G?!7.*:C-@=0?DS M,ZGH&IU.5,604R)!&^.62&JH?]?&6:]_V>GW.N>]V5GO^NSR^E/O].+R[-/5 MKY?_U>M=]WH) ?\(K#$2_T# Z:?3WNE5@NR1F-_)DAKWMPFRJ^%E_]/=Y>6@ MWSL?]D87'V^NSBXO+@;#P>C\XNSVHM/K]?H?+_I75^?P9_^R]VM2E,C2%ZU+;IAMC%!G]%V,\'IX: ]LVGI!8&$\4VX%:IZ$L$30C(..* M:QKQ9=>2O"LW:]H%H@Y04<[,DXA/S[3+ &#C:Q%S+8B8 M*XZHI*M0Z/4[Y_V(2<@UCQE4%8*:ITOON8LER-#?97 ),T4^ARK*J8.YSU3( M?)Z@#)G.=YF0RDHQH2UGO=ZG;E"8,'Q)R#K7;BS(4-Z$W/=R7?Y%<1%N9H93/W>TDM6#PG(J[E-4/_XP(4_>X_'\;!6'D"_=TP/C-G[7%I!!U_[)EJ "R!$I\ZD==T\%6G M?P;-H$+D4GNIL/7'O52(NC'6_:FHUOQ^7ZD^Q9H[%G2I M+47TIK/UX2(E2@>4ZKJDQQC\H[,=;$J;H&A\.E9+J/FA9E-DYY3Z?I">S- 9 MKM 1^Q>5'#$[&1ZB@^=^/52-Y$1>WS62/X M1V<[H5>J/QT#[%%[%)6JOVK7GXYI0P6(ZWI2U:J>\L"BR[2=7=9ZP5_L4J14A:%]1A3RO?P M'ZS:$@NXJ"H#Z_K<37.DA?F"6A/W-_7WFL.ZQ@W:)<$=DI1QFL0V?7L/QJUF MQ7SAVPB+%$11.SW1A:%"X&O"3:0M#Y2[:^ZM*9<,9K1$G*T$K#A=?#E!,#L1 MC'^ A:> 6T22J6 7/ 5ZJE%")2,)DDD4,=P2*<3$7PQBQ]7@%//E1$!_L>F/ M7#1TWZ91 ?VZC;KK,/EM>AO3:)OTC0RWR;RNXLPDTC,;Q/>?-PX?_@\$<0I:JSS"T'.%9S,+ M'JT;8N-*>[JB5(H$A!6(=0#V$UZ*[U:HX2V, MK=@6V8.1'1*Q&MG>2RU@MTPZ7#_6P!6E&DILBZLV.(HW&V^I,#E;HRZ3Q8TO MF$M%$DP=I0[!3RHDBH7@PU8.PA9):D&K#MH-$0SZ43*\SH4LCTX'V$4&,"4% MH4K*:>&J#M>(,/X/8OMTLHAWK>]=(;E:'.3W-AV/#L;+#(PHT5 B$X6E.J@#$R3^]2Z>UU35Q0 DZ;1@-/O M9< ))1B1B!:AZ@B-/7XS"9 MG&J8NZ0P^Q?THS)Z'6YG&=P2TN(Y*9;7PE@CXE@13E>>;5$N[O[TF=SDAQA9 M,AUHY]F8(B'D/\G:$W\U EDM8#4 DY[Y?:)6NH\V<0LBPC21#JR/6;!0A!'( M,)20%J7J*-V[0$9GY+5@-$R6Z[#)9CL";D.QMZA41^4KE6-/B$?*U5"4BTR: M1H=.-K4!$@P488",8,QK,3HH#?7HV:PPKBBCUV&7S6?DIJ6,#Y'$=M]F_]75 MK'CQFT^I0R^;M$BOM(P/@:@6MH,BPA+D"HEUX&5S&(7188OB$<+$,@SS234( MGF43'=F0L87N\"BE!+E\2AUPV2Q(-F)I@3O6MN? LI1VN-,2']*ZI9(PN\:6 M:*D4'>#9]$G!=BE.H7%%R4-EQH>PKM8?#@ME:WM#71DZ7\AF9?)#WM83CND) MFHW7VEYQB#R=AV13014V>5M_.6[TIMO1K>TQATG4^4PV155E_[AUFA^YWDX] MECE'-4Z=$V0S89GU>-X2O87ZL&W1VD-!968=X-GTV>YV:MN_CPIZR0YJ;1_8 M5Y;.);(YN=*=VM9#CALV9+)Q]>.$>B)T_E GS=?ZPH_U!>R)GJN2=-%E1B./ MCWR)^Y%"^/BY2CW7J"-1XRGG.>G$$D\):@XSCE'=!KB,$=1N1-6WSG.,[''] M8:2. )UK9!.6.9GF=O3XD0Z0?JZ#?1&O#O9LVC(7]KQ=AQ;RHT(N)K[$FZCP MPL$]D<\3H7. G!-D.@<01J*>U@^.X@>^XQ"^F2R>A"_4M9(P!=?R@C(!.A^H M'JM]LQ?E5<'?/FIMW:Z/RK@J8WD 2S1+6;[ M>(7LE)H^9WCMQ]VK:?L6A/C<*-Z52:_!,.5D&RX6J M,\=/54#G>E6.]*$#)I0TMEH:D9K& O0T$HKBZ!2J:D2Z&J&R@=3_?]/7YV[R M%BYXVKVEZW-XY:?R&?3H/\KN4AG,A=I9".X(^W)2C3:X,49=_WH-[Z#E[R5U M4,<30_A QJ2/''_GGK^."!F0G!C!WVO*F6?-E!C+Y^&GLRZS;3Q#\>5$ S#@CMMH+(;8Z7+K)H%J)M(EP/E'FS'TNU.O)XH'R)>5/%"^HB_>4 MOJVA!T;0X88!!W>_ ">=,UG<4CF'.V#\ MI*BJB%JBG*9A[IVCK#I'5F),6+Z'(9:\7D$Y-_VY:HX?8](#A7XHR6P%T_2: M@@ZF>*#.G/+(IA*"G=YI>0YA[IO"@YUD[!%W1$QFPW2X:TA1:=.LB%*[DT68 M?U:1T[T+<=>*N$N\/WS,3!PB(LOJ<.PX8D#WIJ-I==WC0T'US4ZP-F;L-#FU MR@9/S XE#^"40XQ5<<#.;!(W/5J+5G3W'N*)S/7 C,@*%:"[9NFH MFF;5B'$A9RN8K?\%"J>&T(+"QMG@^5RN0$_/7ZZF[#7/DC*2IMESPSP'^ACT MAX'UC)W.BMP)8NE;^DQM;ZV63[Y<>3PS7^S-WK1V@+6[YUI!1O%WCW]/];2" MTJ99,5LQ7FA$06'C;/ VQ"'#%770K5(FY)8US8+1M_^^']V/'T80HYNAK@)S M0,3=C)D#%5NI$:,Z0]-L#?P).GL81<2+L>P,7$K6-+L>"-Z'S"RJBRTJ$#;- MMBF5,GA7@%8)0=-L>6 V%1)BU$>R40H[^*L8CX19,4 E%.\FT/WJ8_/CJMFS M?%-"S/>GSX!GYMW0<)J%AR#D&*S7W'LF]F01S[I16QPL)ME@L.*E2\K?=FFT M\Z74$TP/MMR$0,<9X#*2GYX\T=B3[ZVWVP5="<&1O3GXY2EY?&<>+&%461)) M ]TGB[1-D:T5"-^+S7D(^VKX8L5=J MC2@=<([IA? >RMW1ISI?XX:;(A,PK0)C1U+[WQF,FKZ,#-,U0A4)C6N..ZC1 MP7S\HY(+$POE:G<-^L3(XS=$T,2;*5WNN/Q^S,E&6.+:^L%SY>IMVZ&.!Z";?O#6R@IJ(GM$W[+F1X0$TF4:&L3QX7RKG4< M64V96S4[:+LC*J8V4JU10G#<$;6ZA85[P[ZCCFT\TV- .%E@+C)C=CPA_ZS: MWHDCP9*=4S#MWCUF7SRVU,:L636MF=J^CW;L)_R)2I_#4FSDNY: D?NKAX?Z MUC8+?N8V=_._,O=[:9W\95QPAS/5Y"ZV5._%VG@AES9(;&^M5I%P.CV860G6 M%_!.!I]HDKJE-L/C@'CS3FF3U&!HW+KA@;C^ @A]M>1QK:F_7MN;6.-DM%>) M-&D@_H3+&Y]E*[;F'6C_R+T5FZN#G'@:)(ZZTZ^;ECE+NWTB[1?94$K2-'M@ M8N-T ;,<"XRS^,F'N;-BJLD6;DKZ#IJ% MK]YT#0\NB5%Z(C*M9_[^_,UJ!SRB#*M=Y2/1>=)[6/T"NAQ/-)!7YOA.;,:0 MK(%HNU>Y-_M[Z1UXSA8#VN"KH4W!7KR.JFD;\KFPP9J#P[(MG*;N7"L9$]?A M:%:H#,MQ+MG_*#%Q5AHB1Y.MB0V@I:R(\V[U^7;L#A5_ZXWWN=Q>_C?T8,B& M7O+-1;TY,Z&'XN]FAK^ &YXSV-V5WY>_*?U;$\N-R8OPF<1CUQ3HTRO!PN)F MN?C.X8E0Y]R#%7%9X]9189XD5% D?^DUG4O)IVE<^F3[H>G0)D)]3^^YF1.K MQ21-FS,2M_S<@N!GM261:Y6>L&FVC>F2V(_<,RG%_4A=6 M 185K$I0O0>KINQ5;U2"J&DVA9H*_& ^^A@HS 8]^G.;F9/%@N(H_97*8&\J M#E/V8FU,8D$S/:M4^0L.D>X2O_-72R[U_;#C,"'P; X\119N?QXR:)I]N=]+ MZPR]%^H&]B0.H6\S$<'KW8Y1CZ=I_60@9ROZ0/AW*J?$IJ)@.:8E:YI=J.5D MH2[,"?,$9!E^#1@XZA,$.6HK>ON36.%DNP=GLS(0N[TQW8>+2AO31ZM\_8C* M/Q.FY,;W+OZ=0[N)O"\PM,1-<]_9BS=;>;X@@)!-89&(MSVE/@HJ(VFP/1 T ME!J3*F^:):K'XR$5->!#WPFN5-F>7[W9;$FB\PLOA%O)P60 UN#54-$1F>#S MY,1%HE'&^I7N)/D;, -(3_-]-3]>BIXQ+QUYN*1)FFT M,XFK6M\6K6_3$;5 6WLJ,<$?W9:YV\TU1&_9VS]W!7ZF3G[[7U!+ P04 M" !F@F)+L7Y)2@,) "?;P %0 &-E;7 M,C Q-S Y,S!?8V%L+GAM;.5= M6W/J.!)^WZK]#U[F9:9V#09.PB&5S!2!9(LJ9I(BF:EY.Z78(JB.+3&2G<#^ M^I7$Q5Q\DT$FRN2%X$B?^FNWI%:WI%S_,@]\ZPU2A@B^J37K3LV"V"4>PJ\W MM8C9@+D(U7[Y^9__N/Z7;5N#^R>KYX;H#0X0S!46OT]#ZT?U)BLQ5@3'T M?;BP[M>D_V.-1OVZU?-]:RP*,VL,A1Z@5U]A^6M%\K>#V4UM2XGS%^K7"7UM MM!RGW5@7K"U+7LT9VBG]WEZ7;3;^_'7TY$YA &R$68!(LEY%/(\41WZ!/,B(\\_M6[!;YX!4]3 M"$.6QV?,8;X5A]E5U8J#"WPW\N6+$]QVBL)Y"+$'O36 $/OT)*4<7!*?N#M\ M5^U(^Y@ ]B*-A(\]KP#,9',-Z(=L_41JQG::*UOY8?7XVR.%,X"\N_D,8@;[ M$:5/L^;Y7UPCZ@=,$GCS^ 'T$5&@4!-=,:P!EAB+?+&+?8WPAVU5]( M.H9FX1\IF4$:+AYYIPNY+H4>9Z)+?1'SH?00+,:F4DST1H4+++S=RIR%HGW0FD+?DC>$;Q!$L.^ND@NC6 M^U&&?@8+'\,0( R].T Q]RP8M]ZRGH>$7P_\1^[ M#G$?S% (_#X) H*?0N)^5^J^!=!T>Y=Q6^J.Y$%=[6[7JNN5DS>QNF:195-3 MXGN0,N'=A0L5B9-J5V 0* SDDH O$@@.>5>#V.6CAJIMI,)4-TR6'!^K%)&K MYS@CR."DMER&*U9[U#$^61\U3&0 M>&:WB171^O2*2"H5\V\;Q;\8X\39*:;\Y1-2/G0@8KX7GY!O$7\OUL#E)]1 M$1<^UD#'* TDN1W)<]IF^153_?J9J&:LD&/&W<_$."V>L:'+"1M*=S_2L#V> MI82?8M;&>FS9K-,"AC%Q8SVT#.(% KZQ LQRT8HI(#%D'U,VRT7;RZN0_;\D M$#3+)TLGF)UVB_F:Y8&E\TW/D\92&$>7C5G\*Z*M:7#NYOF:A_PLQ?Y<^'X)[ M7H PXB( L9EUU4%5Y,^%TJ]_R,NR=RE:^KJ.9N&&.(24=ZL21G!05;NH;[PU86A#S,=FN&Y?3>8T#-TV M&TXAY?XJ69O?LOT2:L]#JJKS+9L=$5:N^VU7URPR=QO+";M7\:Q^8S()DJ-9 M4S..^6QS>H&I&<:"XP0I,J29FF4LHX.]J:A4MM'^"-PSAE>2Y!^8FFNCTS-,A9]\PFK6U/3C >K'I(5>#@ZNWB> MZ)8(RM[[Y/U$P:T#N \9VXJEU+W>12\([!ZGM_/K1C';!*J>S2D-)1U7]5%CB.TCU4YF:VLT7%, M=H!TG\D(" W1_^30_C!9G?WGO@!ABL<&,W%TD_"E<'S.X"X,O.5*]/HD$'8@ MY2EA7D41]9_SI=!%LDT5\7?KF1;KTG3^!2RD-_%,>NY?$:(P=2.#"@<5U(H( M/DSD=M(A8Y&XU4"Y*V?CZ#\<[D+HL7ONV:];'F+N0P#_,7KQD?LPF4"Q6E%B M5!RT0GI2NP]RB<'NYI"ZB,5>M"JM%##M>:;9QEBV]W>IY9W2,/2/6V)=P;7X MAOCZY7;Q.U?9$&_F+GF!T')7FSQ*$O%G:7L!<@>ZHUHZCR*64=XJ%%&XI?,H M8A-*T:Z(PBV=Y=J41SY&$F_?7U7:_J&$>]9@4BD5D-.]85/3:)KT5GB(,#4+ MITEOA><84S-W)YK%21&'Q-@4W^F55,#W-#5-J%=9.>L/4T\P:E!:YC*T5%+R M W=%56<[05%%0A"ELID?6&VJKCE)C3Z9FO0\O6)V@X>F'L(\O5Z*QH1-/<"I M06.920%3SWN>7D\Y*:!2YT(_YZ"=G_8K=:+T[Z*LI*1OJ1.J?Q>%'>3]33W? M6I&R#K9]F'I&M@I]9>T!.OILK9;=:?%_4UB]Z_7FPKVO W%3C5]LBUI)S'/L M4U,5M9(+?+F)3B!CTA3NX3&W^*8B57%0Z237$>>Y_&9FD]3'PLS_/>C3_ E M+2:O-_\][>?_ U!+ P04 " !F@F)+T,:>H%\> !]]0$ %0 &-E;7 M M,C Q-S Y,S!?9&5F+GAM;.U=ZV_C.)+_?L#]#[[LEUW<)7&2[J2[,;T+Y[67 M@],)\IC9_31@9-HF6A8]>B3Q_/5'RK8HVWJP*%$B[0RPBXYM%JN*9+%8]6/Q MEW^\3]S.*_8#0KWO>T<'W;T.]APZ(-[H^UX4[*/ (63O'W__S__XY;_V]SN7 MUX^=GA.25WQ) L>E0>3COS[>_JWSK_.'?J=/O)\O*,"=2^I$$^R%G?W.. RG MWPX/W][>#@;#P*$'#IT<#HF'/(<@=S_ _BMQ<'#8V=]?=G+A8Q0R?CJ7*,2= M^+]OG>/NT=G^47?_I/MTW/UV?/;M<_?@].SX\]P>.3_1"'=N+E,_^WIQ=O3YZNRL=]0]N>A>GWXZ_WI\=GK: MN^A=GYP>7Y[N=[O=HT^G1U^_GK!_'IUUOZ0YI].93T;CL/-7YV\QRTP5GH== M%\\ZUTNA_Z?3[U\<='JNVWG@/PXZ#YCK 0\.%K3 M^J/#XV[WY'#YP[WY+[^]!V3EUV\GR]\>'?[KMO_HC/$$[1,O"!DKHA4GD]6. M2?GU,/XV^2GK?A FOTUS\_EP_B7[:4"^!7%7?>K$0RDA0B?W%_RO_>7/]OE' M^T?'^R='!^_!8(^IJ]/Y!?F.3UW\@(>=F-UOX6R*O^\%9#)UN9CQ9V,?#W,9 M67+/Z7_FE/^"7'>OLR#\_'"S*3/QPL,!F1PN?G,8-SC4QQ#K"WM\8N\/\!!% M;@AC+Z-Y,\S2"2*>,J^+UCI9C;O8G^#)"_:!?*XVU@%[R>Z@;&: M26#!L"RW#IY,][E9ZWX]Z<9L/;%/7&:F^[&-6&>&B\7;^"@V^\N6AS%#JTW7 M.)&E%*)WZM');$Y2;$J7.'!\,N6VYVYX'@7$PT'0&PP(_P2Y-]Z0^I/8-%WB M$!$W*!/T@='_O0;ZJ\I=2,T6)/'BIEP9*[_$[R'V!GBP;,_E;% K,7^,0Y;^3C^#=/V)^P M?3&,9V-:;I?O'-1??NBB%^S.NZW8R6&>2.D%-$3!2[R*F LT0F@:J_80NV&P M_"06?K][M-B'_K+X^/>E5J_>27A!@S XDI&KJ+5FAJ_^B$@XN\7AF YNO%<< MA+%:WSSF1(W)])X9#?8W\Y,@<@"(YHJ7,\5N,?M-B)[&V$=3'(7$"6X7YE=R M_A10D-)U@)V#$7T]'&#"U?R)_X,S^BFE7?;1[U=>R)1PN=C RIG;;&,4.[\? MU\Q0'X^0.^^A]TX"69XVFFE>(+?,-$^BB?PDRVFHFTWTKLCF:D/-;#X@;X3A M3*XT,YY%Z:52D4G999/1"&IVSU% @KOAO<^.JLQX\KWT";VX4KM""8$:6&%N M$[X)\41*&Q)$$I:$9];SG17:S*]>TEVXV)(GQ'F;H4\G4JPL^J2E:J3^ /O? M]X[86;][T.WN=:8^H3ZSDM_WV'2, L8?G^8UX\'TO]".L32N9)Q,9+:U.0)HYSX56/I5K19. &2?OM'CY2WI= M)&%=A%B?31!KQ:E0DRHMTUE[,JT>Z',%6ML>:.YV*H3Z:K-0JZY,(M21A*DQ MWFID.I5"Q&,3%EB6W2CRH6FV_RZD.C%!J@RS 10J+5*+EC!_@>6>O&CY:52( M9J1!!#DO"I&!1/SC%I=@S>)G!7B$G"VZ*#7)64. 3JCC5%8=OQRN1E#KC25? M(^+_BMP(WPV3'-Z-%S"?F/->9U2YAIY:C2]7X5_O<3GA[!8CSBGGYS<2CI\] M^L)SK]PGN/&F41@\8'8HGR*/J2 >26 (.Z^Y9BU>^)BMX&6G\J'DXO86,MU @&^U6VBD+ZNU9H:3 M=3$W8'W\BMTC>!BUD$Q3(J3,LUCO_TN8B^X[8X4Y!"2\$V(VL(:2KL]GFUS$ M,PNZKF0IZD[V4 _/;I'_$X?7D3< 9$#+*#0U(O.]=#%/!G=K'LZ&/[3J#IW/ MXN87+@J""K.T=AX^E*?,0[/60/1>P0"L$VG#:B=:K[#1%M)K0:AK'_\18<^I M:0/:(+=U(C6[=K+XJ+"*\LDU)](Y^G&,HT)E<%" M$I-Y#%$8:_P"Q9&T )0_KZ^OIM+LM6N'0H=]>Y/S2LLI6W_YIL"B+#[$4F:I MH=C,VY/WUZ<':Y "$$^@1 6;CID)P((FC<.ZMRV2HUT35H*D2<@Y>&2)K.& M90)N VP]VE.9(7@)@*'1%1B@Y8$C$W 83=JCPO"?4(9T#ML XR03(RW;IXJB MO4;@6:#F1Z=2TBHQ&AZHEC'(4DM65D<@/@R&$U8U'5D9.2,03G)FHB =F2MD MQLH_-A5W6%W.M)1&0A&E$N*T!&$@9+3CZ%5CI*< _I%HY:3%PT@[6LF'] BE M&(EK;"0HJ /G)?3ZQ0R Y",9>61('.2%":0SZ'F#"^J%/G)JA4C6TE>K(,EJ M$@!Q9O=H%B]+ZJ#>NQK=L3DBX7] MX<3;%O_C&LM?.RRA4A]3-WSN('&;&VE)6B@R4K=Z(C>&(S;=UPL&<)A_S:I.H0@_:-+&K7R0V$*GG=\.ZEM[?0 M( C, H*/3^,"SZ(V?7]BQ M!-]C/_9*^5$I023(C47=W8*W<#Q.TU=704T/" ML8.M'S8DWFI?4 &O@I!,^!U"2._2(BE25W57Y@>EN5_!5\'C&,5>D>_SF_CQ M1L%G/HW"Y=H ^R\J7=0E3GI1ISNL+$0^82CK%]$D_ M4?_GXF-Y@9MBI]H(IV@I#N4*!2@SC>Y6[>Q15RX9$>8$,.O:% M-%17_KU/!U'L;?X1$>;S/]'SY2)@?XQ]&HW&O>G4IZ_(O1OV(K:E\&@TV#XH M]Z-\^IL?(^^&RFM-@E(])^9+N1-"&85ZF+E'I.K1?4X"?&P)@HB; 6Z4)Q/J M<8\&!S?>U;LSYIX \].6L=)E D;^;*)"6Y\ &OA6B#[B,)RCSY/P!/"B>@$% M>"22I_3( -\S"2?(B6OE()>)ZD +P)93@C*7F_< LE9*!\K8]?/_W5S?]&^O MB8=Y2?Y84#93ILB;]WCU"IKY)02:9?N),0J_I5= Q&KV&[A: MF-$W]#IA+@EP:5E")WC [4=O\,IWU0%_FH5C&YE)3AW\$N<3N#*5Z8/-/CO] MA^.%T_Q(WO_-.H'622^D 6:(^$'(:&&LQ$IV:]TSDVW!R"?TV0NFV"%#@@<* M2RN?B-7L-V$9EIBK)1-@NY!- +P=\S/U-%@N58YV(V$4 FJ$2Y'1'IYQ&3?4 MCV.,J= I?)\NHZ2[EE&5$;6.Y\V[X; MIOB"+O<< BIGN0GV*Q\S2^EH1X],(V9G4.H4><%C+]B?(C^<_4 3!4\10'2K MQ6NB MQ:Q^ :<)GMM3L=8SR(W#@D>]_39=R4.+UJC>B;3]-4 T+GY:9M5 FK$3.<H=6 UH6 M?!.7*MO;00RSGSG1TT13GXQWM(H#R%0RRBT$-MVSJBYO6EJC7:GRY 8MSAT) M.8VNO *0LRA=ETC[N<7=7J=]5\ZL)IHY;<\',,WPYZ73A:ZD*P^T9OI+4 7% MXF88_],6S82<\:]!XI2\9T8;BG+42[ZX&RO_S&CO7WX'R,-]"4&W9*O+@=DE MB:N$B9K:3-FTK*;*ET6%$HWV"K0JL?":L%"0T:ZC M;@30ZF7N1"GRCY)OHU+*+N8G:CK9W7TNO_Z"T,[N;G/U%-5(-&EVDJJ1G3"C MK$JBGL^[NPR;JJ0N@N#+G5ZTMW)>*2@OUXH-E',#D<_5"L" M)[H[-OJ1%]V3JJ#TL]#0[LZN"H6_A?IV=RZ&@W(TPB<0ZOW9^H[M/N MGAD ;SLDZMKA((K4BQV)HK[L[KPJ41)R5OP D5[>ZI!?Z<7Z(U^6O4>E^A[%-OQ)GG M#Y+6^. DE.Q\#K3TMJ0TL^#:].E'7B_H*\_ZA\]L6;'/B!/BP04*QHL'5!>0 MG/DT28M:6+A>M0/M;P%X/!RY\F3RL\>F-V-HROX.9QPF2<)X]6 >C&0+)40C M4-FB"IUH?RQL95R0ZW)/I<_^%P#?"RNBTZ@0\=.ZCU,?H\&=]ROR"=\('J#O M2LK3;&&"#>.+KTM\W,+ P][.A))N=!Q70&QIG<>#H3Z6973!KTU,J!^2 M/V/SFZ2+V'G:(5/DLJWUAE]W8,M@&2:4MIEPPO#'8SCD,0K(6 M=H<7U'O%/K\CA-[)))J<4]^G;\0;+6UK-=YEZ(.GC./PJ&SK M24_!8D>0GSK*'0U!M0+UZN+\C[>3<< M8IX(XCOYS?G= [P(K21!S6*EC3R\9&A6:\L8;J"8:;I3:"'3S;;:2\N^4O>5 MKZS5=0>>WR6$P(^3L*-=GR(/SE!A<]T53E<=2/!\S6[?*-/@TKL9K<'>#!LI MGG+!3L3#*JHO"I61:=1G5RO*G$_#8N8;L+FK74/G<%;K1AD&5W_.;-XHRYL! M5C#;*1)-%U4NDX66J'K["QP73=!<[5A7G[C ;N0*:6LQXFJR6E-YN'0GHY+N M@E5UAB67:Y:W)@JBMGCA4ZZ<=KZGFBOCQNPU_*YOT0F"EIQN$AF/S88GE<@H M>:04TEI0SE!R?6Z>_T5%,^-K>.<&/G($S-A$V[SC)66"U&2TI@)?0;@MC>B2 MBV4*F8U&FP#. K 0=2+_%Z-O44C(KY:'$/*W> ZH3W[U3))0A-%0/EE%9*T" MJ>2@J%IYO+5ZR$GP"M&-=C^EUP(X(9_433,;G:D<&"K#4@CY+3H]@S?#0LR, MJ-YJ]/%$>0H40:,LJ5RK+/LZSDW(:[N]JP&Y*$KUVC[Q*R)8A2*D5X%>)+48 M,HXMYY?(F<."V3:&@QJ!U15[:15GK\Z(ET M KB8"#0KO;*C+TA*LY+=6#MH*0C$",T6W5XS4[6LP"&?JBNGU:PP/_#;A8O( M)& LX,%\I"O(DTVN69%ZR\=)?F+OG.T>D1_V_!<2^ER,._^6[31I@12DE.ZA M8<%=E]<-X*Q5$2Y-I>')B":8WZP>,CN+Y*"223@AS91@+?6;*Y]JL M($TV.3 <:&YK^,[#B*9N&4O:WMSV8$;8_'+O?>I@S(L8!RX MP/RM(%!CJXA&8T/,35'&ZUN@85ZG83'SC2XOWK7ZXA*M&_6NV'P% SOS*#3- M^&;T1X7Y?GL(3PF):+G:MQ_G63)E:?%ZL@CJ66!,Z,R#H0).,]:A2UWXL03\.TE)+1:J+0[+1Z$;A%U +51&>>) D$S;%2;I?R M-DI%UK2D1F=42TZW5")P("3=#FM<%N,QXB%JW?*F0FV6/%I<2=Y4P%.@X MSE('B.* LR6 MRIGI9R8OY#<:.QG)FS87DVVOF,@ 00NPML'$%J!4AYQ:8-0F@D)!7VJKI1:FE M3O3!U1\1O_M8'SA-C7BKF#0@RWI#YS$S_'6> ?/_^/LJ:#[G1=7:\YGXS?*M MAS?D#Q:OH5V]8]\A 7]Y? ZE_PV3T9C-Q!XOVS_"R^_O?>* <@E-7./']/Z8Q$$I"GB@XXXSX820>,@'"YN]L M+;7'(?GQ:UOLZWA\Y1/1"J1U5V]B??/8$F,I?E ,,@B;;:&ZCA\4>>.A=>84 M,?L<7Y"+<<+IJ;H<2_",5R4/%4-Z-O[ X?S%-GD9E&CK-J5\:JKM)P;8>G8( MB;\"Y:9E*38AV(KK\H.&N/<2Q*_7@04JH 2NQ!H^C?$M\G_BD)NY0+4*6RD= MW1IF9AFQH7WV@BEVR)"P 0>#7@J(:)\@; OAZEJR (6]Y!" ^RIOV)N;VBGR M9GTR(%,K08>@*AV MQV"U6W!AQ\SVS7DS<.1M1F/-[,[M+I^VU.-!?_!TR2%@)=L- (3V[;& !AX M6T)(^Q8UQH,H.4J^& ],EL#(RS>#FFA@V$">%#7(L[V "TJ%UGD M 5,EG]V2*I+PHPU5.J&94'!2^Q:V>HX6(ANQ=<(#]5SRXIOYU%+)? M+RU$7;A)A;X,@U%")&@L$7B!IB1$[GQ)Y[*EF"B4):XYG?(;XHL4 +7(:6AE MXG#[TX9YCUR^T:93GBV-(_LRTU>'A\ M5GG:MI"0;IO+? ,ZPSCES,)%*"#2!-14R2>-_X]?,V8G&?4%K*?_#Z6!^V_ M=HK.@<9SK>$'_.<#_K.1(_N _\CG3M?6DT5PGVP34DN,I=@TVH,.:D5%UH") MM&[=5,JC,P&39)"F2MQW >DQ.RVD65N0@YM0F04OKP*WKM5SM)#4^)TK,W"0 M(5C&EM/FFU126PY,MK1D1N\5):NQ,+1G A*Q;?3XL1%/(C<)I&[QJ>LZ@=1K M60LAGM$)6>G#HD)^2:C E)HSPJ_D9J?.Y]!42+>;*(4PW% TF$TDXN!LK_ ' M?XHWX&E[[OH%3Y3-P/3W' GW@X;_QN$#=NC((W_&Z"!"^%T/<^+^&IW?,Q^=N-MV',(#*$5 MMMK.6.2)LRS%-F<]??*,SYRU9BV4>;!$>5$X9CX#T,9HZ-Q4=2W"&W=1&(0H M+K8-?T=20^?VP$;*&7HD[]6X62-@"3#$=EA([8E-Y6AEE31HU4Y-M5M*&=8Z M>FLZ'5NCAK)SMU5GR$YE>FM:P^7!=3/2PCKBSV;G*N7CSVN[LB49QGKBZT;' M)#59S/J=7*%/LV^@FJ7/_#.6)2D!L_6Y>=*WI>!!K6IM)2!EPAMTADW@M%)V MT$IJC'8G>OUD=I$'N_2:DYD1Q2:D_?IF\$I5Z6>;*8<<:/RF24L-Q 5 M>5F?CNL.3US?8IWOE>O(#WR-+#[A>_I"GK4;S ^8+T(F''\IAM^C9MO5$_8G MQ^#0B@DLFQJP6KU.SD5K/M">T7D3ZJIK6J36H2TSN0K+AL]D:U)&.M6E."V> MIU/LQ_^*JPE6UUQ=?-BDQ#Y],T*)&WQ :"5&1/-*;-QYE?21:FZ3V:GKZG#% M[C]4!NR^B;<8U+D^GVWR#2[%HJ/[EO$1RMS7#IJHRHFY M$Y)7QEQ-V$0)TF8A$XL8;JH0Q+RLT8T7A'X4WWN["\?8?QHC+UG_4^+C06HNL_.4Z6Q?-ZX9' M-L*6]:J>-6Q,$._ZSQ9J]Q5M\ ,Y:[S9*URDYVCP:LQ M<*;L5Z^Y+D,EC^#C%<2/&G);]VI?Z:*S\ 6WC_?;Y'"X'V4.ZRIB\5'F\*/, M(4CE9I0Y-/OYNX^GW0Q]@DO2#O&9#T@*X;$0@3K=@S)>@)"H;3@QY!H MS[DEHW+ZL9]DCDK3>68Q(!8BO"WPIF 0B60TOEAXM[-]5(QA0YO&]AM]'#-! M68;X@U@AV%[=W/O92M1$U[F*)&%+IZ+_> M"UDW'OL9?D+ON,Y7KX%46[V&)A^/7HX MQ/RVFM#D YOT_#(B\:+XSBY;#O%Z@4@#H0I%83T_7F.V#I'[&#*:20= '%8) M%!>UH'NPAMN.PK1([* CA2+,\ M"@TQ_NP%4^R0(<$#!9Q8/A'=[',+P5V()0O@"K#9!)J:YW.S.\*>,P.#N0J( MM,"^$NZJA%#3D"HYN:C4$&P_^JE\$M/2=68/JJG8TE I8V@+1*ET3\@0=WW? ML@I@!)K*>2Z&8="AHI*T)7Y6H; 9I6';#*-(+=[J\EJ#GRH] 5"Y4Y8E6"KP ME@TY_EKRW+"ZV[(>T%"H(*@WBO8#AWT:!/?8CR.)/2;?@+@1'[]'[$2,-8*# MJW?'C09X<,VTPB.141@/X-WPDO]T(\@Y+Q=5^+]" M/B\#)D2?T,@#A1!KZO#CVIQ4W'3Y5*VH P87H8"(9O9_0SR#HA!"6FNH^YY= MYI16NVA83FN+A&D@CEK1W)S/L@F ;U3J9*.Q^YD5I:AP2;.>GLV>:TIQP_KZ M;#K$6+NV,N]NUC-QMC^$J6F1TX9,H&'1TZ*(4Q,[4JG:5_=@>UXV,DQYU@2R MI;TZFNM$FQ#&UB1IP0G'B,BN'JEE[T6;'>75Z4;4%*L0FI2^/I(12_SED//' M2[[__?\!4$L#!!0 ( &:"8DOS3=6A%%< (TR!0 5 8V5M<"TR,#$W M,#DS,%]L86(N>&UL[;U[=&QX0C68DBOC[P!,5SA.TOL_?[?+CZ)\E23?@;R(TCA".(5_ M_NX9YM_]M[_\W__7?_X_1T?@]/P&+%9%\@A/DWR%<+[+X/?/UZ]?7\3I?X=7H[?'1^^/;=\=_?/?+'W\Z M?OWS+^]_^O"'/_R_Q\=_/#[N$/BU'"#H_(\0>/W3Z^/7'SI?NXI6OT?W$%R< M=K[VX>27MS^=_?++XNWQ^Y/C\Y]__/CAW2\__[PX69R___G=Z<]'Q\?';W_\ M^>V'#^_)']_^_OF??)L/[$;]:_/5/.%]D9!]^^9_?KJ\63W 3724I-1T5A0@ M3_Z8LP\O\8JI4X(O(/P&_=M1_;4C^M'1VW='[]^^?LKC[XC( /C/#"-X#=> M_O?+]840[L,;^HTW*;PGYA5?1G<0$78I[3\^9'#-_QW*LM[/* L?* MO?Z8L M_!N/6O&$?Z3)YLM(@)Y,X?+S[ PR^B0H$%>KV"6X/@L-2Q:/EGC?-\44698 MUB+"!GF_)1$/FN5ZGZ1)?G$1([XQ8#E>O[_'CFQ@FA.C;'^D?CN@?CH[?5L'U MW\A'?S]+BZ1X/B$S>A:A"T+^Z7_ YSXNHE$>9_6';#!__F[DQV\:!NE7Z2Q# M?D27(3 ]^G(C2^?OZ&X@U0SF>)>Q*4A:C$5KZW\I84"% Q@0($C_^8;QTN-Z MD:UZV%&VJF')'R>0JV^\66$R86Z+(]2UD'6&-Z/BJV#QI&S>B QA!3=;JNQ? MCC^\/V:JII_\O5Z[+=*XI'J1KG&V85/XXBXG *M"1O4*Q)1,09JN&=.(*R1& M^KN_-"M;LD F2V=F*DF+_=J'E:BK#2N+,605E2)I54,00>7%'4SP6XWZOX9* M,A A:_!;,@K9P-C_C7(\[/[8-KR -*WY?%\26+A1((08I(1H &8URS$Z/Y&=5@ M-_BQML_VZ%@,?R4.F4]BEH[R'0GYLL>3L@E)SL,@.2%B@Y9[GN2K"/T7C+)S M\DFN:KM[/]>6ZH"21?LMD0"% @S+MP6+=( E)!26O(=V/"EJXY9<>LX,6^X1 MF"G=#BW[]ES%C( LFJ<+KDWOR2DTN0OL>DSD!BS[-HOH,=3-\^8.(UEK'OQ( M69*]WYNWVHH\*.G[LE.^9+%0 B%($)S0WD!:?HXWTDI;_6\V\ M9I^,M;1F"P,HCM^DID#L>$HN 8D8J4K7;Z*[S^YDCMN @YWLLJRW %/<-XI_ MKVP%(E+FG:U"ZJT(?>\@)Q6!9:04F-"1NKR-31KG"8+9"4&XQYGB8=C@IYKQ MK$?%VHS!4$ -XW?"X(L<3P@E'/$B!L+EQ(2X-81YS"J@HS)KC(SNZ*!#+ M%4E_SX"YD@E-TGUSKF7MV*Q/HOQAD<;T/V?_V"6/$2),Y(OB),JR9[+V^#5" M.ZFTA2)!+65(T;;@!@2O+'UK07TZ@YK.L);\0MQ*+2D/FV%X'^PBX%@568B_?)1;NIQ;K%1;JCP(NW,"N> MK\BXV7T"LKC9TC0-F0'4XN\8'[)UGZ9S ZQ/Z@ ( BN#6M&?- <:"OK4H+SS$#'9#*[>1-;J!M;UQ=71ZLX8$+;Z& MCS#=0=WC&R$1S2,% 3T;!S@E%,A*++\'.5.ZP-(R"E'N:"#R"L;U84YW7M*S M=Q&%V=.D34N_#'(U,F[D8[()3MC\98EKXV[G$C5R(LI6M@E=\Q50T+_:*")IW#7;-NL+ZCVB+\S^!$M+O%=Y)O6!Y<06I@\H'NC"5X%T? MF%YEU8: \:)\T8W[<]U*^R$E*W<:JNU/3E'^!/[]]?'Q6["-,O!($?\$?GIU M?'Q,_P_RL@5!M"L><);\$\9_ BFN/TWRG&;?<09PVZ( 1 6X(<8--W
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end